Cystic Fibrosis · Web of Medicine

On this page

Quick Reference

RxDrug of choiceElexacaftor/tezacaftor/ivacaftor (ETI) for eligible patients ≥6 years with at least one F508del allele.

AltAlternativesIvacaftor for gating mutations; tezacaftor/ivacaftor or lumacaftor/ivacaftor for F508del homozygotes not on ETI.

⊘AvoidAvoid non-dihydropyridine CCBs (diltiazem, verapamil); avoid routine systemic corticosteroids during exacerbations; avoid concomitant azithromycin + IV tobramycin during exacerbation treatment.

DxTest of choiceSweat chloride test (≥60 mmol/L diagnostic); HRCT chest for bronchiectasis detection.

ScKey scoreFEV1 percent predicted (severity staging: mild >70%, moderate 40-70%, severe <40%); Lung clearance index (LCI) for early small-airway disease.

→When to referLung transplant evaluation when FEV1 <30% predicted, especially with hypercapnia (PaCO2 ≥50 mmHg), frequent exacerbations (≥2/year), or supplemental oxygen/NIV need.

CF is a multisystem genetic disease dramatically improved by early diagnosis and CFTR modulator therapy. Core management includes airway clearance, infection control, and aggressive treatment of exacerbations with short-course IV antibiotics.

Cystic fibrosis (CF) is the most common life-limiting autosomal recessive disease in white populations, caused by biallelic CFTR mutations that disrupt epithelial ion transport. The clinical hallmarks, chronic progressive lung disease with bronchiectasis, pancreatic exocrine insufficiency, and elevated sweat chloride, begin in infancy, but early diagnosis through newborn screening and the revolutionary introduction of CFTR modulator therapy have transformed survival from early childhood to a median of >36 years. Management now centers on genotype-directed modulator therapy (elexacaftor/tezacaftor/ivacaftor as first-line), combined with airway clearance, aggressive treatment of pulmonary exacerbations, and surveillance for multisystem complications including CF-related diabetes and bone disease.

Overview and Recommendations

Background

•Cystic fibrosis (CF) is an autosomal recessive disorder caused by biallelic pathogenic variants of the gene, leading to defective chloride and bicarbonate transport across epithelial surfaces. This results in progressive obstructive lung disease, pancreatic exocrine insufficiency, and multisystem complications, making it the most common life-limiting autosomal recessive disease in white populations.
•Incidence is 1 in 2500-3500 live births in Europe and North America, with median predicted survival now exceeding 36 years due to modern therapies. Over 1900 CFTR mutations have been identified; functional classes I-VI predict disease severity and guide modulator therapy. The F508del mutation (class II) accounts for approximately 70% of CF alleles in populations of European descent.
•The pathophysiology begins with CFTR dysfunction abolishing anion secretion, leading to airway surface liquid (ASL) depletion, mucus hyperconcentration, and impaired mucociliary clearance. This creates a cycle of chronic infection (especially and ), neutrophilic inflammation, and progressive bronchiectasis visible on CT as early as 3 months of age.
• has shifted diagnosis to early infancy, altering natural history and allowing early intervention. However, in low-resource settings, delayed diagnosis still leads to advanced bronchiectasis at presentation. The distinction between classic CF (sweat Cl >60 mmol/L) and non-classic CF (borderline sweat) determines eligibility for .

Evaluation

•Suspect CF in any infant with (15-20% of newborns), persistent cough, poor growth, or chronic diarrhea. Also suspect in older children or adults with recurrent sinopulmonary infections, , or unexplained bronchiectasis.
•Perform as the diagnostic gold standard; a value ≥60 mmol/L on two separate occasions is diagnostic. For borderline values (30-59 mmol/L), proceed to CFTR genotyping to identify two confirmed CF-causing mutations.
•Order as the cornerstone of lung function monitoring. Measure FEV1 percent predicted; an obstructive pattern (FEV1/FVC < lower limit of normal) is typical. FEV1 declines an average of 1-3% predicted per year without modulator therapy.
•Obtain to detect bronchiectasis (airway-to-artery ratio >1), air trapping, and mucus plugging. Bronchiectasis is present in 29% of infants at 3 months and 62% by 3 years in newborn-screened populations. Use low-dose protocols to minimize radiation.
•Collect sputum for routine bacterial culture, including nontuberculous mycobacteria (NTM) and fungal studies. In non-expectorating children, is superior to cough swab for pathogen detection. Reserve for unresolved cases or suspected NTM.
•Assess pancreatic function by measuring fecal elastase-1; levels <200 μg/g indicate , present in ~85% of classic CF patients. Also screen for with annual oral glucose tolerance test starting at age 10.
•Evaluate bone health with dual-energy X-ray absorptiometry (DXA) scan every 1-2 years in adults; low bone mineral density occurs in 25-35% of adults. Check vitamin D levels and supplement as needed.
•Consider from multiple-breath washout as a more sensitive marker of early lung disease, especially in children under 6 years who cannot perform spirometry. LCI predicts future exacerbations and bronchiectasis.

Management

•Initiate as first-line for all eligible patients. For those ≥6 years with at least one F508del allele, start (ETI). Dosing: for patients <30 kg, give ELX 100 mg once daily, TEZ 50 mg once daily, IVA 75 mg every 12 hours; for ≥30 kg, give adult dose (ELX 150 mg, TEZ 75 mg, IVA 150 mg), two tablets in the morning, one tablet in the evening.
•For patients with gating mutations (e.g., G551D) not eligible for ETI, start 150 mg every 12 hours. Ivacaftor improves FEV1 by 10.6 percentage points and reduces exacerbations by 55%.
•Add adjunctive chronic therapies: 7% 4 mL inhaled twice daily to improve mucociliary clearance; 2.5 mg inhaled once daily; and 250-500 mg (or 10 mg/kg) three times weekly for patients with chronic Pseudomonas infection to reduce exacerbations.
•For acute (defined by worsening symptoms and ≥10% decline in FEV1), admit for IV antibiotics. Use dual antipseudomonal coverage: 3 g IV thrice daily plus 5-10 mg/kg IV once daily. For ceftazidime allergy, substitute 2 g IV thrice daily.
•Assess response at days 7-10. If early responder (FEV1 improvement ≥10 percentage points from nadir), complete 10 total days. If non-early responder, continue to 14 days. Do not extend beyond 14 days; STOP2 trial showed no benefit from longer courses.
•Continue during exacerbation: encourage twice-daily sessions using oscillatory devices or inhalation. Do not routinely add systemic corticosteroids; they do not improve FEV1 recovery and may cause hyperglycemia.
•For hypoxemia, titrate oxygen to target SpO2 ≥92%. For hypercapnia (PaCO2 >45 mmHg) or nocturnal desaturation, consider (NIV). NIV during sleep improves event-free survival.
•Refer for evaluation when FEV1 falls below 30% predicted, especially with hypercapnia, frequent exacerbations (≥2/year), or need for oxygen/NIV. ETI can often suspend the need for transplant but reassess at 3-6 months.
•Manage with insulin therapy; oral hypoglycemics are not recommended. Monitor renal function and avoid nephrotoxic drugs in those with CKD. Screen for colorectal cancer starting at age 40; earlier post-transplant.
•In children, avoid concomitant use of and intravenous during exacerbation treatment; this combination is associated with worse FEV1 recovery and shorter time to next exacerbation. Use weight-based ETI dosing carefully.

Board Review — High Yield

•F508del, Most common CFTR mutation in European descent; class II (defective trafficking). ETI is first-line for patients with at least one copy.
•Sweat chloride ≥60 mmol/L, Diagnostic threshold for classic CF; borderline (30-59) requires genetic confirmation.
•Lung clearance index, More sensitive than FEV1 for early airway disease; can be measured in preschoolers via multiple-breath washout.
•STOP2 trial, For CF exacerbations, 10 days IV antibiotics is non-inferior to 14 days in early responders; no benefit beyond 14 days.
•Elexacaftor/tezacaftor/ivacaftor, Improves FEV1 by 13.8 points, reduces exacerbations by 63%, lowers sweat chloride by 42 mmol/L (phase 3 trial).
•SIMPLIFY trial, In stable patients on ETI with FEV1 ≥70%, discontinuing hypertonic saline and dornase alfa is non-inferior to continuing.
•Pseudomonas aeruginosa, Dominant pathogen; chronic infection accelerates FEV1 decline. Azithromycin 3 times weekly reduces exacerbation risk by 44%.
•Meconium ileus, Present in 15-20% of newborns; predicts bronchiectasis by age 3 (OR 3.17).
•CF-related diabetes, Affects 31% of adults; annual OGTT from age 10. Associated with worse lung function and mortality.
•Avoid systemic corticosteroids during exacerbations, No improvement in FEV1 recovery or time to next exacerbation; may cause hyperglycemia.

Deep Dive — Evidence Details

1. Definition, Classification and Nomenclature

▸CF is defined by biallelic CFTR mutations causing defective epithelial ion transport, diagnosed by sweat chloride >60 mmol/L (classic) or borderline values with genetic/functional confirmation (non-classic).
▸Mutation classes I-VI predict disease severity and guide modulator therapy; class I-III typically cause severe disease, while IV-VI retain residual function.
▸F508del is the most common mutation in European-descent populations, but genetic heterogeneity is substantial in non-European groups, where CF remains underdiagnosed.

HY High Yield: Mutation class predicts both natural history (class I-III → severe; IV-VI → mild) and eligibility for specific CFTR modulators: e.g., ivacaftor for class III gating mutations, elexacaftor/tezacaftor/ivacaftor for F508del (class II) [11,26].

Cystic fibrosis (CF) is a genetic disorder inherited in an autosomal recessive manner that impairs the normal clearance of mucus from the lungs, which facilitates the colonization and infection of the lungs by bacteria, — Cystic fibrosis — Cystic fibrosis (CF) is a genetic disorder inherited in an autosomal recessive manner that impairs the normal clearance of mucus from the lungs, which...Wikipedia ↗

Cystic fibrosis (CF) is an autosomal recessive disorder caused by biallelic pathogenic variants of the CF transmembrane conductance regulator (CFTR) gene, leading to defective chloride and bicarbonate transport across epithelial surfaces and resulting in progressive obstructive lung disease, pancreatic exocrine insufficiency, and multisystem complications ^[1]^A1c^[3]^A1c^[14]^C4.

Also Called / Synonyms: CF; mucoviscidosis (historical).

Key Terminology Used Throughout This Article:

Classic (typical) CF: One or more characteristic phenotypic features (chronic sinopulmonary disease, pancreatic insufficiency, elevated sweat chloride >60 mmol/L) plus evidence of CFTR dysfunction ^[37]^D5.
Non-classic (atypical) CF: Organ system involvement with normal (<30 mmol/L) or borderline (30-60 mmol/L) sweat chloride requiring identification of two CF-causing mutations or direct CFTR functional measurement by nasal potential difference ^[37]^D5.
CFTR-related disorder: Single-organ manifestation (e.g., congenital bilateral absence of the vas deferens, recurrent pancreatitis) with borderline CFTR function that does not meet full CF diagnostic criteria ^[65]^D5.
Pulmonary exacerbation: Acute worsening of respiratory symptoms (increased cough, sputum, dyspnea) warranting intensified antibiotic therapy ^[1]^A1c.
Pancreatic sufficient vs pancreatic insufficient: Approximately 85% of patients with classic CF are pancreatic insufficient by age 1 year ^[14]^C4.
Mutation classes (I-VI): Functional classification of CFTR variants based on the underlying molecular defect ^[26]^D5^[32]^D5.

Classification of CFTR Mutations

Over 1900 CFTR mutations have been identified; the functional class predicts disease severity and guides modulator therapy ^[14]^C4^[26]^D5^[32]^D5^[33]^B2b.

Table: CFTR Mutation Classes

Class	Defect	Example Mutation	Functional Consequence
I	No protein synthesis	G542X, W1282X	Premature stop codon, truncated nonfunctional protein
II	Defective trafficking	F508del	Protein misfolded, retained in endoplasmic reticulum and degraded
III	Defective gating	G551D	Channel reaches cell surface but fails to open normally
IV	Reduced conductance	R117H	Channel at membrane but chloride flow is diminished
V	Reduced synthesis	3849+10kbC>T	Splicing defect yields fewer functional transcripts
VI	Reduced stability	N287Y	Accelerated turnover of CFTR from the cell surface

Class I-III mutations generally produce more severe disease (pancreatic insufficiency, earlier lung function decline), while class IV-VI retain residual function and are associated with milder phenotypes ^[14]^C4^[33]^B2b. The F508del mutation (class II) accounts for approximately 70% of CF alleles in populations of European descent but is less frequent in Asian, Middle Eastern, and African populations ^[12]^B2a^[51]^C4^[71]^C4.

Clinical Significance

CF is the most common life-limiting autosomal recessive disease in white populations, with an incidence of 1 in 2500-3500 live births in Europe and North America. Median expected survival has increased from early childhood to 36 years in the early 2000s and continues to improve with modern therapies ^[3]^A1c^[25]^D5. In low- and middle-income countries, CF remains underdiagnosed; delayed recognition contributes to advanced bronchiectasis at presentation, as seen in Indian cohorts where median age at diagnosis is 2.58 years despite symptom onset at 2.25 months ^[71]^C4. The physiologic class anchoring this disease is obstructive lung disease, driven by defective mucociliary clearance, airway mucus plugging, chronic infection, and progressive bronchiectasis ^[56]^D5.

Pearl: The distinction between classic CF (sweat Cl >60 mmol/L, two identifiable mutations) and non-classic CF (borderline sweat, requires functional or genetic confirmation) determines eligibility for CFTR modulator therapy, misclassification risks either denying effective treatment or applying it without indication ^[65]^D5.

2. Pathophysiology and Mechanism

▸CFTR dysfunction leads to ASL depletion, mucus hyperconcentration, and impaired mucociliary clearance, the primary initiating events.
▸Mucus plugs create hypoxic niches that trigger IL-1α-mediated sterile neutrophilic inflammation, amplifying lung damage even before infection.
▸CFTR modulators partially restore epithelial ion transport and reduce inflammation, but residual systemic immune dysregulation often persists.

HY High Yield: The earliest functional defect in CF is ASL volume depletion, detectable before any infection, making airway hydration a primary therapeutic target.

From this molecular defect, a cascade of ion transport failure, airway surface liquid (ASL) depletion, and mucus hyperconcentration initiates the progressive lung disease that dominates cystic fibrosis morbidity. The following numbered chain traces the key pathogenic events.

Ion Transport Failure and ASL Depletion

CFTR dysfunction abolishes anion secretion. The CFTR protein functions as a cAMP-dependent channel transporting chloride (Cl⁻) and bicarbonate (HCO₃⁻) across epithelial surfaces ^[83]^D5. Loss of HCO₃⁻ secretion acidifies the ASL and impairs mucin unfolding, while loss of Cl⁻ secretion, combined with unopposed Na⁺ absorption via the epithelial sodium channel (ENaC), dehydrates the ASL ^[104]^D5^[110]^D5.
ASL volume collapse impairs mucociliary clearance. Normally, the periciliary liquid layer maintains ciliary beating and mucus transport. In CF, ASL height falls below the critical threshold needed for ciliary function, causing mucus to adhere to airway surfaces, the earliest functional abnormality detectable in newborn CF pigs ^[138]^D5.

Mucus Hyperconcentration and Airway Obstruction

Mucus becomes hyperconcentrated and tenacious. Sputum from CF patients shows increased percent solids, elevated concentrations of the gel-forming mucins MUC5B and MUC5AC, and dramatically higher osmotic pressure and viscoelastic moduli (elastic modulus G', viscous modulus G″) ^[84]^C4^[96]^C4. This hyperconcentrated mucus cannot be cleared by cilia or cough, forming adherent plugs that obstruct airways ^[56]^D5^[137]^D5.
Plugs create hypoxic niches and trigger sterile inflammation. Oxygen diffusion is severely limited through thick mucus plaques, inducing epithelial hypoxia. Hypoxic cell death releases IL-1α, which drives neutrophilic inflammation even in the absence of detectable infection, a phenomenon termed sterile inflammation ^[90]^D5^[143]^D5.

Chronic Infection and Dysbiosis

Impaired bacterial killing permits early colonization. Acidic ASL and defective CFTR-dependent antimicrobial peptide secretion reduce the airway's intrinsic bactericidal activity ^[23]^D5^[110]^D5. Infants with CF show a nasal microbiota compositionally distinct from healthy controls as early as the first months of life, with increased relative abundance of Staphylococcaceae ^[79]^B2b.
Pathogen succession follows. By age 6 years, , Staphylococcus aureus , and other classic CF pathogens dominate the lower airway microbiota, replacing the Streptococcus-predominant community of early childhood ^[95]^B3b^[98]^D5. P. aeruginosa adopts a mucoid biofilm phenotype that is virtually impossible to eradicate ^[130]^D5^[144]^D5.

Neutrophilic Inflammation and Tissue Destruction

A disproportionate neutrophilic response amplifies injury. CF airways recruit massive numbers of neutrophils that release neutrophil elastase (NE), myeloperoxidase, free DNA, and neutrophil extracellular traps (NETs) ^[103]^D5^[107]^D5^[109]^D5. Sputum NE activity is the strongest predictor of lung function decline ^[112]^D5.
Protease-antiprotease imbalance drives bronchiectasis. NE overwhelms endogenous antiproteases (α₁-antitrypsin), degrading elastin and other structural proteins in the airway wall. This, together with matrix metalloproteinases, causes irreversible airway dilatation, bronchiectasis, visible on CT as early as age 3 months ^[76]^A1b^[107]^D5.

Cellular and Molecular Inflammatory Pathways

Epithelial and immune cells are intrinsically dysregulated. Single-cell transcriptomics of CF nasal epithelial cells reveals impaired interferon signaling and reduced expression of MHC class I and II genes, compromising antiviral host defense ^[15]^C4. CF sputum shows a shift from alveolar macrophages to recruited monocytes and immature, proinflammatory neutrophils ^[88]^C4. Macrophages exhibit defective phagocytosis and efferocytosis, perpetuating inflammation ^[92]^D5^[102]^D5. ETI (elexacaftor/tezacaftor/ivacaftor) partially restores these signatures, improving epithelial homeostasis and reducing neutrophil and monocyte activation ^[15]^C4^[39]^B2b.
Systemic inflammation persists despite modulator therapy. Even after 3-12 months of ETI, neutrophil and monocyte counts remain elevated compared to healthy controls, and the plasma proteome retains a distinct inflammatory profile, indicating that CFTR correction alone does not fully reverse the abnormal immune milieu ^[39]^B2b^[154]^B2b.

Modifying Factors

Sex hormones modulate the pathophysiology: estrogen increases ENaC activity and may worsen ASL dehydration, contributing to the well-described sex disparity in CF outcomes (worse pulmonary function in females) ^[152]^D5. Acquired CFTR dysfunction from cigarette smoke exposure further impairs mucociliary clearance in patients with , highlighting the centrality of this pathway across airway diseases ^[75]^A1b^[85]^D5.

Pearl: Airway disease in CF begins not with infection, but with ASL dehydration and mucus hyperconcentration, a concept that explains why early hydration therapies (hypertonic saline) and CFTR modulators, which restore ion transport and thin mucus, are the most effective upstream interventions.

Steps in CF Lung Disease Pathogenesis

Step	Event	Key Mediator	Consequence
1	CFTR dysfunction	Loss of Cl⁻/HCO₃⁻ secretion	ASL depletion, acidification
2	ASL dehydration	Unopposed ENaC activity	Ciliary collapse, mucostasis
3	Mucus hyperconcentration	↑ MUC5B, MUC5AC	Plug formation, airway obstruction
4	Sterile inflammation	IL-1α from hypoxic cells	Neutrophil influx
5	Bacterial colonization	↓ Antimicrobial peptides	Dysbiosis, biofilm formation
6	Neutrophil-dominated inflammation	NE, NETs, ROS	Protease-antiprotease imbalance
7	Structural lung damage	NE, MMPs	Bronchiectasis

3. Epidemiology, Etiology and Risk Factors

▸CF prevalence and survival are improving, with adults now outnumbering children in high-resource settings, but under-diagnosis persists in non-European populations.
▸Meconium ileus, early neutrophil elastase activity, pulmonary artery enlargement, and female sex are strong independent predictors of worse lung disease.
▸Smoking in CFTR variant carriers increases chronic bronchitis risk by 52%, and respiratory viral infections (seasonal) are the dominant trigger of exacerbations.

HY High Yield: Female sex is consistently associated with worse outcomes in CF, higher exacerbation frequency and mortality, yet the mechanism remains incompletely understood and may involve sex hormone modulation of CFTR function and immune responses [202, 227].

From the molecular defect in CFTR-mediated chloride transport emerges a disease whose burden and expression are shaped by a complex interplay of genetic, environmental, and healthcare factors. Cystic fibrosis is the most common life-shortening hereditary disease in white populations ^[83]^D5. Prevalence estimates from population-based registries exceed 8,200 individuals in the UK alone (2003 estimate) ^[194]^B2b. The disease is increasingly recognized in populations of non-European descent, though under-diagnosis persists in Asia and the Arab world due to lower clinical suspicion and limited genetic testing ^[226]^D5^[12]^B2a^[25]^D5.

Temporal trends and demographic shifts

Survival has transformed dramatically: median age at death exceeded 30 years by the 2000s, up from less than 1 year in 1938 ^[183]^D5. Projections for children born in 2000 exceed 50 years median survival ^[194]^B2b. Adults now outnumber children in well-resourced CF care systems, and the prevalence of nontuberculous mycobacterial infection is rising (pooled prevalence 7.9%, 95% CI 5.1-12.0%, increasing over 2010-2019) ^[187]^C4^[198]^D5.

Risk factors

Risk factor	Effect estimate (OR/HR)	Evidence level	Source
at presentation	OR 3.17 (95% CI 1.51-6.66) for bronchiectasis by age 3	2b (prospective cohort)	^[203]^B2b
Free neutrophil elastase activity in BAL at 3 months	OR 3.02 (1.70-5.35) for bronchiectasis; at 12 months OR 7 for persistent disease	2b	^[203]^B2b
Pulmonary artery enlargement (PA:A >1)	OR 3.49 (1.18-10.3) for 1-year exacerbation risk	2b	^[178]^B2b
CF-causing CFTR variant + smoking history	OR 1.52 (one-sided p=0.0060 meta-analysis) for chronic bronchitis	2a	^[167]^B2a
Gas trapping on expiratory CT	OR 2.05 (1.17-3.59) for bronchiectasis	2b	^[203]^B2b
Female sex	Higher mortality and exacerbation rate (OR not reported in provided studies)	2b	^[202]^D5^[227]^D5
Lung transplantation	HR 1.65 (1.40-1.95) for major adverse cardiac events vs general population	3b	^[175]^B3b

Non-modifiable drivers include CFTR genotype (F508del homozygosity confers the most severe classical phenotype, while p.Arg117His-5T with a severe trans mutation approaches similar severity ^[246]^B2b), younger age at onset of infection/inflammation, and female sex, which is consistently associated with accelerated lung function decline and higher mortality ^[202]^D5^[227]^D5. Modifiable factors include cigarette smoke exposure, which in CFTR variant carriers increases chronic bronchitis risk by 52% ^[167]^B2a, and infection-related factors: respiratory viral infections (which peak seasonally) trigger the majority of exacerbations, during lockdowns, exacerbation rates fell by up to 50% internationally ^[185]^D5. Mucoid Staphylococcus aureus , present in 9.1% of CF patients, is associated with worse lung function in females ^[6]^B2b.

Special considerations

Newborn screening has shifted the population to earlier diagnosis, altering natural history ^[198]^D5. Female lung transplant recipients with CF are at elevated risk for cervical dysplasia (OR 3.98, 1.17-11.82) and should prioritize HPV vaccination ^[210]^C4. The increasing prevalence of less typical gram-negative pathogens and NTM in the aging CF population demands vigilant microbiologic surveillance ^[200]^D5^[187]^C4.

The interplay of these risk factors directly shapes the clinical presentation of CF, from meconium ileus in infancy to bronchiectasis and chronic infection in later life, which are detailed in the next section.

Pearl: The combination of meconium ileus and free neutrophil elastase activity in bronchoalveolar lavage at 3 months predicts bronchiectasis by age 3 with an OR of 7 at 12 months; aggressive early surveillance and anti-inflammatory strategies are warranted in these infants ^[203]^B2b.

4. Clinical Presentation

▸Cough, poor growth, and diarrhoea constitute the classic presenting triad, but meconium ileus in newborns strongly predicts early bronchiectasis.
▸Phenotypic variants range from classic pancreatic-insufficient disease to atypical single-organ presentations with borderline sweat chloride.
▸Red flags, acute dyspnoea, haemoptysis, pneumothorax, or >10% FEV1 decline, require immediate intervention to prevent further lung damage.

HY High Yield: Examine for digital clubbing and upper lobe crackles; their presence in a child with recurrent sinopulmonary infections is CF until proven otherwise.

! Warning: Acute haemoptysis >30 mL or sudden pleural pain with dyspnoea may signal pneumothorax or bronchial artery bleeding, evaluate emergently.

From the and genetic underpinnings, the clinical phenotype emerges early, often in infancy, and progresses through life. The hallmark is a triad of chronic suppurative lung disease, exocrine pancreatic insufficiency, and elevated sweat chloride, but expression varies widely.

Presenting Symptoms

The majority present within the first year of life. In a prospective Indian cohort (n=313), the most common symptoms were chronic cough (89.5%), poor growth (76.9%), and chronic diarrhoea (62.3%) ^[71]^C4. at birth is a presenting feature in 15-20% of newborns and strongly predicts later bronchiectasis (OR 3.17) ^[203]^B2b. Cough is daily, productive of thick, purulent sputum; sputum purulence correlates with neutrophilic inflammation and protease activity ^[292]^B3b. Wheeze and dyspnoea on exertion appear as airflow obstruction develops. Respiratory symptoms follow a relapsing-remitting course punctuated by acute pulmonary exacerbations, defined by increased cough, sputum volume and purulence, dyspnoea, and decline in FEV1 of ≥10% ^[1]^A1c^[297]^D5. In infants, respiratory symptoms during viral detection are paradoxically less frequent than in healthy controls (17% vs 23%; OR 0.64) ^[286]^B2b. Exacerbations accelerate lung function decline and worsen quality of life ^[288]^B2a.

Neurological and Systemic Examination Findings

Autonomic dysfunction is common: excessive salt loss in sweat leads to hyponatraemic dehydration and heat prostration. Digital clubbing is nearly universal in established disease. Chest examination reveals coarse crackles, often over the upper lobes, and prolonged expiration with wheeze. Hyperinflation (barrel chest) and use of accessory muscles signal advanced obstruction. CFTR expression in the nervous system has been documented ^[293]^D5, and patients may report neuropathic pain or exhibit subtle autonomic abnormalities, though a formal neurological exam is usually normal. Musculoskeletal findings include hypertrophic pulmonary osteoarthropathy and, rarely, arthropathy.

Phenotypic Variants

Variant	Key Features	Approximate Frequency
Classic CF	Pancreatic insufficiency, sweat Cl⁻ >60 mmol/L, progressive lung disease,	85-90% of diagnosed patients ^[37]^D5
Atypical (non-classic) CF	Pancreatic sufficiency, sweat Cl⁻ 30-60 mmol/L, later onset, milder lung disease, single-organ involvement (e.g., sinusitis, obstructive azoospermia)	5-15% ^[37]^D5
Pancreatic-sufficient CF	Maintains exocrine function; often diagnosed later; better nutritional status but still at risk for lung disease	Variable; more common in non-classic CF
CF with ABPA	complicates CF in up to 15%; presents with wheeze, eosinophilia, elevated IgE, and radiographic infiltrates ^[36]^D5	2-15%

Red Flags

Any of the following requires urgent evaluation: acute worsening of dyspnoea with respiratory rate >30/min or SpO₂ <90%; haemoptysis (>30 mL suggests active bleeding) ^[311]^B2a; pneumothorax (sudden pleuritic chest pain, deviated trachea); autonomic instability (hyponatraemic seizure, heat stroke); signs of distal intestinal obstruction syndrome (abdominal pain, palpable mass, obstipation). FEV1 decline of >10% predicted from baseline defines a pulmonary exacerbation and mandates prompt treatment ^[1]^A1c^[297]^D5.

Atypical Presentations

Delayed diagnosis is especially common outside Caucasian populations. In Chinese patients, age at diagnosis ranged 10-28 years, and many lacked symptoms ^[55]^C4. Isolated sinus disease, recurrent pancreatitis, or male infertility may be the first clue. ABPA can mimic asthma with wheeze and fleeting infiltrates. In non-CF bronchiectasis, a single CFTR mutation with borderline sweat chloride may still respond to CFTR modulators ^[64]^B3b.

Pearl: In any infant with persistent cough, poor growth, or meconium ileus, sweat chloride testing should be performed, delayed diagnosis is associated with irreversible bronchiectasis at 3 years in >60% of children ^[203]^B2b.

5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)

▸Pulmonary function testing (spirometry for FEV₁ % predicted; LCI in young children) is the primary tool for monitoring lung disease severity and progression.
▸HRCT chest is the imaging gold standard for detecting bronchiectasis, with AI-driven quantification enabling objective longitudinal assessment.
▸Bronchoscopy with BAL has a limited, targeted role in routine CF care; it is reserved for specific microbiological or inflammatory investigations when noninvasive sampling fails.

Dx Diagnostic Essentials: Sweat chloride ≥60 mmol/L on two separate occasions remains the gold standard for establishing the diagnosis of cystic fibrosis [37].

HY High Yield: Lung clearance index (LCI) is more sensitive than FEV₁ for detecting early CF lung disease, a normal FEV₁ does not rule out significant structural changes, especially in children [347,329].

From the clinical presentation of chronic sinopulmonary infection, pancreatic insufficiency, or , the diagnostic trajectory proceeds with confirmatory testing and a comprehensive pulmonary evaluation. The sweat chloride test remains the diagnostic gold standard: a value ≥60 mmol/L on two separate occasions is considered diagnostic, consistent with the 2005 European Diagnostic Working Group algorithm ^[37]^D5. Genetic testing for two CF-causing CFTR mutations provides confirmation when sweat chloride is borderline (30-59 mmol/L) ^[37]^D5. This section focuses on the pulmonary workup that quantifies functional impairment, structural damage, and microbiological status.

Pulmonary Function Testing

Spirometry is the cornerstone of lung function monitoring in CF. Forced expiratory volume in 1 second (FEV₁) expressed as percent predicted best reflects disease severity and prognosis. An obstructive pattern (FEV₁/FVC < lower limit of normal) is typical; FEV₁ declines an average of -1.4% predicted per year without modulator therapy and improves by a mean 13.0 ppFEV₁ after elexacaftor/tezacaftor/ivacaftor initiation ^[379]^C4. Lung volumes measured by plethysmography reveal hyperinflation (increased total lung capacity, elevated residual volume/total lung capacity ratio) as air trapping progresses ^[114]^D5. Diffusing capacity of the lung for carbon monoxide (DLCO) is usually preserved until advanced disease.

The lung clearance index (LCI) from multiple-breath washout testing is more sensitive than FEV₁ for detecting early ventilatory inhomogeneity, especially in children. In a study comparing CF patients and healthy controls, LCI had an area under the receiver operating characteristic curve (AUC) of 0.93 versus 0.88 for FEV₁ in adults ^[347]^C4. LCI also detects treatment response during pulmonary exacerbations, though results may be discordant with FEV₁ in 42.5% of episodes ^[335]^B2a. Preschool LCI testing is standardized by an ATS technical statement for children aged 2-6 years ^[4]^A1c. Arterial blood gases are reserved for advanced disease to identify hypoxemia (PaO₂ <60 mmHg) or hypercapnia (PaCO₂ >45 mmHg), which signal the need for supplemental oxygen or noninvasive ventilation.

Imaging

High-resolution computed tomography (HRCT) of the chest is the imaging gold standard for detecting structural CF lung disease. Bronchiectasis, defined as an airway-to-artery ratio >1, lack of tapering, or visualization within 1 cm of the pleural surface ^[270]^D5, is present in 29% of infants at 3 months and 62% by 3 years of age in newborn-screened populations ^[203]^B2b. Additional findings include peribronchial thickening, mucus plugging, air trapping on expiratory imaging, and tree-in-bud opacities. Visual scoring systems (Bhalla, Brody, PRAGMA-CF) are used in research but are time-consuming. Artificial intelligence-driven volumetric quantification now allows automated assessment; a deep-learning algorithm achieved a Dice similarity coefficient of 0.71 against ground-truth labels and detected significant reductions in peribronchial thickening and mucus volumes after lumacaftor/ivacaftor therapy ^[336]^C4.

Magnetic resonance imaging (MRI) is emerging as a radiation-free alternative. Hyperpolarized ¹²⁹Xe ventilation MRI quantifies ventilation defect percentage (VDP), which predicts future pulmonary exacerbations: patients with abnormal VDP (>3%) had a nearly threefold higher exacerbation incidence rate (2.80; 95%) ^[196]^B2b. After elexacaftor/tezacaftor/ivacaftor initiation, VDP improved by a mean 43% relative reduction in children, with one-third of patients showing VDP improvement despite no change in FEV₁ ^[371]^B2b.

Bronchoscopy and Bronchoalveolar Lavage

Bronchoscopy with bronchoalveolar lavage (BAL) allows direct sampling of the lower respiratory tract for microbiology and inflammation. In young children who cannot expectorate sputum, BAL yields a higher organism detection rate than oropharyngeal cultures and can identify bacteria in 24% of culture-negative cases ^[95]^B3b. However, a randomized controlled trial in infants found that BAL-directed therapy did not improve outcomes compared with standard care based on clinical features and oropharyngeal cultures ^[358]^A1a^[360]^A1a. The CF Foundation guidelines recommend against routine use of BAL for monitoring or guiding initial therapy ^[367]^A1c. BAL is reserved for specific indications: suspected nontuberculous mycobacterial (NTM) infection not confirmed by sputum ^[9]^A1c, workup, or unexplained clinical deterioration ^[342]^D5. Neutrophil elastase activity in BAL fluid is a strong predictor of subsequent bronchiectasis (odds ratio 3.02 for structural lung disease at 3 years) ^[203]^B2b and of imminent pulmonary exacerbations (hazard ratio 3.00 for high neutrophil elastase) ^[345]^B2b.

Diagnostic Algorithm

A structured approach for the pulmonary workup is outlined below:

Step 1: Confirm CF diagnosis with sweat chloride (≥60 mmol/L) and/or CFTR genotyping ^[37]^D5. Step 2: Obtain baseline spirometry (% predicted FEV₁, FVC, FEV₁/FVC). In children <6 years or those unable to perform spirometry, perform multiple-breath washout for LCI ^[4]^A1c. Step 3: Order non-contrast HRCT chest (prefer low-dose protocol ^[332]^C4) to quantify bronchiectasis, air trapping, and mucus plugging. Consider expiratory images for air trapping assessment. Step 4: Collect sputum for routine bacterial culture, including NTM and fungal studies. If sputum is unavailable, obtain a deep throat swab or, for specific unresolved questions, induced sputum or BAL. Step 5: Conduct BAL only when there is a high suspicion for NTM infection, atypical organisms, or ABPA, or when clinical deterioration is unexplained despite negative conventional cultures ^[342]^D5. Step 6: Schedule serial monitoring: spirometry every 2-4 months in stable patients; imaging (CT or MRI) every 2-3 years, or sooner if clinical status changes.

Pearl: In CF, a normal FEV₁ does not exclude significant lung disease, LCI and HRCT frequently detect structural or functional abnormalities years before spirometric decline becomes apparent, particularly in children ^[347]^C4^[203]^B2b.

Key Pulmonary Tests in Cystic Fibrosis

Test	Typical Findings	Clinical Significance
Spirometry (FEV₁ % predicted)	Obstructive pattern; FEV₁ decline -1.4%/yr (pre-modulator)	Disease severity marker; prognostic ^[280]^B3b^[379]^C4
Lung Clearance Index (LCI)	Elevated (normal <7-8 units in adults)	Detects early ventilatory inhomogeneity; more sensitive than FEV₁ in mild disease ^[347]^C4
Plethysmography (TLC, RV/TLC)	Hyperinflation; elevated RV/TLC	Indicates air trapping; correlates with CT gas trapping ^[114]^D5
DLCO	Preserved until advanced disease	Low DLCO suggests emphysema or severe parenchymal destruction
HRCT chest	Bronchiectasis, peribronchial thickening, mucus plugging, air trapping	Gold standard for structural disease; scoring systems (Bhalla, Brody) ^[203]^B2b^[336]^C4
¹²⁹Xe MRI (VDP)	Ventilation defect percentage >3%	Predicts exacerbation risk; more sensitive than FEV₁ to improve after modulator therapy ^[196]^B2b^[371]^B2b
BAL	Neutrophilic inflammation; elevated NE, IL-8	Research and specific diagnostics; predicts bronchiectasis and exacerbations ^[203]^B2b^[345]^B2b

6. Severity, Staging and Risk Stratification

▸FEV₁ percent predicted remains the primary severity classifier (mild >70%, moderate 40-70%, severe <40%) and tracks disease progression.
▸CFTR modulator therapy, especially ETI, dramatically improves FEV₁, LCI, sweat chloride, and exacerbation rates, altering the natural history of severity.
▸Chronic MRSA infection, low BMI, and frequent exacerbations are independent risk factors for severe lung disease and should drive aggressive management.

HY High Yield: Annualized FEV₁ decline >2% predicted per year despite optimal modulator therapy is a red flag for accelerated progression and warrants transplant evaluation.

Once the diagnosis is confirmed, the next step is to quantify disease severity and stratify prognostic risk to guide therapy intensity, surveillance intervals, and timing of lung transplantation referral.

Lung Function-Based Staging

Forced expiratory volume in 1 second (FEV₁) percent predicted remains the cornerstone of severity classification. The Cystic Fibrosis Foundation defines mild disease as FEV₁ >70% predicted, moderate as 40-70%, and severe as <40% ^[172]^A1b. In adults, the annual rate of FEV₁ decline averages -1.36 percentage points per year before CFTR modulator therapy, improving to -0.48 percentage points per year after initiation of dual modulators ^[248]^B2b. The lung clearance index (LCI₂.₅) is a more sensitive marker of early small-airway disease; a decrease of 2.29 units (95% CI 1.97-2.60) was observed in children aged 6-11 years after 24 weeks of elexacaftor/tezacaftor/ivacaftor (ETI) ^[252]^A1b. In school-age children, ETI improved LCI₂.₅ by a median -1.0 units (F/MF) and -0.8 units (F/F) ^[392]^C4.

Multidimensional Severity Scores

No single CF-specific composite score is universally adopted, but the Bhalla score (chest CT) and MRI global score quantify structural lung damage. ETI reduced the MRI global score by a median -4.0 points in F/MF and -3.5 points in F/F children ^[392]^C4. The FACED score (FEV₁, age, chronic Pseudomonas colonization, radiological extension, dyspnea) was developed for non-CF bronchiectasis but has been applied to CF populations ^[395]^B2c. In adults, pulmonary artery enlargement (PA:A ratio >1) on CT is independently associated with a 3.49-fold increased odds of pulmonary exacerbation ^[178]^B2b.

Biomarkers of Disease Activity and Prognosis

Sweat chloride concentration reflects CFTR function and correlates with clinical outcomes. ETI reduced sweat chloride by -51.2 mmol/L (95% CI -55.3 to -47.1) in children ^[252]^A1b and by -41.7 mmol/L (95% CI -43.8 to -39.6) in adults ^[260]^B2b. Sputum neutrophil elastase activity, calprotectin, IL‑1β, and IL‑8 decrease significantly after ETI and correlate with FEV₁ improvement ^[308]^B2b. Neutrophil extracellular traps (NETs) are elevated in CF sputum and associated with more severe lung disease ^[147]^B3b. Body mass index (BMI) is a key nutritional prognosticator; ETI increased BMI z‑score by 0.39 (95% CI 0.19-0.59) over 192 weeks in children ^[387]^C4.

Risk Stratification for Pulmonary Exacerbations

Frequent exacerbations (≥2 per year) predict accelerated lung function decline and increased mortality. Chronic infection with or methicillin-resistant Staphylococcus aureus (MRSA) confers higher risk. In South Africa, chronic MRSA was associated with severe lung disease (adjusted OR 16.75) ^[376]^C4. The presence of p.Arg117His‑5T genotype with a class I/II mutation in trans produces a severity similar to F508del homozygotes, though lung function decline is delayed to older age ^[246]^B2b.

Impact of CFTR Modulators on Severity Trajectory

ETI has transformed the severity landscape. In the PROMISE study, ppFEV₁ improved by 9.76 percentage points (95% CI 8.76-10.76) at 6 months ^[260]^B2b. The annualized rate of ppFEV₁ change after ETI initiation was 0.02 percentage points (95% CI -0.14 to 0.19), indicating no evidence of pulmonary function loss over 4 years ^[262]^C4. In children, ETI reduced the pulmonary exacerbation rate to 0.05 per year ^[387]^C4. Dual modulators (lumacaftor/ivacaftor, tezacaftor/ivacaftor) slowed FEV₁ decline from -1.36 to -0.48% pred/year ^[248]^B2b. Ivacaftor monotherapy in eligible children accelerated height and FVC attainment, with a mean FVC increase of 662 mL in males and 530 mL in females by age 20 ^[224]^B2b.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
Should LCI replace FEV₁ for routine monitoring?	CFF guidelines maintain FEV₁ as primary endpoint for adults ^[172]^A1b	ERS statement supports LCI as sensitive outcome in children ^[392]^C4	Moderate	LCI is complementary, not a replacement, in clinical practice
Is there a role for routine cardiac risk assessment?	ATS/CHEST recommend standard CV risk factor ^[175]^B3b	ESC guidelines do not specifically address CF	Low	CF-specific CV risk calculators are lacking; clinical vigilance is warranted

Pearl: The single most actionable prognostic step is to calculate the annualized FEV₁ decline rate; a loss >2% predicted per year despite optimal modulator therapy should trigger intensification of airway clearance, anti-infective therapy, and early transplant evaluation.

CF Severity Staging by FEV₁ Percent Predicted

Stage	FEV₁ % predicted	Clinical Implications
Mild	>70%	Normal or near-normal function; annual monitoring; early modulator therapy
Moderate	40-70%	Increased exacerbation risk; intensify airway clearance and antibiotics
Severe	<40%	High risk of respiratory failure; evaluate for lung transplantation

Key Risk Factors for Rapid Disease Progression

Risk Factor	Strength of Association	Reference
Chronic MRSA	aOR 16.75 for severe lung disease	^[376]^C4
Low BMI (<18.5 kg/m²)	HR 2.23 per 10-year age increase	^[376]^C4
Frequent exacerbations (≥2/year)	IRR 0.49 reduction with macrolides	^[176]^A1a
p.Arg117His-5T genotype	Similar severity to F508del homozygotes	^[246]^B2b

7. Acute Management and Exacerbation Rescue

▸STOP2 trial established that 10 days of IV antibiotics is non-inferior to 14 days for early responders; 21 days offers no advantage over 14 days.
▸Routine adjunctive corticosteroids do not improve FEV1 recovery or time to next exacerbation and should be avoided.
▸Hypertonic saline during admission improves symptom resolution but does not shorten length of stay.

Rx Drug of Choice: **Drug of choice for inpatient exacerbation:** Ceftazidime 3 g IV thrice daily plus tobramycin 5-10 mg/kg IV once daily [418].

! Warning: Do NOT routinely add systemic corticosteroids; they do not improve FEV1 recovery or reduce subsequent exacerbation risk, and may cause hyperglycemia [285,417,433].

From the severity and risk stratification established in the preceding section, the clinician now faces the acute pulmonary exacerbation (PEx), defined by worsening respiratory symptoms, a drop in percent-predicted FEV1 (ppFEV1), and increased systemic inflammation. The STOP2 trial provides the key evidence base for : intravenous (IV) of 10 days are non-inferior to 14 days in early responders, while prolonged courses beyond 14 days offer no additional benefit ^[251]^A1b.

Step 1: Initial Assessment and Severity Classification

Mild PEx: ppFEV1 > 75% predicted, no hypoxemia (SpO₂ ≥ 94%), CRP < 30 mg/L. Managed as outpatient with increased airway clearance techniques (ACTs) and optional oral antibiotics (e.g., ) if no improvement within 48 h ^[284]^A1b.
Moderate-Severe PEx: ppFEV1 decline ≥ 10% from baseline, SpO₂ < 92% on room air, CRP ≥ 30 mg/L, or need for IV antibiotics ^[461]^B2b. Admit for inpatient care.

Step 2: Antibiotic Therapy (Inpatient)

Empiric dual antipseudomonal coverage is standard.

First-line: 3 g IV thrice daily + tobramycin 5-10 mg/kg IV once daily ^[418]^A1b. For ceftazidime allergy: aztreonam 2 g IV thrice daily ^[418]^A1b.
Duration guided by early response: After 7-10 days of treatment, reassess ppFEV1. If early responder (ppFEV1 improvement ≥ 10 percentage points from nadir), complete 10 total days (non-inferior to 14 days; mean ppFEV1 change 12.8 vs 13.4, difference -0.65 [95% CI -3.3 to 2.0]) ^[251]^A1b. If non-early responder, continue to 14 total days; extending to 21 days is not superior (mean ppFEV1 change 3.3 vs 3.4) ^[251]^A1b.
Continue CFTR modulator therapy (e.g., / / ) throughout the exacerbation; it does not alter antibiotic choice.

Step 3: Airway Clearance and Supportive Care

Hypertonic saline (HS): 4 mL of 7% NaCl inhaled three times daily during admission does not shorten length of stay but improves symptom resolution (congestion, dyspnea, sleep) and increases the likelihood of regaining pre-exacerbation FEV1 (75% vs 57%; number needed to treat = 6) ^[441]^A1b.
MetaNeb®: Twice-daily sessions of oscillating positive expiratory pressure + continuous high-frequency oscillation improved ventilation inhomogeneity (LCI -0.84 units, 95% CI -1.66 to -0.02) compared with usual ACTs ^[282]^A1b. Consider device availability.
Dornase alfa: Continue if already prescribed; the SIMPLIFY trial showed it can be safely discontinued in stable patients on ETI, but during exacerbation there is no evidence to withdraw ^[318]^A1b^[448]^B2b.
Oxygen therapy: Titrate to target SpO₂ ≥ 92%. Long-term oxygen during exacerbation has not been shown to improve survival, but corrects hypoxemia and may improve exercise duration ^[467]^A1a.

Step 4: Adjunctive and Escalation Therapies

Corticosteroids: Do NOT routinely use. Two RCTs, Waters 2024 ( 1 mg/kg twice daily for 7 days in non-responders) and Dovey 2007 (prednisone 2 mg/kg/day for 5 days), failed to show significant improvement in FEV1 recovery or time to next exacerbation ^[417]^A1b^[433]^A1b. Secondary analysis of STOP2 confirmed no benefit (mean ppFEV1 difference -0.2, 95% CI -2.7 to 2.3) ^[285]^B2b. Reserve for specific indications (e.g., ABPA).
(adjunctive): In a single small RCT (n=39), doxycycline 100 mg PO twice daily for 8 days reduced sputum MMP-9 by 63% and improved FEV1 recovery (P<0.05) and time to next exacerbation (P<0.01) ^[419]^A1b. Evidence is too limited for routine use; consider in refractory cases after multidisciplinary discussion.
Non-invasive ventilation (NIV): Indicated for acute hypercapnia (PaCO₂ > 45 mm Hg) or persistent hypoxemia despite oxygen. NIV during sleep increases event-free survival over 12 months (absolute risk reduction 46% at 12 months) ^[323]^A1b.

Step 5: Monitoring and Transition

Daily: Spirometry, SpO₂, symptom scores (e.g., CFQ-R respiratory domain). Check serum tobramycin trough every 2-3 doses.
Discharge criteria: ppFEV1 returned to >90% of baseline, SpO₂ ≥ 94% on room air, symptoms improved.
Step-down to oral antibiotics is not routine; prolonged oral courses after IV do not prevent recurrence ^[251]^A1b. Schedule follow-up within 2 weeks.

Management of CF Pulmonary Exacerbation

Drug	Dose	Route	Frequency	Duration	Notes
Ceftazidime	3 g	IV	thrice daily	10-14 d	First-line for P. aeruginosa ^[418]^A1b
Tobramycin	5-10 mg/kg	IV	once daily	10-14 d	Monitor trough levels
Aztreonam (if allergy)	2 g	IV	thrice daily	10-14 d	Alternative to ceftazidime ^[418]^A1b
Hypertonic saline (7%)	4 mL	inhaled	thrice daily	During admission	Improves symptom resolution ^[441]^A1b

Drug of choice for inpatient exacerbation: Ceftazidime 3 g IV thrice daily plus tobramycin 5-10 mg/kg IV once daily ^[418]^A1b.

Warning: Do NOT routinely add systemic corticosteroids; they do not improve FEV1 recovery or reduce subsequent exacerbation risk, and may cause hyperglycemia ^[285]^B2b^[417]^A1b^[433]^A1b.

Pearl: For adults with CF exacerbation, 10 days of IV antibiotics is non-inferior to 14 days in early responders, and prolonged courses beyond 14 days do not improve outcomes (STOP2) ^[251]^A1b.

8. Long-term and Definitive Management

▸Elexacaftor/tezacaftor/ivacaftor is the most effective CFTR modulator, producing >10 percentage point ppFEV1 gains and >60% exacerbation reduction in eligible patients.
▸Azithromycin and hypertonic saline independently reduce exacerbation frequency and should be continued unless contraindicated or deprescribed after modulator initiation.
▸Lung transplantation offers around 8‑year median survival but benefit in children remains controversial; prognostic models help identify adults likely to benefit.

Rx Drug of Choice: **First‑line CFTR modulator:** elexacaftor/tezacaftor/ivacaftor (ETI) - adult dose: ELX 200 mg + TEZ 100 mg + IVA 150 mg every 12 h; pediatric weight‑based dosing per label [252,262].

Following resolution of an acute exacerbation, the therapeutic priority shifts to preventing future events and arresting disease progression. The backbone of modern long-term care is CFTR modulator therapy, which targets the underlying molecular defect.

Step 1: Initiate CFTR Modulator Therapy

Elexacaftor/tezacaftor/ivacaftor (ETI) is first‑line for patients ≥6 years with at least one F508del allele. In Phe508del‑minimal function genotypes, ETI produced a 13.8‑percentage‑point increase in ppFEV1 at 4 weeks (sustained through 24 weeks), a 63% reduction in pulmonary exacerbations, and a -41.8 mmol/L decrease in sweat chloride ^[268]^A1b (1b). Among children 6-11 years with F/MF genotypes, ETI improved the lung clearance index (LCI₂.₅) by -2.26 units (95% CI -2.71 to -1.81) and ppFEV1 by 11.0 percentage points ^[252]^A1b (1b). Long‑term data over 192 weeks confirm durable benefit: the annualized rate of change in ppFEV1 was 0.02 percentage points (95% CI -0.14 to 0.19), indicating no loss of lung function ^[262]^C4 (4). For patients with gating mutations (e.g., G551D), ivacaftor 150 mg every 12 h improved ppFEV1 by 10.6 percentage points and reduced exacerbation risk by 55% ^[170]^A1b (1b). Dual therapy with tezacaftor/ivacaftor yields a 4.0‑percentage‑point ppFEV1 increase and 35% fewer exacerbations ^[172]^A1b (1b). Lumacaftor/ivacaftor provides a more modest benefit (2.6-4.0 percentage points, 30-39% exacerbation reduction) ^[173]^A1b (1b).

Drug Combination	Population	ppFEV1 Change	Exacerbation Reduction	Sweat Chloride Change	Evidence Level
ETI	F508del‑MF (≥12 yr)	+13.8 points (4 wk) ^[268]^A1b	63% ^[268]^A1b	-41.8 mmol/L ^[268]^A1b	1b
ETI	Children 6-11 yr F/MF	+11.0 points ^[252]^A1b	Not reported	-51.2 mmol/L ^[252]^A1b	1b
Ivacaftor	G551D (≥12 yr)	+10.6 points ^[170]^A1b	55% ^[170]^A1b	-48.1 mmol/L ^[170]^A1b	1b
Tezacaftor/ivacaftor	F508del/F508del	+4.0 points ^[172]^A1b	35% ^[172]^A1b	-8.4 mmol/L ^[172]^A1b	1b
Lumacaftor/ivacaftor	F508del/F508del	+2.6-4.0 points ^[173]^A1b	30-39% ^[173]^A1b	-6.1 mmol/L ^[173]^A1b	1b

Step 2: Adjunctive Chronic Therapies

Add for patients with chronic infection. In the OPTIMIZE trial, azithromycin 3 times weekly reduced the risk of pulmonary exacerbation by 44% (HR 0.56, 95% CI 0.37-0.83) in children with early Pa ^[415]^A1b (1b). Inhaled hypertonic saline (7%, 4 mL twice daily) improves mucociliary clearance; a 48‑week trial showed a 56% relative reduction in exacerbations and a 68‑mL higher FEV1 vs control ^[437]^A1b (1b). Dornase alfa (2.5 mg once daily) is standard but may be discontinued in patients on ETI with ppFEV1 ≥70% without loss of lung function ^[318]^A1b^[448]^B2b (1b, 2b).

Step 3: Airway Clearance and Exercise

Regular airway clearance techniques (ACTs) remain fundamental; Cochrane reviews confirm ACTs improve sputum clearance, though no single method is superior ^[217]^A1a^[301]^A1a^[302]^A1a (1a). Exercise can substitute for ACTs in selected patients; the ACTIVATE‑CF trial showed that adding 3 h/week of vigorous physical activity increased exercise capacity but did not improve FEV1 ^[414]^A1b (1b).

Step 4: Lung Transplantation

Lung transplantation is definitive for end‑stage disease. Among adults with CF and FEV1 ≤50% predicted, a prognostic model incorporating FEV1%, number of IV‑treated exacerbations, and supplemental oxygen need predicted 2‑year death or transplant (C‑statistic 0.75) ^[504]^B2b (2b). Post‑transplant median survival is approximately 8 years ^[505]^B2b (2b).

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
Discontinue mucoactive therapies after ETI?	SIMPLIFY - discontinuing hypertonic saline or dornase alfa is non‑inferior to continuing ^[318]^A1b	Expert opinion - many practitioners continue both for added clearance	Moderate	Shared decision‑making; discontinue only if stable with high ppFEV1
Systemic corticosteroids for exacerbations?	STOP2 analysis - no benefit on ppFEV1 recovery or time to next exacerbation ^[285]^B2b	Select clinicians - prescribe for perceived severe inflammation	Moderate	Avoid routine use; no evidence of improved outcomes

Pearl: Initiate elexacaftor/tezacaftor/ivacaftor as first‑line for all eligible patients ≥6 years; early and sustained use normalizes lung function trajectory and often permits simplification of the chronic treatment regimen ^[262]^C4^[268]^A1b^[510]^C4.

History and Evolution of Treatment

▸Ivacaftor (2011) was the first CFTR modulator, demonstrating a 10.6 percentage point FEV₁ improvement and 55% reduction in exacerbations in G551D patients, ushering in the era of mutation-directed therapy.
▸Elexacaftor/tezacaftor/ivacaftor (2019) achieved a 14.3 percentage point FEV₁ gain and 63% lower exacerbation rate (NNT=3) in F508del-minimal function genotypes, now standard for ~90% of the CF population.
▸SIMPLIFY (2022) showed that discontinuing hypertonic saline or dornase alfa in modulator-responding patients was non-inferior for lung function, enabling reduced treatment burden.
▸Multiple high-potential strategies failed: ataluren (nonsense mutations), inhaled ENaC inhibitors, microbiome-directed antibiotics, and adjunctive corticosteroids for exacerbations.

Long-term strategies evolved iteratively through decades of clinical trials, each phase targeting a different step in the CF disease cascade, before the era of CFTR modulation fundamentally altered the therapeutic landscape.

The Pre-Modulator Era: Targeting Mucus and Infection

Early treatment focused on restoring airway hydration and clearing secretions. The landmark trial by (2006) randomized 164 patients to inhaled 7% hypertonic saline or 0.9% saline twice daily for 48 weeks. While the slope of lung function decline did not differ, the hypertonic-saline group had a 56% relative reduction in pulmonary exacerbations (76% vs. 62% exacerbation-free; absolute risk reduction 14%, NNT = 7) and higher FEV₁ (+68 mL) ^[437]^A1b. (2006) confirmed that hypertonic saline sustained mucus clearance for ≥8 hours and improved FEV₁ by 6.62% vs. baseline ^[269]^A1b. Nebulized (recombinant DNase) was established earlier through phase III data but is not detailed here. Inhaled (420 mg twice daily) improved FEV₁ by 7.0% over 2 weeks in a crossover trial ^[429]^C4. Inhaled evolved from to : (2002) showed tobramycin nebuliser solution improved FEV₁ by 6.7% vs. 0.37% with colistin (p=0.006) ^[532]^A1b. (AZLI, 75 mg three times daily for 28 days) improved FEV₁ by 10.3% predicted and CFQ-R respiratory score by 9.7 points ^[431]^A1b.

Anti-inflammatory strategies had mixed success. given three times weekly to infants (COMBAT CF trial) did not reduce bronchiectasis prevalence at 36 months (88% vs. 94%; OR 0.49, 95% CI 0.12-2.00) but reduced hospital days for exacerbations (mean difference -6.3 days) ^[76]^A1b. Adjunctive (1 mg·kg⁻¹ twice daily, maximum 60 mg·day⁻¹) in non-responders at day 7 of intravenous antibiotics failed to improve FEV₁ recovery (50% vs. 39% achieving >90% baseline; difference 11%, 95% CI -11% to 34%) ^[417]^A1b. (8 days during hospitalization) reduced sputum MMP-9 by 63.2% and prolonged time to next exacerbation (p<0.01) ^[419]^A1b.

The CFTR Modulator Revolution

The first targeted therapy, , a CFTR potentiator, was tested in patients with the G551D gating mutation. In the pivotal phase III trial (Ramsey et al., 2011), ivacaftor 150 mg every 12 hours improved FEV₁ by 10.6 percentage points vs. placebo at 24 weeks, reduced pulmonary exacerbations by 55% (HR not reported; NNT not calculable from reported data), and decreased sweat chloride by -48.1 mmol/L (p<0.001 for all) ^[170]^A1b. This proof-of-concept opened the era of mutation-specific therapy.

For patients homozygous for , the corrector-potentiator combination /ivacaftor was evaluated in two phase III trials (TRAFFIC and TRANSPORT). Pooled analysis showed an absolute FEV₁ improvement of 2.6-4.0 percentage points and a 30-39% reduction in exacerbation rate ^[173]^A1b. However, the magnitude was modest compared with later regimens. /ivacaftor (EVOLVE trial) provided an additional 4.0 percentage point FEV₁ improvement and 35% lower exacerbation rate vs. placebo in F508del homozygotes ^[172]^A1b. /ivacaftor also benefited residual function heterozygotes (EXPAND trial), with a 6.8 percentage point FEV₁ increase vs. placebo ^[171]^A1b.

The next-generation corrector combined with tezacaftor/ivacaftor (ETI) transformed outcomes for patients with at least one F508del allele. In the phase III trial for Phe508del-minimal function genotypes (Middleton et al., 2019), ETI increased FEV₁ by 14.3 percentage points, reduced exacerbations by 63% (HR 0.37, 95% CI 0.25-0.55; NNT = 3 to prevent one exacerbation over 24 weeks), and lowered sweat chloride by -41.8 mmol/L (p<0.001) ^[268]^A1b. In children aged 6-11 years with F/MF genotypes, ETI improved lung clearance index by -2.26 units and FEV₁ by 11.0 percentage points vs. placebo ^[252]^A1b. Real-world data from Denmark (n=392) showed a mean ppFEV₁ improvement of 13.0% and reversal of annual lung function decline from -1.4% to +2.7% per year ^[379]^C4.

The once-daily next-generation combination /tezacaftor/ demonstrated non-inferiority to ETI in SKYLINE trials, with sweat chloride improvements approaching normal values ^[263]^A1b. In children aged 6-11 years, vanzacaftor-based therapy was safe and well-tolerated in a 24-week single-arm study ^[271]^C4.

Lessons from Abandoned and Failed Trials

Several high-profile approaches did not succeed. , a read-through agent for nonsense mutations, failed to improve FEV₁ in the overall population (difference 3.0%, 95% CI -0.8 to 6.3; p=0.12) but showed signals in a subgroup not receiving chronic inhaled tobramycin ^[319]^A1b. The inhaled ENaC inhibitor was terminated after a phase II futility analysis (BALANCE-CF 1) showed no improvement in ppFEV₁ (-0.8% vs. placebo) ^[421]^A1b. (50,000 IU twice daily) was safe but did not improve FEV₁ or sputum clearance ^[255]^A1b. Microbiome-directed antibiotic therapy (CFMATTERS) added a third antibiotic based on sputum sequencing and did not improve FEV₁ recovery (-1.1%, 95% CI -3.9 to 1.7) and trended toward more exacerbations (median 3 vs. 2; p=0.044) ^[418]^A1b. Adjunctive for pulmonary exacerbations in STOP2 analysis showed no benefit in FEV₁ recovery or time to next exacerbation ^[285]^B2b.

Current Questions: Reducing Treatment Burden

With highly effective modulators, the SIMPLIFY study (Mayer-Hamblett et al., 2022) randomized patients on ETI to discontinue or continue or . Discontinuation was non-inferior for 6-week change in ppFEV₁ (non-inferiority margin -3%), and patients who stopped both therapies reported lower treatment burden ^[318]^A1b^[448]^B2b. These data inform the ongoing transition toward minimalist regimens in responder populations.

Pearl: The evolution from symptomatic therapy to CFTR correction has transformed CF from a pediatric fatal disease to a chronic adult condition, the NNT of 3 for exacerbation prevention with ETI ^[268]^A1b is among the most compelling in respiratory medicine, though modulator access remains genotype-limited and challenges of adherence, body image, and long-term safety persist.

Landmark Trials Shaping CF Therapy

Trial (Year)	Intervention	Population	Key Outcome
Ramsey (2011) ^[170]^A1b	Ivacaftor 150 mg q12h	G551D mutation	ΔppFEV₁ +10.6 pts; exacerbations ↓55%
TRAFFIC/TRANSPORT (2015) ^[173]^A1b	Lumacaftor/ivacaftor	F508del homozygotes	ΔppFEV₁ +2.6-4.0 pts; exacerbations ↓30-39%
EVOLVE (2017) ^[172]^A1b	Tezacaftor/ivacaftor	F508del homozygotes	ΔppFEV₁ +4.0 pts; exacerbations ↓35%
Middleton (2019) ^[268]^A1b	Elexacaftor/tezacaftor/ivacaftor	F508del-minimal function	ΔppFEV₁ +14.3 pts; exacerbations ↓63%; NNT=3
SKYLINE (2025) ^[263]^A1b	Vanzacaftor/tezacaftor/deutivacaftor	F508del + others	Non-inferior to ETI; sweat chloride near-normal
SIMPLIFY (2022) ^[318]^A1b	Discontinue HS or DA vs continue	Patients on ETI	6-week ΔppFEV₁ non-inferior (margin -3%)
Elkins (2006) ^[437]^A1b	7% hypertonic saline vs 0.9% saline	All CF	Exacerbations ↓56%; NNT=7
WILLOW (2025) ^[411]^A1b	Brensocatib 10/25 mg	Non-CF bronchiectasis	Prolonged time to first exacerbation (not reviewed here)

9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)

▸Long‑term oxygen therapy lacks robust survival data in CF; NIV during sleep improves event‑free survival.
▸Cardiopulmonary exercise testing (peak work rate ≤49.2% predicted) identifies patients with >45% 2‑year risk of death or lung transplant.
▸Bronchoscopy for routine airway surveillance is not recommended; its role is limited to specific therapeutic indications.
▸Lung transplantation provides a clear survival benefit (69% risk reduction), but Burkholderia cenocepacia and B. gladioli increase post‑transplant mortality.
▸Highly effective CFTR modulators often reverse the indication for transplant listing, but long‑term close monitoring for persistent inflammation and comorbidities is essential.

HY High Yield: In patients with advanced CF (FEV₁ <40% predicted), peak work rate from CPET is a stronger predictor of 2‑year death or transplant than FEV₁ alone, a simple, actionable exercise measure.

! Warning: Infection with Burkholderia cenocepacia (non‑epidemic strains) or B. gladioli substantially increases post‑lung‑transplant mortality; pre‑transplant eradication or alternative strategies should be urgently considered.

As the evolution of CFTR modulator therapy has transformed survival, a growing proportion of patients live long enough to develop advanced lung disease requiring specialised respiratory support and procedural interventions. This section covers the pulmonology‑owned tools beyond the exacerbation algorithm (Section 7) and the inhaler/systemic evidence ladder (Section 8).

Long‑term Oxygen Therapy

Evidence for chronic oxygen supplementation in CF is limited. A Cochrane review of 11 studies (172 participants) found no statistically significant improvement in survival, lung function, or cardiac health with long‑term oxygen therapy ^[467]^A1a^[470]^A1a. Short‑term oxygen during sleep and exercise improves oxygenation but is associated with mild hypercapnia; it modestly prolongs exercise duration ^[467]^A1a. Despite the absence of robust trial data, oxygen is prescribed when resting PaO₂ < 55 mm Hg or SpO₂ < 88%, extrapolating from guidelines. The CF Foundation recommends oxygen for persistent hypoxemia, but clinicians should recognise that the evidence base is weak.

Non‑invasive Ventilation

NIV during sleep improves event‑free survival in adults with CF and sleep desaturation. A 12‑month randomised trial of NIV ± O₂ versus low‑flow oxygen (LFO₂) reported 33% (95% CI 5‑58%) more event‑free survival at 3 months and 46% (95% CI 10‑68%) more at 12 months in the NIV group ^[323]^A1b. No significant differences were seen in spirometry, arterial blood gases, or hospitalisations ^[323]^A1b. NIV is therefore a reasonable adjunct in patients with nocturnal hypoventilation, hypercapnia, or progressive respiratory failure, especially while awaiting lung transplantation. In the era of highly effective modulators, rates of NIV use decline: in the French ETI compassionate programme, NIV use fell by 30% (P < 0.001) ^[474]^C4.

Pulmonary Rehabilitation and Exercise

Exercise training is a core component of CF care. Unsupervised exercise programmes in obstructive lung disease yield clinically meaningful improvements in health‑related quality of life: the St. George’s Respiratory Questionnaire improved by -11.8 points (95% CI -21.2 to -2.3) compared with usual care ^[571]^A1a. A randomised pilot trial of exercise as an airway clearance technique (ExACT) in 48 patients on elexacaftor‑tezacaftor‑ivacaftor showed it was safe, with no serious adverse events, and suggested potential efficacy (FEV₁ change +2.1% predicted vs -0.8% predicted in usual care) ^[320]^A1b. Web‑based physical activity promotion (ActivOnline) after hospital discharge was no better than usual care, partly because baseline activity levels were already high ^[442]^A1b. Inspiratory muscle training (IMT) at high intensity (≥70% MIP) improved exercise capacity, respiratory muscle strength, and endurance in bronchiectasis ^[283]^A1b and in CF meta‑analyses increased maximal work capacity and minute ventilation ^[602]^A1a. Cardiopulmonary exercise testing (CPET) provides independent prognostic information: each 10% predicted increase in peak V̇O₂ reduces the risk of death or lung transplantation by 40% (adjusted HR 0.60, 95% CI 0.43‑0.90) ^[611]^B3b; a peak work rate ≤49.2% predicted identifies a subgroup with 45.2% probability of death/LTx at 2 years versus 10.9% for those above that threshold ^[611]^B3b.

Interventional Pulmonology and Bronchoscopy

Bronchoscopy in CF has a narrow therapeutic role. Routine surveillance bronchoscopy to guide antimicrobial therapy in infants showed no benefit over standard care (oropharyngeal cultures) in a Cochrane review of two trials (187 children) ^[358]^A1a^[360]^A1a. The CF Foundation recommends against bronchoscopy for routine airway cultures, favouring oropharyngeal swabs (grade B) ^[367]^A1c. Endobronchial biopsy is feasible in children as young as 2 months; using large forceps (2.0 mm) and taking at least two specimens yields evaluable tissue in 72% of children ^[570]^C4. Therapeutic bronchoscopy (e.g., for mucus plugging, haemoptysis control) is reserved for selected cases, but the overall evidence for routine bronchoscopic interventions is limited ^[342]^D5. BAL inflammatory markers (IL‑8, neutrophil elastase) predict pulmonary exacerbations ^[345]^B2b but are not yet recommended for routine clinical decision‑making. Pleural drainage for pneumothorax and are rarely needed; the former is managed with chest tube insertion, and the latter is not standard in CF.

Lung Transplantation Referral and Outcomes

Lung transplantation confers a survival benefit: a 69% reduction in the instantaneous risk of death (95% CI 51‑80%) ^[577]^B2b, and 98.9% of CF recipients are expected to achieve a 2‑year survival benefit ^[614]^B3b. The survival benefit is constant above a lung allocation score (LAS) of approximately 50 in CF ^[594]^B2b. Referral should be considered when FEV₁ falls below 30% predicted, especially with hypercapnia (PaCO₂ ≥ 50 mm Hg), frequent exacerbations (≥2/year), or the need for oxygen or NIV ^[583]^B2b^[504]^B2b. Hemoptysis, particularly massive, increases the risk of death or transplant (OR 2.2 overall, OR 3.2 in advanced disease) ^[473]^B2b. Crucially, initiation of elexacaftor‑tezacaftor‑ivacaftor in advanced disease (median FEV₁ 29% predicted) leads to rapid improvement: mean FEV₁ increase of +15.1 percentage points, 50% reduction in oxygen and NIV use, and suspension of transplant listing in many patients ^[576]^B2b^[474]^C4. However, inflammatory stem cell variants persist despite modulator therapy, suggesting that inflammation may not fully resolve ^[482]^D5.

Post‑transplant survival in CF is favourable: 82% at 1 year, 70% at 3 years, 62% at 5 years, and 51% at 10 years in a large UK cohort ^[595]^B2b. Median survival is 7.9 years (95% CI 7.2‑8.6) in the US ^[505]^B2b. Recipients aged ≥30 years have superior survival compared with those aged 18‑29 years (HR 0.44, 95% CI 0.2‑0.9) ^[615]^B3b. Underweight (BMI < 17 kg/m²) does not independently increase mortality (adjusted HR 1.09, 95% CI 0.90‑1.32) ^[505]^B2b. Infection with Burkholderia cenocepacia (non‑epidemic strains) and B. gladioli are associated with higher post‑transplant mortality (HR 2.52 and 2.23, respectively), while B. multivorans is not ^[575]^B2b. Non‑tuberculous mycobacteria, especially M. abscessus, increase the risk of invasive disease but do not preclude transplantation ^[597]^B2b. Chronic lung allograft dysfunction (CLAD) affects 74% at 5 years and 38% at 10 years ^[595]^B2b; risk factors include pseudomonal colonisation ^[590]^B2b and gastro‑oesophageal reflux (GERD, HR 2.89 for BOS) ^[225]^A1a. Endoscopic sinus surgery before transplant may reduce antibiotic use and hospital stay ^[512]^B2a. Socioeconomic disparities exist: Medicaid recipients have 1.56‑fold higher odds of not being accepted for transplant (95% CI 1.27‑1.92) ^[580]^B2b.

Pearl: In patients with advanced CF lung disease, initiation of elexacaftor‑tezacaftor‑ivacaftor can rapidly improve FEV₁ by >15 percentage points and often suspends the need for lung transplantation, but persistent airway inflammation and stem cell variants mean that transplant evaluation should not be prematurely abandoned, reassess at 3‑6 months.

Key Factors in Lung Transplantation Referral for Cystic Fibrosis

Factor	Threshold / Finding	Risk Estimate	Source
FEV₁	≤30% predicted	HR 6.8 for waitlist death	^[583]^B2b
PaCO₂	≥50 mm Hg	HR 6.9 for waitlist death	^[583]^B2b
Pulmonary exacerbations	≥2/year (IV antibiotics)	OR 1.35 per exacerbation	^[504]^B2b
Oxygen therapy	Continuous or nocturnal	OR 3.71 for 2‑year death/LTx	^[504]^B2b
Hemoptysis (massive)	In advanced lung disease (FEV₁<40%)	OR 3.2 for death/LTx	^[473]^B2b
Peak work rate (CPET)	≤49.2% predicted	45.2% vs 10.9% 2‑year death/LTx	^[611]^B3b
Burkholderia cenocepacia	Non‑epidemic strains	HR 2.52 post‑transplant mortality	^[575]^B2b
B. gladioli	Any	HR 2.23 post‑transplant mortality	^[575]^B2b
BMI <17 kg/m²	Alone	Not an absolute contraindication (HR 1.09)	^[505]^B2b

10. Complications

▸Pneumothorax before age 20 reduces long-term survival odds by 98%; early pleurodesis is recommended per CF Foundation guidelines [280].
▸In-hospital mortality for CF patients on invasive mechanical ventilation (non-bridge) is 44.5%, but survival is improving over time [616].
▸Nonpulmonary complications (CVD, CKD, cancer, kidney stones) occur at rates 2-3 times the general population and present a median 20 years earlier, necessitating early screening [617].

! Warning: Pulmonary hypertension (mean PA pressure ≥25 mm Hg) in advanced CF carries a mortality hazard ratio of 4.17 when severe, yet it is frequently underdiagnosed. Echocardiography should be performed at least annually in patients with FEV₁ <40% predicted [625].

HY High Yield: The three strongest independent predictors of death in CF patients requiring mechanical ventilation are female sex (OR 1.54), acute renal failure (OR 1.99), and malnutrition (OR 1.44) [616].

Despite advances in airway clearance and respiratory support, patients with cystic fibrosis remain at risk for a spectrum of pulmonary and systemic complications that require vigilant monitoring and proactive . The evolving adult population, now comprising over 60% of the CF cohort, faces an expanding burden of age-related and treatment-related sequelae ^[633]^B2c.

Pulmonary Complications

Pneumothorax occurs in 3-4% of patients and is associated with significantly reduced survival (OR 0.02 for long-term survival when occurring before transfer to adult care) ^[280]^B3b. CF Foundation guidelines ^[2]^A1c recommend observation for small pneumothoraces, needle aspiration or chest tube drainage for larger or symptomatic ones, and pleurodesis (chemical or surgical) for recurrent episodes. Massive hemoptysis (>240 mL in 24 h) requires bronchial artery embolization (BAE), which achieves immediate hemostasis in 85-95% of cases, though recurrence is common in the setting of chronic parenchymal destruction ^[311]^B2a. BAE is safe even in advanced disease and does not preclude future lung transplantation ^[2]^A1c.

Respiratory failure is the leading cause of death. In patients requiring (IMV) without bridging to transplant, in-hospital mortality is 44.5%, though survival has improved over time (odds ratio per year 0.94) ^[616]^B2c. Female sex (OR 1.54), acute renal failure (OR 1.99), and malnutrition (OR 1.44) independently predict death ^[616]^B2c. Non-invasive ventilation (NIV) improves gas exchange and reduces work of breathing during exacerbations and for nocturnal support ^[120]^A1a.

Pulmonary (PH), defined as mean pulmonary artery pressure ≥25 mm Hg, is present in up to 40% of patients with advanced lung disease and independently doubles mortality risk (for mild PH; for severe PH) ^[625]^B3b. PH involves endothelin-1 and NF-κB pathways, and endothelial dysfunction may be partially reversible with CFTR modulation ^[630]^C4.

Extrapulmonary Complications

CF-related diabetes (CFRD) affects 31% of adults and is associated with worse lung function and higher mortality ^[553]^C4. Screening with annual oral glucose tolerance testing from age 10 is standard. The introduction of highly effective modulator therapy (HEMT) has reduced CFRD incidence ^[633]^B2c. Bone disease, low bone mineral density occurs in 25-35% of adults, responds to calcium plus calcifediol; in non-responders, alendronate increases lumbar spine bone mineral apparent density by 16.3% versus 3.1% with placebo (p = 0.001) ^[622]^A1b.

Chronic kidney disease (CKD; eGFR <60 mL/min/1.73 m²) develops in 3.7 per 1000 person-years, with risk factors including older age, insulin-dependent diabetes (HR 2.34), and number of pulmonary exacerbations (HR 1.13 per exacerbation) ^[644]^B2b. Cardiovascular disease rates are 2.9-fold higher than the general population, occurring a median 20 years earlier ^[617]^B3b. Cancer (especially colorectal, cervical, and lung) is elevated (RR 1.9), prompting earlier starting at age 40 ^[617]^B3b. Cervical dysplasia is common post-transplant (OR 3.98), reinforcing HPV vaccination ^[210]^C4.

Treatment-Related and Hospital-Acquired Complications

Peripherally inserted central catheters (PICCs) have a primary complication rate of 3.11 per 1000 catheter-days (occlusion or thrombosis), with no catheter-related bloodstream infections in contemporary series using ≤4.5 F single-lumen catheters under ultrasound guidance ^[624]^B2b. CFTR modulator therapy, while transformative, causes mild transaminase elevations in 4.5% of patients, transient with calcifediol, and potential drug interactions with immunosuppressants after transplant ^[622]^A1b^[642]^C4. Weight gain shifts BMI distribution, underweight declines from 12.5% to 1.8%, but overweight rises to 27.7%, introducing new cardiometabolic risks ^[642]^C4.

Standard VTE prophylaxis with low molecular weight (e.g., 40 mg subcutaneously daily) is indicated for hospitalized patients, especially those with PICCs or prolonged immobility. Pain management follows a multimodal approach: acetaminophen or NSAIDs for mild pain, opioids for severe procedure-related or fracture pain. Rehabilitation, including early mobilization, ongoing airway clearance, and nutritional optimization, should begin immediately after exacerbation stabilization. Hospital-acquired pneumonia and pressure injury prevention follow standard ICU bundles.

Complication	Frequency	Prevention	Management
Pneumothorax	3-4% ^[280]^B3b	Avoid barotrauma; early pleurodesis	Observation, chest tube, pleurodesis ^[2]^A1c
Massive hemoptysis	1-5% per year	Treat exacerbations; BAE	BAE (first line); surgical resection rarely ^[2]^A1c^[311]^B2a
Respiratory failure (IMV)	6.3% of admissions ^[616]^B2c	NIV, early transplant referral	NIV; IMV with lung-protective ventilation ^[120]^A1a
Pulmonary hypertension	40% in advanced disease ^[625]^B3b	Optimize lung function; CFTR modulators	Pulmonary vasodilators if severe ^[630]^C4
CFRD	31% of adults ^[553]^C4	Annual OGTT screening	Insulin therapy
Bone disease	25-35%	Calcium + vitamin D	Alendronate if no response to supplements ^[622]^A1b
CKD (eGFR <60)	3.7/1000 person-years ^[644]^B2b	Minimize nephrotoxic drugs	Avoid NSAIDs; adjust antibiotic doses
PICC thrombosis	3.11/1000 catheter-days ^[624]^B2b	≤4.5 F single-lumen, US guidance	Anticoagulation, line removal
CFTR modulator AE	Transaminitis 4.5% ^[642]^C4	Monitor LFTs	Dose reduction/discontinuation if >5× ULN

Pearl: Pulmonary hypertension is a potent independent mortality multiplier in advanced CF (HR >4 for severe PH) ^[625]^B3b; screening with echocardiography at least annually in patients with FEV₁ <40% predicted can identify candidates for early transplant referral and targeted vasodilator therapy.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
Pleurodesis before lung transplant	CF Foundation: chemical pleurodesis acceptable ^[2]^A1c	Some transplant centers: avoid due to surgical difficulty	Expert consensus, low-quality evidence	Individualize; surgical pleurodesis may complicate transplant
CFTR modulators post-transplant	Case series suggest benefit for extrapulmonary manifestations ^[511]^B2a	Drug interactions with calcineurin inhibitors require monitoring	Very low certainty	Consider in selected patients with multidisciplinary oversight

11. Prognosis and Natural History

▸Median survival has risen to >50 years for children born in the modulator era, but women still have higher mortality.
▸CFTR modulators (especially ETI) reduce FEV1 decline, improve growth, and lower airway inflammation, bending the natural history curve.
▸Lung clearance index (LCI) is a more sensitive predictor of death or transplantation than FEV1 in early disease.

HY High Yield: LCI >3 z-scores above normal confers a 4% higher hazard of death or lung transplant per unit increase, even after adjusting for FEV1 [585].

Beyond these complications, the trajectory of cystic fibrosis lung disease is defined by progressive decline in lung function punctuated by acute exacerbations, with survival now extending into the fifth decade under modern therapy. The untreated course is one of relentless deterioration: structural airway damage begins in infancy, often before symptoms emerge ^[205]^D5^[661]^D5. Lung function, measured by forced expiratory volume in 1 s (FEV1), declines at a mean rate of 1-3% predicted per year in adults, with faster decline during adolescence and in those chronically infected with ^[3]^A1c^[183]^D5. Exacerbations accelerate this decline; each treated exacerbation is associated with an additional loss of approximately 0.2-0.5% predicted FEV1 that may not fully recover ^[1]^A1c^[251]^A1b.

Survival

Median survival has risen from approximately 6 months in 1938 to >36 years by the early 2000s, driven by centralised care, improved nutrition, airway clearance and ^[3]^A1c^[183]^D5. The Cystic Fibrosis Foundation Patient Registry reported a median predicted survival of **** for children born in 2018, reflecting the impact of CFTR modulator therapies. Women have a higher mortality than men (hazard ratio 1.3-1.6), a disadvantage that persists across age groups and is not fully explained by differences in lung function or infection ^[202]^D5.

Factors That Bend the Curve

CFTR modulators are the most powerful disease-modifying intervention. Ivacaftor, in children and young adults with gating mutations, increased mean FVC by 662 mL (males) and 530 mL (females) by age 20 compared with untreated controls, and accelerated height attainment ^[224]^B2b. Elexacaftor/tezacaftor/ivacaftor (ETI) improves FEV1 by 10% and reduces sputum neutrophil elastase, IL-1β and IL-8 over 2.5 years, with reductions correlating with clinical improvement ^[308]^B2b^[653]^C4. In school-age children (6-11 years), real-world ETI improved lung clearance index (LCI) by -0.79 units and FEV1 by 5.6% predicted at 12 months ^[238]^B2b. In children aged 2-5 years, lumacaftor/ivacaftor improved chest MRI global scores and stabilised LCI trajectories ^[390]^C4.

Inhaled hypertonic saline (7%, twice daily) reduced exacerbation frequency by 56% (relative reduction) over 48 weeks and improved FEV1 by 68 mL ^[437]^A1b. In preschool children, hypertonic saline reduced the percentage of lung volume occupied by abnormal airways by 0.67% on CT (PRAGMA-CF %Disease) ^[423]^A1b. (10 mg/kg three times weekly) in infants reduced hospital days for pulmonary exacerbations by a mean of 6.3 days and decreased antibiotic courses ^[76]^A1b.

Lung clearance index (LCI) is more sensitive than FEV1 in detecting early disease and predicts survival: each 1 z-score increase in LCI is associated with a 4% higher hazard of death or lung transplantation (HR 1.04), even after adjusting for FEV1 ^[585]^B2b. Structural and functional MRI measurements also predict future exacerbations - patients with ventilation defect percent >3% had a nearly threefold higher exacerbation incidence rate (rate ratio 2.80, 95%) ^[196]^B2b.

Lung transplantation remains the only option for end-stage disease. In children with CF, only 5 of 514 listed patients derived a clear survival benefit, and most had a significant estimated risk of harm (283/514) ^[349]^B2b. However, among adults with CF, median survival after lung transplant is approximately 6.0 years (IQR 2.3-11.9), comparable to other indications ^[407]^B2b. Pre-transplant BMI <17 kg/m² is associated with worse post-transplant survival, but BMI recovery within 1 year after transplant mitigates this risk ^[662]^B3b.

Adherence to therapy remains a major modifiable factor. Non-adherence to medications (estimated 53% in bronchiectasis cohorts) and airway clearance (41%) accelerates lung function decline and increases exacerbation risk ^[665]^D5.**

Pearl: The strongest predictor of long-term survival in cystic fibrosis is the rate of FEV1 decline from adolescence through young adulthood - protecting it with early CFTR modulator therapy, meticulous airway clearance, and aggressive treatment of exacerbations is the central goal of care.

12. Special Populations & Pregnancy

▸Pediatric CFTR modulator dosing is weight-based: <30 kg receives half the adult dose; long-term data show sustained lung function improvement and very low exacerbation rates.
▸During pregnancy, highly effective modulator therapy preserves ppFEV₁ and reduces exacerbations, but modulators cross the placenta and safety data remain limited; planned pregnancies yield better maternal and neonatal outcomes.
▸Concomitant azithromycin and intravenous tobramycin during pediatric pulmonary exacerbations is associated with worse lung function recovery and shorter time to next exacerbation.

HY High Yield: In children, avoid systemic corticosteroids for pulmonary exacerbations, they do not improve lung function outcomes [522]. Also avoid combining azithromycin with IV tobramycin during exacerbation treatment [693].

Given the prognostic trajectory outlined above, must be tailored across the lifespan and in special circumstances. Each population demands distinct diagnostic thresholds, treatment modifications, and safety considerations.

Pediatrics

CFTR modulator therapy is now standard in children as young as 6 years. In a phase 3b randomized trial of children aged 6-11 years with F508del/minimal function genotypes, elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) produced a mean decrease in lung clearance index₂.₅ (LCI₂.₅) of 2.29 units (95% CI, 1.97-2.60) versus 0.02 units with placebo, and a between-group difference in ppFEV₁ of 11.0 percentage points (95% CI, 6.9-15.1) ^[252]^A1b. Dosing is weight-based: children <30 kg receive ELX 100 mg once daily/TEZ 50 mg once daily/IVA 75 mg every 12 hours; those ≥30 kg receive the adult dose ^[252]^A1b. Long-term extension data over 192 weeks show sustained improvements in ppFEV₁ (+9.6 percentage points), sweat chloride (-57.9 mmol/L), and a pulmonary exacerbation rate of only 0.05 per year ^[387]^C4. Real-world effectiveness in the PROMISE Pediatric substudy confirmed a mean LCI₂.₅ decrease of -0.79 (95% CI, -1.04 to -0.55) and ppFEV₁ increase of 5.6% (95% CI, 3.4%-7.7%) at 12 months ^[238]^B2b.

For children with F508del homozygosity, dual modulators (lumacaftor/ivacaftor or tezacaftor/ivacaftor) produce a modest ppFEV₁ improvement of 2.3% (p = 0.023) and a mean sweat chloride reduction of 14 mmol/L ^[703]^C4. Inhaled remain central; however, chronic use in children is associated with a lower risk of acquiring new methicillin-resistant Staphylococcus aureus , nontuberculous mycobacteria, and Burkholderia cepacia complex ^[692]^B2b. During pulmonary exacerbations, systemic corticosteroids are not associated with improved lung function outcomes (mean ppFEV₁ difference -0.36; 95% CI, -1.14 to 0.42) ^[522]^B2b. Concomitant azithromycin and intravenous tobramycin during exacerbation treatment is associated with worse ppFEV₁ recovery (-0.93%; 95% CI, -1.78 to -0.07) and shorter time to next exacerbation (HR 1.22; 95% CI, 1.14-1.31) ^[693]^B2b.

Pregnancy

Prepregnancy counseling is essential. Women with CF who become pregnant have similar respiratory trends to nonpregnant peers, but require more intensive monitoring: outpatient visits increase by 62% during pregnancy, and diabetes treatment prevalence more than doubles (from 9.3% to 20.6%) ^[676]^B2b. Babies with CF are more likely to be born preterm (12.7% vs 5%) and have low birth weight (11.9% vs 4.2%), with CF reducing birth weight by a mean -179 g (Denmark) to -210 g (Wales), about 40% mediated through shorter gestation ^[680]^B2b.

CFTR modulator use during pregnancy is increasingly common. In a multicenter retrospective study, women on highly effective modulator therapy (HEMT) had a preserved ppFEV₁ during pregnancy (adjusted mean change +2.60; 95% CI, 0.23-4.97) compared with a decline in unexposed women (-2.36; 95% CI, -3.56 to -1.16), and pulmonary exacerbations decreased after pregnancy in the HEMT group ^[679]^B2b. However, modulators are unlicensed in pregnancy; they cross the placenta and are detectable in breastmilk, with reported associations including infant liver dysfunction and cataracts ^[697]^D5. The MATRIARCH_CF prospective study is actively evaluating maternal and child outcomes ^[697]^D5. Planned pregnancies are associated with higher gestational age (36.9 vs 34 weeks) and birth weight (2639 g vs 2155 g) compared with unplanned pregnancies ^[201]^C4. Lung transplant recipients with CF who become pregnant have a mean FEV₁ decline from 83.9% predicted before pregnancy to 77.3% at 1 year postpartum (p = 0.04), and 10 of 39 developed chronic lung allograft dysfunction after delivery ^[494]^C4.

Elderly

As survival improves, an increasing number of adults with CF reach older age. Data remain sparse, but management should account for age-related comorbidities (cardiovascular disease, osteoporosis, renal impairment) and polypharmacy. CFTR modulator therapy should continue unless contraindicated; dose adjustments for renal or hepatic impairment follow standard prescribing information. Lung function decline may accelerate after age 40, and surveillance for CF-related diabetes and bone disease becomes paramount.

Immunocompromised

Lung transplant recipients with CF are at risk for chronic lung allograft dysfunction and opportunistic infections. Aspergillus species are common; (ABPA) requires systemic corticosteroids and antifungal therapy ^[36]^D5. Nontuberculous mycobacterial (NTM) infection, particularly Mycobacterium abscessus, is challenging. as part of a multidrug regimen is safe and reasonably tolerated: in a cohort including 24 CF patients, 50% converted to negative NTM cultures within 12 months, and only 14% stopped due to adverse drug reactions ^[675]^B3b. demands a high index of suspicion in the non-neutropenic host, including lung transplant recipients, as timely treatment is crucial ^[36]^D5.

Pearl: In children, weight-based dosing of ELX/TEZ/IVA (<30 kg vs ≥30 kg) is critical; avoid concomitant azithromycin and IV tobramycin during exacerbations due to antagonism ^[693]^B2b. In pregnancy, HEMT preserves lung function but safety data are evolving, planned pregnancy and multidisciplinary follow-up improve outcomes ^[679]^B2b^[201]^C4.

Prevention, Screening & Surveillance

▸Annual influenza vaccination is recommended despite the absence of randomized trial evidence, as registry data link influenza season to a 2.1% excess of pulmonary exacerbations [724, 740].
▸Sputum induction is superior to cough swab for pathogen surveillance in young children (pathogen yield 38% vs 14%) and comparable to bronchoalveolar lavage [704].
▸CFTR modulator therapy (ETI) reduces culture positivity for Pseudomonas aeruginosa but may create diagnostic uncertainty; surveillance for cardiometabolic risk factors is warranted [42, 732, 746].

HY High Yield: Annual influenza season is associated with a 2.1% excess of pulmonary exacerbations requiring IV antibiotics in the CF population [724].

Beyond the considerations of pregnancy, a comprehensive preventive framework targeting infection, inflammation, and comorbidities is essential across all life stages. Primary prevention begins with modifiable exposures. Tobacco smoke exposure, present in one-third of children with CF, is a critical target: the CEASE‑CF randomized intervention (nicotine replacement therapy plus counseling) achieved a 78% 7‑day point prevalence reduction and decreased mean hair nicotine from 2.7 to 1.1 ng/mg over 6 months ^[458]^A1b. All caregivers of people with CF (pwCF) should be screened for tobacco use and offered cessation support embedded in the CF care team.

Vaccination

Annual influenza vaccination is recommended for all pwCF aged ≥ 6 months despite the absence of randomized trial evidence; registry data show influenza season is associated with a 2.1% excess of pulmonary exacerbations requiring IV (incidence rate ratio 1.08, 95% CI 1.06‑1.10) ^[724]^B2b^[740]^A1a. (PCV13 followed by PPSV23 according to age) is included in routine childhood schedules, although no CF‑specific trials exist ^[736]^A1a^[742]^A1a. COVID‑19 vaccines induce robust serologic responses after the second and third doses; reduced antibody titers occur in lung transplant recipients, warranting individualized boosting ^[735]^B2a. Human papillomavirus (HPV) vaccination must be prioritized: among adult female CF lung transplant recipients, 35% had abnormal Pap smears and 4 developed , none of those with HPV morbidity had been vaccinated ^[210]^C4. vaccines are not recommended; three randomized trials showed no reduction in chronic infection (relative risk 0.91, 95% CI 0.55‑1.49) ^[739]^A1a^[743]^A1a.

Secondary Prevention and Surveillance

Microbiology surveillance is the cornerstone of early infection detection. Self‑obtained respiratory samples are feasible (99% success) and acceptable, with moderate agreement for any CF pathogen (kappa 0.583) and substantial agreement for methicillin‑susceptible Staphylococcus aureus (kappa 0.748) ^[460]^C4. In non‑expectorating children, sputum induction is superior to cough swab: pathogen yield 38% vs 14% (OR 7.5, 95% CI 3.19‑17.98) and comparable to bronchoalveolar lavage ^[704]^B2b. Annual surveillance BAL in young children tracks neutrophil elastase activity, which is a key predictor of future bronchiectasis (OR 3.02, 95% CI 1.70‑5.35) ^[203]^B2b^[715]^B2b.

Lung function surveillance using the lung clearance index (LCI) from multiple‑breath washout is a sensitive, noninvasive marker of early lung disease. LCI is elevated in infants with CF, worsens with Pseudomonas aeruginosa infection and inflammation, and increases by 0.29 units/year in routine clinical surveillance ^[708]^C4^[716]^B2b. LCI has good positive predictive value (83‑86%) for bronchiectasis in preschool and school‑age children, but poor negative predictive value (50‑55%), it cannot replace CT to exclude structural disease ^[673]^C4.

Chest imaging with ultra‑low‑dose CT (radiation equivalent to two frontal chest X‑rays) is recommended biennially to assess bronchiectasis and trapped air using validated scoring (e.g., PRAGMA‑CF) ^[711]^C4^[710]^D5. Cumulative cancer mortality from annual CT from age 2 is ~ 2% by age 40 and 13% by age 65; biennial scanning halves this risk ^[710]^D5. Cystic fibrosis‑specific magnetic resonance imaging (MRI) is a radiation‑free alternative that detects bronchial artery dilatation (a marker of disease severity) with Youden index 0.62 (cutoff global score 15.5) ^[751]^B2b.

Serologic and biomarker surveillance for P. aeruginosa (antibodies, exhaled hydrogen cyanide) lacks sufficient sensitivity or positive predictive value for routine clinical use ^[728]^C4^[754]^B2b.

Emerging Considerations with CFTR Modulators

Elexacaftor/tezacaftor/ivacaftor (ETI) reduces chronic P. aeruginosa detection from 51.4% to 24.8% , but molecular methods often detect persistent DNA, creating diagnostic uncertainty ^[732]^B2a. ETI also induces weight gain and increases visceral and epicardial fat, even in patients with normal BMI, necessitating surveillance of blood pressure, lipids, and glucose metabolism ^[42]^D5^[746]^C4. Individualized nutritional plans and cardiometabolic risk factor monitoring should accompany modulator therapy.

Cancer Screening

risk is elevated in CF, particularly after lung transplantation (pooled incidence 0.56%, mean time to diagnosis 8.8 years) ^[618]^A1a. Screening should begin at age 40 (or earlier post‑transplant) per expert consensus, with intervals tailored to findings.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
Routine annual BAL in asymptomatic young children	AREST CF programs support annual BAL for infection/inflammation surveillance ^[708]^C4^[711]^C4	Many centers reserve BAL for clinical indication	Low	BAL identifies inflammation that predicts future bronchiectasis, but invasiveness limits universal adoption
Surveillance CT frequency	Biennial low‑dose CT ^[710]^D5	No consensus; annual CT used in some research protocols	Moderate	Balance diagnostic yield against cumulative radiation risk
Role of molecular microbiology during CFTR modulator therapy	Support combining PCR with culture ^[732]^B2a	No recommendation from guidelines	Low	Uncertainty about clinical significance of PCR‑positive/culture‑negative results

Pearl: Annual surveillance with sputum induction outperforms cough swab for pathogen detection in non‑expectorating children (OR 7.5) ^[704]^B2b; the LCI is a practical, non‑invasive tool for monitoring ventilation inhomogeneity but cannot replace CT for detecting bronchiectasis ^[673]^C4.

Summary of Surveillance Modalities in Cystic Fibrosis

Modality	Interval	Indication	Key Evidence
Oropharyngeal swab / sputum culture	Every 3 months	Routine pathogen surveillance	Self‑collection feasible ^[460]^C4; sputum induction superior to cough swab ^[704]^B2b
Bronchoalveolar lavage (BAL)	Annually (age 0‑6)	Detects lower airway inflammation (neutrophil elastase) and infection	Free NE predicts bronchiectasis ^[203]^B2b^[715]^B2b
Lung clearance index (LCI)	Every 3‑6 months	Non‑invasive monitoring of ventilation inhomogeneity	Increases 0.29 units/year; sensitive to infection ^[708]^C4^[716]^B2b
Chest CT (low‑dose)	Biennial	Structural lung disease (bronchiectasis, trapped air)	PRAGMA‑CF scoring; cancer risk ~2% by age 40 ^[710]^D5^[711]^C4
Chest MRI	Annually	Radiation‑free assessment of bronchiectasis, perfusion, BAD	Detects bronchial artery dilatation; correlates with FEV1 ^[751]^B2b
HbA1c, lipids, BP	Annually after ETI start	Cardiometabolic risk factor surveillance	ETI increases visceral fat and blood pressure ^[42]^D5^[746]^C4
Colonoscopy	Starting age 40 or post‑transplant	Colorectal cancer screening	Higher CRC risk post‑transplant (0.56% incidence) ^[618]^A1a

References

[1]
Flume PA, Mogayzel PJ, Robinson KA et al.. “Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations.” American journal of respiratory and critical care medicine (2009). PMID: 19729669 ↗
L1GUIDELINECited in: 1. Definition, Classification and Nomenclature, 4. Clinical Presentation, History and Evolution of Treatment, 11. Prognosis and Natural History
[2]
Flume PA, Mogayzel PJ, Robinson KA et al.. “Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax.” American journal of respiratory and critical care medicine (2010). PMID: 20675678 ↗
L1GUIDELINECited in: 1. Definition, Classification and Nomenclature, History and Evolution of Treatment, 10. Complications
[3]
Flume PA, O'Sullivan BP, Robinson KA et al.. “Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health.” American journal of respiratory and critical care medicine (2007). PMID: 17761616 ↗
L1GUIDELINECited in: 1. Definition, Classification and Nomenclature, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 10. Complications, 11. Prognosis and Natural History
[4]
Robinson PD, Latzin P, Ramsey KA et al.. “Preschool Multiple-Breath Washout Testing. An Official American Thoracic Society Technical Statement.” American journal of respiratory and critical care medicine (2018). PMID: 29493315 ↗
L1GUIDELINECited in: 1. Definition, Classification and Nomenclature, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 12. Special Populations & Pregnancy
[5]
Daley CL, Iaccarino JM, Lange C et al.. “Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline.” The European respiratory journal (2020). PMID: 32636299 ↗
L1GUIDELINECited in: 1. Definition, Classification and Nomenclature, History and Evolution of Treatment, 11. Prognosis and Natural History
[6]
Rumpf CH, Janssen T, Hait RJ et al.. “Mucoid Staphylococcus aureus: A Clinical Trial of Its Prevalence and Association with Lung Function in People with Cystic Fibrosis.” American journal of respiratory and critical care medicine (2025). PMID: 39918841 ↗
L2TRIAL_NONRANDOMCited in: 1. Definition, Classification and Nomenclature, 3. Epidemiology, Etiology and Risk Factors
[7]
Wilschanski M, Miller LL, Shoseyov D et al.. “Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis.” The European respiratory journal (2011). PMID: 21233271 ↗
L2TRIAL_NONRANDOMCited in: 1. Definition, Classification and Nomenclature
[8]
Pasteur MC, Bilton D, Hill AT. “British Thoracic Society guideline for non-CF bronchiectasis.” Thorax (2010). PMID: 20627931 ↗
L1GUIDELINECited in: 1. Definition, Classification and Nomenclature, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), History and Evolution of Treatment
[9]
Floto RA, Olivier KN, Saiman L et al.. “US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis.” Thorax (2016). PMID: 26666259 ↗
L1GUIDELINECited in: 1. Definition, Classification and Nomenclature, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), History and Evolution of Treatment
[10]
Chalmers JD, McHugh BJ, Doherty C et al.. “Mannose-binding lectin deficiency and disease severity in non-cystic fibrosis bronchiectasis: a prospective study.” The Lancet. Respiratory medicine (2013). PMID: 24429128 ↗
L3COHORTCited in: 1. Definition, Classification and Nomenclature, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[11]
Ren CL, Morgan RL, Oermann C et al.. “Cystic Fibrosis Foundation Pulmonary Guidelines. Use of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy in Patients with Cystic Fibrosis.” Annals of the American Thoracic Society (2018). PMID: 29342367 ↗
L1GUIDELINECited in: 1. Definition, Classification and Nomenclature, History and Evolution of Treatment
[12]
Al-Sadeq D, Abunada T, Dalloul R et al.. “Spectrum of mutations of cystic fibrosis in the 22 Arab countries: A systematic review.” Respirology (Carlton, Vic.) (2018). PMID: 30419605 ↗
L2SR_OBSCited in: 1. Definition, Classification and Nomenclature, 3. Epidemiology, Etiology and Risk Factors
[13]
Shapiro AJ, Josephson M, Rosenfeld M et al.. “Accuracy of Nasal Nitric Oxide Measurement as a Diagnostic Test for Primary Ciliary Dyskinesia. A Systematic Review and Meta-analysis.” Annals of the American Thoracic Society (2017). PMID: 28481653 ↗
L1SR_OBSCited in: 1. Definition, Classification and Nomenclature
[14]
McCague AF, Raraigh KS, Pellicore MJ et al.. “Correlating Cystic Fibrosis Transmembrane Conductance Regulator Function with Clinical Features to Inform Precision Treatment of Cystic Fibrosis.” American journal of respiratory and critical care medicine (2019). PMID: 30888834 ↗
L4OTHERCited in: 1. Definition, Classification and Nomenclature, 4. Clinical Presentation
[15]
Loske J, Völler M, Lukassen S et al.. “Pharmacological Improvement of Cystic Fibrosis Transmembrane Conductance Regulator Function Rescues Airway Epithelial Homeostasis and Host Defense in Children with Cystic Fibrosis.” American journal of respiratory and critical care medicine (2024). PMID: 38259174 ↗
L4OTHERCited in: 1. Definition, Classification and Nomenclature, 2. Pathophysiology and Mechanism
[16]
Zhou YH, Gallins PJ, Pace RG et al.. “Genetic Modifiers of Cystic Fibrosis Lung Disease Severity: Whole-Genome Analysis of 7,840 Patients.” American journal of respiratory and critical care medicine (2023). PMID: 36921087 ↗
L2OTHERCited in: 1. Definition, Classification and Nomenclature
[17]
Pincikova T, Paquin-Proulx D, Moll M et al.. “Severely Impaired Control of Bacterial Infections in a Patient With Cystic Fibrosis Defective in Mucosal-Associated Invariant T Cells.” Chest (2018). PMID: 29731053 ↗
L4CASE_REPORTCited in: 1. Definition, Classification and Nomenclature
[18]
Henkle E, Curtis JR, Chen L et al.. “Comparative risks of chronic inhaled corticosteroids and macrolides for bronchiectasis.” The European respiratory journal (2019). PMID: 31000676 ↗
L2OTHERCited in: 1. Definition, Classification and Nomenclature
[19]
Declercq M, de Zeeuw P, Conchinha NV et al.. “Transcriptomic analysis of CFTR-impaired endothelial cells reveals a pro-inflammatory phenotype.” The European respiratory journal (2021). PMID: 33184117 ↗
L5OTHERCited in: 1. Definition, Classification and Nomenclature
[20]
Hardisty GR, Law SM, Carter S et al.. “Ivacaftor modifies cystic fibrosis neutrophil phenotype in subjects with R117H residual function CFTR mutations.” The European respiratory journal (2021). PMID: 32855222 ↗
L4OTHERCited in: 1. Definition, Classification and Nomenclature
[21]
Weckmann M, Bahmer T, Sand JM et al.. “COL4A3 is degraded in allergic asthma and degradation predicts response to anti-IgE therapy.” The European respiratory journal (2021). PMID: 34326188 ↗
L3OTHERCited in: 1. Definition, Classification and Nomenclature
[22]
Hagner M, Albrecht M, Guerra M et al.. “IL-17A from innate and adaptive lymphocytes contributes to inflammation and damage in cystic fibrosis lung disease.” The European respiratory journal (2021). PMID: 33303549 ↗
L3OTHERCited in: 1. Definition, Classification and Nomenclature
[23]
McMahon DB, Carey RM, Kohanski MA et al.. “Neuropeptide regulation of secretion and inflammation in human airway gland serous cells.” The European respiratory journal (2020). PMID: 32029445 ↗
L5OTHERCited in: 1. Definition, Classification and Nomenclature, 2. Pathophysiology and Mechanism
[24]
Fayon M, Hill K, Riberi L et al.. “Guidance for chest-CT in children and adults with cystic fibrosis: A European perspective (part 2: special situations/respiratory complications).” Respiratory medicine (2026). PMID: 42190839 ↗
L1GUIDELINECited in: 1. Definition, Classification and Nomenclature, History and Evolution of Treatment, 10. Complications
[25]
Bell SC, Mall MA, Gutierrez H et al.. “The future of cystic fibrosis care: a global perspective.” The Lancet. Respiratory medicine (2019). PMID: 31570318 ↗
L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature, 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 8. Long-term and Definitive Management, 10. Complications
[26]
Boyle MP, De Boeck K. “A new era in the treatment of cystic fibrosis: correction of the underlying CFTR defect.” The Lancet. Respiratory medicine (2013). PMID: 24429096 ↗
L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature, History and Evolution of Treatment
[27]
Burgel PR, Da Silva J, Girodon E et al.. “Sweat chloride and lung function responses to elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis with two versus one responsive CFTR variants: an analysis of two real-world observational studies.” The Lancet. Respiratory medicine (2025). PMID: 40914184 ↗
L2OTHERCited in: 1. Definition, Classification and Nomenclature
[28]
McCubbrey AL, Curtis JL. “Efferocytosis and lung disease.” Chest (2013). PMID: 23732585 ↗
L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature
[29]
Liou TG. “The Clinical Biology of Cystic Fibrosis Transmembrane Regulator Protein: Its Role and Function in Extrapulmonary Disease.” Chest (2018). PMID: 30359614 ↗
L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature, 3. Epidemiology, Etiology and Risk Factors
[30]
Chotirmall SH, O'Donoghue E, Bennett K et al.. “Sputum Candida albicans presages FEV₁ decline and hospital-treated exacerbations in cystic fibrosis.” Chest (2010). PMID: 20472859 ↗
L2OTHERCited in: 1. Definition, Classification and Nomenclature
[31]
Booton R, Lindsay MA. “Emerging role of MicroRNAs and long noncoding RNAs in respiratory disease.” Chest (2014). PMID: 25010962 ↗
L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature, 8. Long-term and Definitive Management
[32]
Rogan MP, Stoltz DA, Hornick DB. “Cystic fibrosis transmembrane conductance regulator intracellular processing, trafficking, and opportunities for mutation-specific treatment.” Chest (2011). PMID: 21652558 ↗
L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature, 8. Long-term and Definitive Management
[33]
McKone EF, Goss CH, Aitken ML. “CFTR genotype as a predictor of prognosis in cystic fibrosis.” Chest (2006). PMID: 17099022 ↗
L2OTHERCited in: 1. Definition, Classification and Nomenclature
[34]
Dransfield MT, Wilhelm AM, Flanagan B et al.. “Acquired cystic fibrosis transmembrane conductance regulator dysfunction in the lower airways in COPD.” Chest (2013). PMID: 23538783 ↗
L4OTHERCited in: 1. Definition, Classification and Nomenclature
[35]
Chotirmall SH, Smith SG, Gunaratnam C et al.. “Effect of estrogen on pseudomonas mucoidy and exacerbations in cystic fibrosis.” The New England journal of medicine (2012). PMID: 22607135 ↗
L4OTHERCited in: 1. Definition, Classification and Nomenclature, 6. Severity, Staging and Risk Stratification
[36]
Kosmidis C, Denning DW. “The clinical spectrum of pulmonary aspergillosis.” Thorax (2014). PMID: 25354514 ↗
L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature, 4. Clinical Presentation, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History, 12. Special Populations & Pregnancy
[37]
De Boeck K, Wilschanski M, Castellani C et al.. “Cystic fibrosis: terminology and diagnostic algorithms.” Thorax (2005). PMID: 16384879 ↗
L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature, 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[38]
Sosnay PR, Cutting GR. “Interpretation of genetic variants.” Thorax (2013). PMID: 24343785 ↗
L5OTHERCited in: 1. Definition, Classification and Nomenclature
[39]
Maher RE, Cytlak-Chaudhuri UM, Aleem S et al.. “Effect of elexacaftor/tezacaftor/ivacaftor on systemic inflammation in cystic fibrosis.” Thorax (2025). PMID: 40447326 ↗
L2OTHERCited in: 1. Definition, Classification and Nomenclature, 2. Pathophysiology and Mechanism, 8. Long-term and Definitive Management
[40]
Gray RD, Hardisty G, Regan KH et al.. “Delayed neutrophil apoptosis enhances NET formation in cystic fibrosis.” Thorax (2017). PMID: 28916704 ↗
L3OTHERCited in: 1. Definition, Classification and Nomenclature
[41]
Shanthikumar S, Gubbels L, Wong ATC et al.. “Inflammation in preschool cystic fibrosis is of mixed phenotype, extends beyond the lung and is differentially modified by CFTR modulators.” Thorax (2025). PMID: 39929713 ↗
L3OTHERCited in: 1. Definition, Classification and Nomenclature, History and Evolution of Treatment
[42]
Girouard H, Jaber F, Gharib J et al.. “The impact of elexacaftor-tezacaftor-ivacaftor on cardiometabolic risk factors: a systematic review.” European respiratory review : an official journal of the European Respiratory Society (2026). PMID: 41741006 ↗
L5SR_OBSCited in: 1. Definition, Classification and Nomenclature, 13. Prevention, Screening & Surveillance
[43]
Heinz KD, Walsh A, Southern KW et al.. “Exercise versus airway clearance techniques for people with cystic fibrosis.” The Cochrane database of systematic reviews (2022). PMID: 35731672 ↗
L1SR_OBSCited in: 1. Definition, Classification and Nomenclature, 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management, 11. Prognosis and Natural History
[44]
Elkins M, Dentice R. “Timing of hypertonic saline inhalation for cystic fibrosis.” The Cochrane database of systematic reviews (2020). PMID: 32107770 ↗
L1SR_OBSCited in: 1. Definition, Classification and Nomenclature, 8. Long-term and Definitive Management
[45]
Olowoyeye A, Okwundu CI. “Gene therapy for sickle cell disease.” The Cochrane database of systematic reviews (2020). PMID: 33251574 ↗
L1SR_OBSCited in: 1. Definition, Classification and Nomenclature
[46]
Olowoyeye A, Okwundu CI. “Gene therapy for sickle cell disease.” The Cochrane database of systematic reviews (2018). PMID: 30480767 ↗
L1SR_OBSCited in: 1. Definition, Classification and Nomenclature
[47]
Olowoyeye A, Okwundu CI. “Gene therapy for sickle cell disease.” The Cochrane database of systematic reviews (2016). PMID: 27841932 ↗
L1SR_OBSCited in: 1. Definition, Classification and Nomenclature
[48]
Mulimani P, Abas AB, Karanth L et al.. “Treatment of dental and orthodontic complications in thalassaemia.” The Cochrane database of systematic reviews (2023). PMID: 36732291 ↗
L1SR_OBSCited in: 1. Definition, Classification and Nomenclature, 10. Complications
[49]
Chin B, Wee I, Syn NL et al.. “Surgery for chronic arthropathy in people with haemophilia.” The Cochrane database of systematic reviews (2022). PMID: 36448638 ↗
L1SR_OBSCited in: 1. Definition, Classification and Nomenclature
[50]
Wark P, McDonald VM. “Nebulised hypertonic saline for cystic fibrosis.” The Cochrane database of systematic reviews (2009). PMID: 19370568 ↗
L1SR_OBSCited in: 1. Definition, Classification and Nomenclature
[51]
Liu J, Ma L, Yu W et al.. “Genetic and clinical characteristics of pediatric patients with cystic fibrosis: a single-center retrospective study in China.” Orphanet journal of rare diseases (2026). PMID: 41807956 ↗
L4COHORTCited in: 1. Definition, Classification and Nomenclature
[52]
Chen L, A Hoefel G, Pathinayake PS et al.. “Inflammation-induced loss of CFTR-expressing airway ionocytes in non-eosinophilic asthma.” Respirology (Carlton, Vic.) (2024). PMID: 39358991 ↗
L3OTHERCited in: 1. Definition, Classification and Nomenclature, 2. Pathophysiology and Mechanism, 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management
[53]
Schmidt HJ, Bhandari V, Bhandari A et al.. “The future in paediatric respirology.” Respirology (Carlton, Vic.) (2010). PMID: 20409021 ↗
L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature, 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[54]
Bush A, Floto RA. “Pathophysiology, causes and genetics of paediatric and adult bronchiectasis.” Respirology (Carlton, Vic.) (2019). PMID: 30801930 ↗
L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature, 2. Pathophysiology and Mechanism, 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), History and Evolution of Treatment
[55]
Liu Y, Wang L, Tian X et al.. “Characterization of gene mutations and phenotypes of cystic fibrosis in Chinese patients.” Respirology (Carlton, Vic.) (2015). PMID: 25580864 ↗
L4OTHERCited in: 1. Definition, Classification and Nomenclature, 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), History and Evolution of Treatment
[56]
Mall MA. “Unplugging Mucus in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease.” Annals of the American Thoracic Society (2016). PMID: 27115954 ↗
L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature, 2. Pathophysiology and Mechanism
[57]
Kinghorn B, Rosenfeld M, Sullivan E et al.. “Comparison of Longitudinal Outcomes in Children with Primary Ciliary Dyskinesia and Cystic Fibrosis.” Annals of the American Thoracic Society (2024). PMID: 39383539 ↗
L2OTHERCited in: 1. Definition, Classification and Nomenclature, 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification
[58]
King JA, Fenn D, Mossop M et al.. “Changes in Airway Sampling and Pseudomonas aeruginosa Isolation after the Introduction of Elexacaftor/Tezacaftor/Ivacaftor.” Annals of the American Thoracic Society (2026). PMID: 41151043 ↗
L3OTHERCited in: 1. Definition, Classification and Nomenclature
[59]
Solomon GM, Raju SV, Dransfield MT et al.. “Therapeutic Approaches to Acquired Cystic Fibrosis Transmembrane Conductance Regulator Dysfunction in Chronic Bronchitis.” Annals of the American Thoracic Society (2016). PMID: 27115953 ↗
L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature, 3. Epidemiology, Etiology and Risk Factors
[60]
Mossman AK, Svishchuk J, Waddell BJM et al.. “Staphylococcus aureus in Non-Cystic Fibrosis Bronchiectasis: Prevalence and Genomic Basis of High Inoculum β-Lactam Resistance.” Annals of the American Thoracic Society (2022). PMID: 35213810 ↗
L4OTHERCited in: 1. Definition, Classification and Nomenclature, History and Evolution of Treatment
[61]
Carter SC, Franciosi AN, O'Shea KM et al.. “Acute Pulmonary Exacerbation Phenotypes in Patients with Cystic Fibrosis.” Annals of the American Thoracic Society (2022). PMID: 35713619 ↗
L2OTHERCited in: 1. Definition, Classification and Nomenclature
[62]
Adam D, Luczka-Majérus E, Cellier J et al.. “Low-molecular-weight hyaluronic acid improves regeneration of cystic fibrosis airway epithelium.” ERJ open research (2025). PMID: 40726511 ↗
L5OTHERCited in: 1. Definition, Classification and Nomenclature, 2. Pathophysiology and Mechanism
[63]
Ardura-Garcia C, Abellan A, Cuevas-Ocaña S et al.. “ERS International Congress 2021: highlights from the Paediatric Assembly.” ERJ open research (2022). PMID: 35615416 ↗
L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature, 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management
[64]
Papadakis L, Neuringer I, Lee H et al.. “Efficacy of elexacaftor/tezacaftor/ivacaftor in non-cystic fibrosis bronchiectasis patients with a single pathogenic CFTR mutation: a retrospective cohort analysis.” ERJ open research (2025). PMID: 41189580 ↗
L3OTHERCited in: 1. Definition, Classification and Nomenclature, 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[65]
Franciosi AN, Tanzler A, Goodwin J et al.. “Diagnostic agreement among experts assessing adults presenting with possible cystic fibrosis: need for improvement and implications for patient care.” ERJ open research (2022). PMID: 36655218 ↗
L5OTHERCited in: 1. Definition, Classification and Nomenclature
[66]
Green O, Liautaud S, Knee A et al.. “Measuring accuracy of International Classification of Diseases codes in identification of patients with non-cystic fibrosis bronchiectasis.” ERJ open research (2024). PMID: 38500799 ↗
L3OTHERCited in: 1. Definition, Classification and Nomenclature
[67]
Sandot A, Ba I, Massonnaud CR et al.. “Is MUC5B rs35705950 promoter polymorphism associated with chronic lung allograft dysfunction?” ERJ open research (2025). PMID: 41158494 ↗
L3OTHERCited in: 1. Definition, Classification and Nomenclature, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[68]
Simões FB, Kmit A, Amaral MD. “Cross-talk of inflammatory mediators and airway epithelium reveals the cystic fibrosis transmembrane conductance regulator as a major target.” ERJ open research (2021). PMID: 34912883 ↗
L5OTHERCited in: 1. Definition, Classification and Nomenclature
[69]
Zhong L, Xiong Y, Zheng Z et al.. “Effect of short-term inhalation of warm saline atomised gas on patients with non-cystic fibrosis bronchiectasis.” ERJ open research (2020). PMID: 32055629 ↗
L1OTHERCited in: 1. Definition, Classification and Nomenclature, 7. Acute Management and Exacerbation Rescue
[70]
Liberski S, Skulimowski B, Kałużna A et al.. “Ocular surface and anterior segment changes in cystic fibrosis: evidence of a corneal and conjunctival epithelial phenotype - a case-control study.” Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society (2026). PMID: 42086400 ↗
L3CASE_CONTROLCited in: 1. Definition, Classification and Nomenclature, 4. Clinical Presentation
[71]
Bhat JI, Dhochak N, Kumar P et al.. “Clinical Profile of Cystic Fibrosis in India: A Multi-Centric Prospective Study.” Journal of paediatrics and child health (2026). PMID: 42108567 ↗
L4COHORTCited in: 1. Definition, Classification and Nomenclature, 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 10. Complications
[72]
Vasilyeva T, Kashirskaya N, Mukhina A et al.. “A Diagnostic Dilemma: Concurrent Diagnosis of Cystic Fibrosis and Definitive Kabuki Syndrome Type 1.” International journal of molecular sciences (2026). PMID: 41828725 ↗
L4CASE_REPORTCited in: 1. Definition, Classification and Nomenclature
[73]
Fleurent A, Miseur B, Weynand B et al.. “The diagnostic challenge of pancreatic cysts in patients with cystic fibrosis: a case series and review of the literature.” Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society (2026). PMID: 41741305 ↗
L4CASE_REPORTCited in: 1. Definition, Classification and Nomenclature
[74]
Alexander AM, Loo HQ, Askew L et al.. “Intraspecific diversity of Staphylococcus aureus populations isolated from cystic fibrosis respiratory infections.” Microbiology spectrum (2026). PMID: 42405791 ↗
L5OTHERCited in: 1. Definition, Classification and Nomenclature, 8. Long-term and Definitive Management
[75]
Vijaykumar K, Solomon GM, Guimbellot J et al.. “Ivacaftor for Chronic Obstructive Pulmonary Disease: Results from a Phase 2, Randomized Controlled Trial.” American journal of respiratory and critical care medicine (2025). PMID: 39316773 ↗
L1RCTCited in: 2. Pathophysiology and Mechanism, 4. Clinical Presentation, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
[76]
Stick SM, Foti A, Ware RS et al.. “The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial.” The Lancet. Respiratory medicine (2022). PMID: 35662406 ↗
L1RCTCited in: 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 11. Prognosis and Natural History
[77]
Alton EWFW, Armstrong DK, Ashby D et al.. “Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial.” The Lancet. Respiratory medicine (2015). PMID: 26149841 ↗
L1RCTCited in: 2. Pathophysiology and Mechanism
[78]
Young AC, Wilson JW, Kotsimbos TC et al.. “Randomised placebo controlled trial of non-invasive ventilation for hypercapnia in cystic fibrosis.” Thorax (2007). PMID: 17675317 ↗
L1RCTCited in: 2. Pathophysiology and Mechanism, 7. Acute Management and Exacerbation Rescue
[79]
Mika M, Korten I, Qi W et al.. “The nasal microbiota in infants with cystic fibrosis in the first year of life: a prospective cohort study.” The Lancet. Respiratory medicine (2016). PMID: 27180018 ↗
L2COHORTCited in: 2. Pathophysiology and Mechanism
[80]
Torphy TJ, Allen J, Cantin AM et al.. “Considerations for the Conduct of Clinical Trials with Antiinflammatory Agents in Cystic Fibrosis. A Cystic Fibrosis Foundation Workshop Report.” Annals of the American Thoracic Society (2015). PMID: 26146892 ↗
L5TRIAL_NONRANDOMCited in: 2. Pathophysiology and Mechanism, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[81]
Asakura T, Okuda K, Chen G et al.. “Proximal and Distal Bronchioles Contribute to the Pathogenesis of Non-Cystic Fibrosis Bronchiectasis.” American journal of respiratory and critical care medicine (2024). PMID: 38016030 ↗
L4OTHERCited in: 2. Pathophysiology and Mechanism
[82]
McShane PJ, Naureckas ET, Tino G et al.. “Non-cystic fibrosis bronchiectasis.” American journal of respiratory and critical care medicine (2013). PMID: 23898922 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 11. Prognosis and Natural History
[83]
Mall MA, Mayer-Hamblett N, Rowe SM. “Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical Implications.” American journal of respiratory and critical care medicine (2020). PMID: 31860331 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification
[84]
Ramsey KA, Chen ACH, Radicioni G et al.. “Airway Mucus Hyperconcentration in Non-Cystic Fibrosis Bronchiectasis.” American journal of respiratory and critical care medicine (2020). PMID: 31765597 ↗
L4OTHERCited in: 2. Pathophysiology and Mechanism, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[85]
Dransfield M, Rowe S, Vogelmeier CF et al.. “Cystic Fibrosis Transmembrane Conductance Regulator: Roles in Chronic Obstructive Pulmonary Disease.” American journal of respiratory and critical care medicine (2022). PMID: 34982651 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 6. Severity, Staging and Risk Stratification, History and Evolution of Treatment, 10. Complications, 11. Prognosis and Natural History
[86]
Gaston B, Singel D, Doctor A et al.. “S-nitrosothiol signaling in respiratory biology.” American journal of respiratory and critical care medicine (2006). PMID: 16528016 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, History and Evolution of Treatment, 10. Complications
[87]
de Benedictis FM, Bush A. “Corticosteroids in respiratory diseases in children.” American journal of respiratory and critical care medicine (2012). PMID: 21920920 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 8. Long-term and Definitive Management, 10. Complications, 12. Special Populations & Pregnancy
[88]
Schupp JC, Khanal S, Gomez JL et al.. “Single-Cell Transcriptional Archetypes of Airway Inflammation in Cystic Fibrosis.” American journal of respiratory and critical care medicine (2020). PMID: 32603604 ↗
L4OTHERCited in: 2. Pathophysiology and Mechanism
[89]
Mall MA, Hartl D. “CFTR: cystic fibrosis and beyond.” The European respiratory journal (2014). PMID: 24925916 ↗
L5OTHERCited in: 2. Pathophysiology and Mechanism
[90]
Montgomery ST, Mall MA, Kicic A et al.. “Hypoxia and sterile inflammation in cystic fibrosis airways: mechanisms and potential therapies.” The European respiratory journal (2017). PMID: 28052955 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 10. Complications, 11. Prognosis and Natural History
[91]
Rang C, Keating D, Wilson J et al.. “Re-imagining cystic fibrosis care: next generation thinking.” The European respiratory journal (2020). PMID: 32139465 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism
[92]
Gillan JL, Davidson DJ, Gray RD. “Targeting cystic fibrosis inflammation in the age of CFTR modulators: focus on macrophages.” The European respiratory journal (2021). PMID: 33303535 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 8. Long-term and Definitive Management, 10. Complications
[93]
Hiemstra PS, McCray PB, Bals R. “The innate immune function of airway epithelial cells in inflammatory lung disease.” The European respiratory journal (2015). PMID: 25700381 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism
[94]
Frayman KB, Macowan M, Caparros-Martin J et al.. “The longitudinal microbial and metabolic landscape of infant cystic fibrosis: the gut-lung axis.” The European respiratory journal (2024). PMID: 38485151 ↗
L2OTHERCited in: 2. Pathophysiology and Mechanism
[95]
Zemanick ET, Wagner BD, Robertson CE et al.. “Airway microbiota across age and disease spectrum in cystic fibrosis.” The European respiratory journal (2017). PMID: 29146601 ↗
L3OTHERCited in: 2. Pathophysiology and Mechanism, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[96]
Nussstein H, Urbantat RM, Fentker K et al.. “Changes in sputum viscoelastic properties and airway inflammation in primary ciliary dyskinesia are comparable to cystic fibrosis on elexacaftor/tezacaftor/ivacaftor therapy.” The European respiratory journal (2026). PMID: 40967762 ↗
L4OTHERCited in: 2. Pathophysiology and Mechanism, 6. Severity, Staging and Risk Stratification
[97]
Meiners S, Eickelberg O. “What shall we do with the damaged proteins in lung disease? Ask the proteasome!” The European respiratory journal (2012). PMID: 22441749 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism
[98]
Budden KF, Shukla SD, Rehman SF et al.. “Functional effects of the microbiota in chronic respiratory disease.” The Lancet. Respiratory medicine (2019). PMID: 30975495 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism
[99]
Sermet-Gaudelus I, Letierce A, Berteloot L et al.. “Effect of elexacaftor-tezacaftor-ivacaftor on bronchial dilatations in adolescents with cystic fibrosis: a multicentre prospective observational study.” The Lancet. Respiratory medicine (2025). PMID: 41138737 ↗
L2OTHERCited in: 2. Pathophysiology and Mechanism
[100]
Hirota N, Martin JG. “Mechanisms of airway remodeling.” Chest (2013). PMID: 24008953 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism
[101]
Gentzsch M, Mall MA. “Ion Channel Modulators in Cystic Fibrosis.” Chest (2018). PMID: 29750923 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism
[102]
Donnelly LE, Barnes PJ. “Defective phagocytosis in airways disease.” Chest (2012). PMID: 22474147 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[103]
Elizur A, Cannon CL, Ferkol TW. “Airway inflammation in cystic fibrosis.” Chest (2008). PMID: 18252915 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[104]
Donaldson SH, Boucher RC. “Sodium channels and cystic fibrosis.” Chest (2007). PMID: 17998363 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism
[105]
Tibboel J, Reiss I, de Jongste JC et al.. “Sphingolipids in lung growth and repair.” Chest (2014). PMID: 24394822 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[106]
Shi W, Bellusci S, Warburton D. “Lung development and adult lung diseases.” Chest (2007). PMID: 17699136 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism
[107]
Polverino E, Rosales-Mayor E, Dale GE et al.. “The Role of Neutrophil Elastase Inhibitors in Lung Diseases.” Chest (2017). PMID: 28442313 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism
[108]
Patterson KC, Strek ME. “Diagnosis and treatment of pulmonary aspergillosis syndromes.” Chest (2014). PMID: 25367472 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue
[109]
Twaddell SH, Baines KJ, Grainge C et al.. “The Emerging Role of Neutrophil Extracellular Traps in Respiratory Disease.” Chest (2019). PMID: 31265835 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism
[110]
Haq IJ, Gray MA, Garnett JP et al.. “Airway surface liquid homeostasis in cystic fibrosis: pathophysiology and therapeutic targets.” Thorax (2015). PMID: 26719229 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism
[111]
Bradley KL, Stokes CA, Marciniak SJ et al.. “Role of unfolded proteins in lung disease.” Thorax (2020). PMID: 33077618 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 11. Prognosis and Natural History
[112]
Cohen-Cymberknoh M, Kerem E, Ferkol T et al.. “Airway inflammation in cystic fibrosis: molecular mechanisms and clinical implications.” Thorax (2013). PMID: 23704228 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 11. Prognosis and Natural History
[113]
Loebinger MR, Bilton D, Wilson R. “Upper airway 2: Bronchiectasis, cystic fibrosis and sinusitis.” Thorax (2009). PMID: 19952235 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism
[114]
Petousi N, Talbot NP, Pavord I et al.. “Measuring lung function in airways diseases: current and emerging techniques.” Thorax (2019). PMID: 31036773 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, History and Evolution of Treatment, 11. Prognosis and Natural History
[115]
Chang AB, Bilton D. “Exacerbations in cystic fibrosis: 4--Non-cystic fibrosis bronchiectasis.” Thorax (2008). PMID: 18308962 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors
[116]
Bayfield KJ, Douglas TA, Rosenow T et al.. “Time to get serious about the detection and monitoring of early lung disease in cystic fibrosis.” Thorax (2021). PMID: 33927017 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[117]
Goss CH, Burns JL. “Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis.” Thorax (2007). PMID: 17387214 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 10. Complications
[118]
Scocca V, Lauda L, Nocini R et al.. “Nasal Epithelial Organoids as Translational Platforms in Inflammatory, Infectious, and Precision Medicine Applications: A Systematic Review.” Journal of clinical medicine (2026). PMID: 42278883 ↗
L5SR_OBSCited in: 2. Pathophysiology and Mechanism, 11. Prognosis and Natural History
[119]
Lee AL, Burge AT, Holland AE. “Airway clearance techniques for bronchiectasis.” The Cochrane database of systematic reviews (2015). PMID: 26591003 ↗
L1SR_OBSCited in: 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 11. Prognosis and Natural History
[120]
Moran F, Bradley JM, Piper AJ. “Non-invasive ventilation for cystic fibrosis.” The Cochrane database of systematic reviews (2017). PMID: 28218802 ↗
L1SR_OBSCited in: 2. Pathophysiology and Mechanism, 7. Acute Management and Exacerbation Rescue, 10. Complications
[121]
Moran F, Bradley JM, Piper AJ. “Non-invasive ventilation for cystic fibrosis.” The Cochrane database of systematic reviews (2013). PMID: 23633308 ↗
L1SR_OBSCited in: 2. Pathophysiology and Mechanism, 7. Acute Management and Exacerbation Rescue
[122]
Kapur N, Petsky HL, Bell S et al.. “Inhaled corticosteroids for bronchiectasis.” The Cochrane database of systematic reviews (2018). PMID: 29766487 ↗
L1SR_OBSCited in: 2. Pathophysiology and Mechanism, 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue
[123]
Pizzutto SJ, Upham JW, Yerkovich ST et al.. “Inhaled non-steroid anti-inflammatories for children and adults with bronchiectasis.” The Cochrane database of systematic reviews (2016). PMID: 26816298 ↗
L1SR_OBSCited in: 2. Pathophysiology and Mechanism
[124]
Nevitt SJ, Thornton J, Murray CS et al.. “Inhaled mannitol for cystic fibrosis.” The Cochrane database of systematic reviews (2020). PMID: 32358807 ↗
L1SR_OBSCited in: 2. Pathophysiology and Mechanism
[125]
Moran F, Bradley JM, Piper AJ. “Non-invasive ventilation for cystic fibrosis.” The Cochrane database of systematic reviews (2009). PMID: 19160211 ↗
L1SR_OBSCited in: 2. Pathophysiology and Mechanism
[126]
Nevitt SJ, Thornton J, Murray CS et al.. “Inhaled mannitol for cystic fibrosis.” The Cochrane database of systematic reviews (2018). PMID: 29424930 ↗
L1SR_OBSCited in: 2. Pathophysiology and Mechanism
[127]
Goldbeck L, Fidika A, Herle M et al.. “Psychological interventions for individuals with cystic fibrosis and their families.” The Cochrane database of systematic reviews (2014). PMID: 24941199 ↗
L1SR_OBSCited in: 2. Pathophysiology and Mechanism, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[128]
Nolan SJ, Thornton J, Murray CS et al.. “Inhaled mannitol for cystic fibrosis.” The Cochrane database of systematic reviews (2015). PMID: 26451533 ↗
L1SR_OBSCited in: 2. Pathophysiology and Mechanism
[129]
Schultz A, Stick S. “Early pulmonary inflammation and lung damage in children with cystic fibrosis.” Respirology (Carlton, Vic.) (2015). PMID: 25823858 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism
[130]
Williams BJ, Dehnbostel J, Blackwell TS. “Pseudomonas aeruginosa: host defence in lung diseases.” Respirology (Carlton, Vic.) (2010). PMID: 20723140 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism
[131]
Taylor SL, O'Farrell HE, Simpson JL et al.. “The contribution of respiratory microbiome analysis to a treatable traits model of care.” Respirology (Carlton, Vic.) (2018). PMID: 30282116 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[132]
Sibila O, Suarez-Cuartin G, Rodrigo-Troyano A et al.. “Secreted mucins and airway bacterial colonization in non-CF bronchiectasis.” Respirology (Carlton, Vic.) (2015). PMID: 26172851 ↗
L2OTHERCited in: 2. Pathophysiology and Mechanism
[133]
Reyne N, Smith R, Cmielewski P et al.. “Functional Lung Imaging Identifies Peripheral Ventilation Changes in ꞵ-ENaC Mice.” Respirology (Carlton, Vic.) (2025). PMID: 39998270 ↗
L5OTHERCited in: 2. Pathophysiology and Mechanism
[134]
Finch S, Keir HR, Dicker AJ et al.. “The past decade in bench research into pulmonary infectious diseases: What do clinicians need to know?” Respirology (Carlton, Vic.) (2017). PMID: 28657170 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 8. Long-term and Definitive Management
[135]
O'Neill K, Einarsson GG, Rowan S et al.. “Composition of airway bacterial community correlates with chest HRCT in adults with bronchiectasis.” Respirology (Carlton, Vic.) (2019). PMID: 31364220 ↗
L4OTHERCited in: 2. Pathophysiology and Mechanism
[136]
Bleakley AS, Kho S, Binks MJ et al.. “Extracellular traps are evident in Romanowsky-stained smears of bronchoalveolar lavage from children with non-cystic fibrosis bronchiectasis.” Respirology (Carlton, Vic.) (2023). PMID: 37648649 ↗
L4OTHERCited in: 2. Pathophysiology and Mechanism
[137]
Whitsett JA. “Airway Epithelial Differentiation and Mucociliary Clearance.” Annals of the American Thoracic Society (2018). PMID: 30431340 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 4. Clinical Presentation
[138]
Xie Y, Ostedgaard L, Abou Alaiwa MH et al.. “Mucociliary Transport in Healthy and Cystic Fibrosis Pig Airways.” Annals of the American Thoracic Society (2018). PMID: 30431346 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[139]
Ward SA, Grocott MPW, Levett DZH. “Exercise Testing, Supplemental Oxygen, and Hypoxia.” Annals of the American Thoracic Society (2017). PMID: 28590162 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 7. Acute Management and Exacerbation Rescue
[140]
Shei RJ, Peabody JE, Rowe SM. “Functional Anatomic Imaging of the Airway Surface.” Annals of the American Thoracic Society (2018). PMID: 30431349 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 11. Prognosis and Natural History
[141]
Benam KH, Vladar EK, Janssen WJ et al.. “Mucociliary Defense: Emerging Cellular, Molecular, and Animal Models.” Annals of the American Thoracic Society (2018). PMID: 30431350 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism
[142]
Vermaut A, Geudens V, Willems L et al.. “Airway Remodeling in Cystic Fibrosis Is Heterogeneous.” Annals of the American Thoracic Society (2025). PMID: 39700513 ↗
L3OTHERCited in: 2. Pathophysiology and Mechanism, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[143]
Mall MA, Danahay H, Boucher RC. “Emerging Concepts and Therapies for Mucoobstructive Lung Disease.” Annals of the American Thoracic Society (2018). PMID: 30431343 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 7. Acute Management and Exacerbation Rescue
[144]
Boisvert AA, Cheng MP, Sheppard DC et al.. “Microbial Biofilms in Pulmonary and Critical Care Diseases.” Annals of the American Thoracic Society (2016). PMID: 27348071 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[145]
Kantar A, Song WJ, Bush A et al.. “Cough in non-cystic fibrosis bronchiectasis.” ERJ open research (2024). PMID: 39624376 ↗
L5OTHERCited in: 2. Pathophysiology and Mechanism, 4. Clinical Presentation, 11. Prognosis and Natural History
[146]
Yaacoby-Bianu K, Cohen R, Shteinberg M. “Screening and monitoring across the lifespan of an ageing cystic fibrosis population.” ERJ open research (2025). PMID: 41158492 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 10. Complications, 11. Prognosis and Natural History
[147]
Law SM, Hardisty G, Gillan JL et al.. “Neutrophil extracellular traps are associated with airways inflammation and increased severity of lung disease in cystic fibrosis.” ERJ open research (2024). PMID: 39624379 ↗
L3OTHERCited in: 2. Pathophysiology and Mechanism, 6. Severity, Staging and Risk Stratification
[148]
Kim MD, Baumlin N, Dennis JS et al.. “Losartan reduces cigarette smoke-induced airway inflammation and mucus hypersecretion.” ERJ open research (2021). PMID: 33532463 ↗
L2OTHERCited in: 2. Pathophysiology and Mechanism
[149]
Poore TS, Nguyen A, Schaefers L et al.. “Aspergillus fumigatus is influenced by mucus accumulation, airway inflammation and cystic fibrosis transmembrane conductance regulator function.” ERJ open research (2025). PMID: 41031100 ↗
L4OTHERCited in: 2. Pathophysiology and Mechanism
[150]
Diemer S, Chowdhury S, Sahl C et al.. “Characterisation of airway inflammation and proteomes associated with cystic fibrosis-related diabetes.” ERJ open research (2025). PMID: 41220822 ↗
L3OTHERCited in: 2. Pathophysiology and Mechanism
[151]
Allegretta C, Montemitro E, Sgobba MN et al.. “Deleterious effect of Pseudomonas aeruginosa on F508del-CFTR rescued by elexacaftor/tezacaftor/ivacaftor is clinical strain-dependent in patient-derived nasal cells.” ERJ open research (2025). PMID: 40432819 ↗
L5OTHERCited in: 2. Pathophysiology and Mechanism, 7. Acute Management and Exacerbation Rescue
[152]
Lam GY, Goodwin J, Wilcox PG et al.. “Sex disparities in cystic fibrosis: review on the effect of female sex hormones on lung pathophysiology and outcomes.” ERJ open research (2021). PMID: 33532475 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism
[153]
Mizutani M, Bérubé J, Ahlgren HG et al.. “Corticosteroid-resistant inflammatory signalling in Pseudomonas-infected bronchial cells.” ERJ open research (2017). PMID: 28656134 ↗
L4OTHERCited in: 2. Pathophysiology and Mechanism, 7. Acute Management and Exacerbation Rescue
[154]
Pyzia Ł, Francuz T, Pyzia S et al.. “Changes in peripheral blood leukocyte profiles during elexacaftor/tezacaftor/ivacaftor therapy in cystic fibrosis according to baseline lung function.” Respiratory medicine (2026). PMID: 42431153 ↗
L2OTHERCited in: 2. Pathophysiology and Mechanism
[155]
Sun Y, Hu B, Harris Z et al.. “Staphylococcus aureus superantigens drive a concentration-dependent neutrophilic or eosinophilic pulmonary inflammation in mouse models of cystic fibrosis.” Journal of immunology (Baltimore, Md. : 1950) (2026). PMID: 42419962 ↗
L5OTHERCited in: 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[156]
Khampang P, Brockman KL. “Establishment of a chinchilla model of Achromobacter xylosoxidans-induced otitis media.” Microbiology spectrum (2026). PMID: 42405782 ↗
L5OTHERCited in: 2. Pathophysiology and Mechanism, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[157]
Hu Z, Yang L, Ma Y et al.. “Structural and cellular mechanisms of mucus plugging in the larger airways.” Chinese medical journal pulmonary and critical care medicine (2026). PMID: 42396192 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors
[158]
Ivanova MM, Dimitrova PA, Leseva MN. “RNA modifications shape innate immunity and cellular adaptation during bacterial respiratory infection.” Frontiers in immunology (2026). PMID: 42327744 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism
[159]
Sufian S. “Menopause in rare diseases: Shared research concerns and the case for a dedicated subfield.” Maturitas (2026). PMID: 42308878 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism
[160]
Zou Y, Zhao H, Feng M et al.. “Remodeling the pathological airway: advanced nanotechnology for diagnostics and therapeutics in cystic fibrosis.” Journal of nanobiotechnology (2026). PMID: 42298581 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism
[161]
Badaoui M, Luscher A, Ma M et al.. “Cx43 levels guide apicobasal polarity in regenerating airway epithelial cells.” Communications biology (2026). PMID: 42286068 ↗
L5OTHERCited in: 2. Pathophysiology and Mechanism
[162]
Ofori AD, Nasimi Z, Ackah FK et al.. “Genomic Basis of Lifestyle Divergence in Rice-Associated Burkholderia: From Pathogenesis to Plant Growth Promotion.” International journal of molecular sciences (2026). PMID: 42278262 ↗
L5OTHERCited in: 2. Pathophysiology and Mechanism
[163]
Donaldson SH, Pilewski JM, Griese M et al.. “Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR.” American journal of respiratory and critical care medicine (2018). PMID: 28930490 ↗
L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
[164]
Haworth CS, Bilton D, Chalmers JD et al.. “Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials.” The Lancet. Respiratory medicine (2019). PMID: 30658914 ↗
L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 11. Prognosis and Natural History
[165]
Hewer SCL, Smyth AR, Brown M et al.. “Intravenous versus oral antibiotics for eradication of Pseudomonas aeruginosa in cystic fibrosis (TORPEDO-CF): a randomised controlled trial.” The Lancet. Respiratory medicine (2020). PMID: 33007285 ↗
L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 7. Acute Management and Exacerbation Rescue, History and Evolution of Treatment
[166]
Valery PC, Morris PS, Byrnes CA et al.. “Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial.” The Lancet. Respiratory medicine (2013). PMID: 24461664 ↗
L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors
[167]
Saferali A, Qiao D, Kim W et al.. “C FTR variants are associated with chronic bronchitis in smokers.” The European respiratory journal (2022). PMID: 34996830 ↗
L2SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, History and Evolution of Treatment
[168]
Barry PJ, Mall MA, Álvarez A et al.. “Triple Therapy for Cystic Fibrosis Phe508del-Gating and -Residual Function Genotypes.” The New England journal of medicine (2021). PMID: 34437784 ↗
L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
[169]
Bradley JM, O'Neill B, McAuley DF et al.. “Hypertonic Saline or Carbocisteine in Bronchiectasis.” The New England journal of medicine (2025). PMID: 41020514 ↗
L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 11. Prognosis and Natural History
[170]
Ramsey BW, Davies J, McElvaney NG et al.. “A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.” The New England journal of medicine (2011). PMID: 22047557 ↗
L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
[171]
Rowe SM, Daines C, Ringshausen FC et al.. “Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis.” The New England journal of medicine (2017). PMID: 29099333 ↗
L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
[172]
Taylor-Cousar JL, Munck A, McKone EF et al.. “Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del.” The New England journal of medicine (2017). PMID: 29099344 ↗
L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
[173]
Wainwright CE, Elborn JS, Ramsey BW et al.. “Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.” The New England journal of medicine (2015). PMID: 25981758 ↗
L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
[174]
Shoemark A, Shteinberg M, De Soyza A et al.. “Characterization of Eosinophilic Bronchiectasis: A European Multicohort Study.” American journal of respiratory and critical care medicine (2022). PMID: 35050830 ↗
L4COHORTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[175]
Frost F, Nazareth D, Fauchier L et al.. “Prevalence, risk factors and outcomes of cardiac disease in cystic fibrosis: a multinational retrospective cohort study.” The European respiratory journal (2023). PMID: 37474158 ↗
L3COHORTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification
[176]
Chalmers JD, Boersma W, Lonergan M et al.. “Long-term macrolide antibiotics for the treatment of bronchiectasis in adults: an individual participant data meta-analysis.” The Lancet. Respiratory medicine (2019). PMID: 31405828 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management, 11. Prognosis and Natural History
[177]
Laska IF, Crichton ML, Shoemark A et al.. “The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: a systematic review and meta-analysis.” The Lancet. Respiratory medicine (2019). PMID: 31405826 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[178]
Wells JM, Farris RF, Gosdin TA et al.. “Pulmonary artery enlargement and cystic fibrosis pulmonary exacerbations: a cohort study.” The Lancet. Respiratory medicine (2016). PMID: 27298019 ↗
L2COHORTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[179]
Combs MP, Wheeler DS, Luth JE et al.. “Lung microbiota predict chronic rejection in healthy lung transplant recipients: a prospective cohort study.” The Lancet. Respiratory medicine (2021). PMID: 33460570 ↗
L2COHORTCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 11. Prognosis and Natural History, 13. Prevention, Screening & Surveillance
[180]
Frayman KB, Kazmerski TM, Sawyer SM. “A systematic review of the prevalence and impact of urinary incontinence in cystic fibrosis.” Respirology (Carlton, Vic.) (2017). PMID: 28718995 ↗
L5SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[181]
Davies JC, Polineni D, Boyd AC et al.. “Lentiviral Gene Therapy for Cystic Fibrosis: A Promising Approach and First-in-Human Trial.” American journal of respiratory and critical care medicine (2024). PMID: 39236265 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[182]
Ramsey B, Correll CU, DeMaso DR et al.. “Elexacaftor/Tezacaftor/Ivacaftor Treatment and Depression-related Events.” American journal of respiratory and critical care medicine (2024). PMID: 37890129 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors
[183]
Davis PB. “Cystic fibrosis since 1938.” American journal of respiratory and critical care medicine (2005). PMID: 16126935 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[184]
Albert RK, Schuller JL. “Macrolide antibiotics and the risk of cardiac arrhythmias.” American journal of respiratory and critical care medicine (2014). PMID: 24707986 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors
[185]
Cookson W, Moffatt M, Rapeport G et al.. “A Pandemic Lesson for Global Lung Diseases: Exacerbations Are Preventable.” American journal of respiratory and critical care medicine (2022). PMID: 35192447 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors
[186]
Gardner AI, Haq IJ, Simpson AJ et al.. “Recombinant Acid Ceramidase Reduces Inflammation and Infection in Cystic Fibrosis.” American journal of respiratory and critical care medicine (2020). PMID: 32569477 ↗
L5OTHERCited in: 3. Epidemiology, Etiology and Risk Factors
[187]
Prieto MD, Alam ME, Franciosi AN et al.. “Global burden of nontuberculous mycobacteria in the cystic fibrosis population: a systematic review and meta-analysis.” ERJ open research (2023). PMID: 36605902 ↗
L4SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors
[188]
Midulla F, Lombardi E, Rottier B et al.. “Paediatrics in Barcelona.” The European respiratory journal (2014). PMID: 24833764 ↗
L5OTHERCited in: 3. Epidemiology, Etiology and Risk Factors
[189]
Brand PL, Ratjen F, Aurora P et al.. “Paediatrics in Vienna.” The European respiratory journal (2010). PMID: 20075043 ↗
L5OTHERCited in: 3. Epidemiology, Etiology and Risk Factors
[190]
Eber E, Aurora P, Lødrup Carlsen KC et al.. “Paediatrics in Amsterdam.” The European respiratory journal (2012). PMID: 22362855 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors
[191]
Griese M, Kappler M, Gaggar A et al.. “Inhibition of airway proteases in cystic fibrosis lung disease.” The European respiratory journal (2008). PMID: 18757703 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[192]
Gaggar A, Hector A, Bratcher PE et al.. “The role of matrix metalloproteinases in cystic fibrosis lung disease.” The European respiratory journal (2011). PMID: 21233269 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[193]
Addante A, Raymond W, Gitlin I et al.. “A novel thiol-saccharide mucolytic for the treatment of muco-obstructive lung diseases.” The European respiratory journal (2023). PMID: 37080569 ↗
L5OTHERCited in: 3. Epidemiology, Etiology and Risk Factors
[194]
Dodge JA, Lewis PA, Stanton M et al.. “Cystic fibrosis mortality and survival in the UK: 1947-2003.” The European respiratory journal (2006). PMID: 17182652 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors
[195]
Sibila O, Stobo J, Perea L et al.. “Symptoms, risk of future exacerbations, and response to long-term macrolide treatment in bronchiectasis: an observational study.” The Lancet. Respiratory medicine (2025). PMID: 40885209 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management
[196]
Matheson AM, Bdaiwi AS, Willmering MM et al.. “Structural and Functional Pulmonary MRI to Predict Pulmonary Exacerbations in Cystic Fibrosis.” Chest (2025). PMID: 41241146 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 11. Prognosis and Natural History
[197]
Pittman JE, Ferkol TW. “The Evolution of Cystic Fibrosis Care.” Chest (2015). PMID: 25764168 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, History and Evolution of Treatment, 11. Prognosis and Natural History
[198]
Burgel PR, Burnet E, Regard L et al.. “The Changing Epidemiology of Cystic Fibrosis: The Implications for Adult Care.” Chest (2022). PMID: 35850286 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management, History and Evolution of Treatment, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 10. Complications
[199]
Chin M, Brennan AL, Bell SC. “Emerging Nonpulmonary Complications for Adults With Cystic Fibrosis: Adult Cystic Fibrosis Series.” Chest (2021). PMID: 34774529 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 10. Complications
[200]
Green HD, Jones AM. “Managing Pulmonary Infection in Adults With Cystic Fibrosis: Adult Cystic Fibrosis Series.” Chest (2022). PMID: 35167860 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors
[201]
Lee FG, Coscia LA, Constantinescu S et al.. “Pregnancy Outcomes in 53 Female Lung Transplant Recipients.” Chest (2025). PMID: 40350146 ↗
L4OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 10. Complications, 12. Special Populations & Pregnancy
[202]
Sodhi A, Cox-Flaherty K, Greer MK et al.. “Sex and Gender in Lung Diseases and Sleep Disorders: A State-of-the-Art Review: Part 2.” Chest (2022). PMID: 36183784 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 10. Complications, 11. Prognosis and Natural History, 12. Special Populations & Pregnancy, 13. Prevention, Screening & Surveillance
[203]
Sly PD, Gangell CL, Chen L et al.. “Risk factors for bronchiectasis in children with cystic fibrosis.” The New England journal of medicine (2013). PMID: 23692169 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 13. Prevention, Screening & Surveillance
[204]
Uchida K, Beck DC, Yamamoto T et al.. “GM-CSF autoantibodies and neutrophil dysfunction in pulmonary alveolar proteinosis.” The New England journal of medicine (2007). PMID: 17287477 ↗
L3OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[205]
Regamey N, Jeffery PK, Alton EW et al.. “Airway remodelling and its relationship to inflammation in cystic fibrosis.” Thorax (2010). PMID: 20889525 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 10. Complications, 11. Prognosis and Natural History
[206]
Kwok WC, Pates K, Shah A et al.. “Antimicrobial resistance in chronic lung infection: the road to resistance.” Thorax (2026). PMID: 40623822 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management, 11. Prognosis and Natural History
[207]
Keogh RH, Cosgriff R, Andrinopoulou ER et al.. “Projecting the impact of triple CFTR modulator therapy on intravenous antibiotic requirements in cystic fibrosis using patient registry data combined with treatment effects from randomised trials.” Thorax (2021). PMID: 34556554 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors
[208]
De Soyza A, Brown JS, Loebinger MR. “Research priorities in bronchiectasis.” Thorax (2012). PMID: 23242949 ↗
L5OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification
[209]
Schlüter DK, Ostrenga JS, Carr SB et al.. “Lung function in children with cystic fibrosis in the USA and UK: a comparative longitudinal analysis of national registry data.” Thorax (2021). PMID: 33975926 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors
[210]
Thornton C, Somayaji R, Chu A et al.. “Human papillomavirus (HPV) and cervical dysplasia in adult female cystic fibrosis (CF) lung transplant recipients.” Thorax (2022). PMID: 35121654 ↗
L4OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 8. Long-term and Definitive Management, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 10. Complications, 13. Prevention, Screening & Surveillance
[211]
Prayle A, Watson A, Fortnum H et al.. “Side effects of aminoglycosides on the kidney, ear and balance in cystic fibrosis.” Thorax (2010). PMID: 20627927 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors
[212]
McCullough B, Busby J, O'Neill B et al.. “Mucoactive agents in bronchiectasis: a systematic review and meta-analysis.” European respiratory review : an official journal of the European Respiratory Society (2026). PMID: 42342264 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 11. Prognosis and Natural History
[213]
Hu Y, Diao S, Li H et al.. “The efficacy and safety of inhaled antibiotics in the treatment of lower respiratory tract infection: An updated meta-analysis and evidence map of systematic reviews.” International journal of antimicrobial agents (2026). PMID: 42229866 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History, 12. Special Populations & Pregnancy
[214]
Cao H, Qian Y, Zhang Z. “Genetic diagnosis in fetuses with biliary tract system abnormalities: a meta-analysis and systematic review.” BMC pregnancy and childbirth (2026). PMID: 42218417 ↗
L2SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 13. Prevention, Screening & Surveillance
[215]
Radtke T, Smith S, Nevitt SJ et al.. “Physical activity and exercise training in cystic fibrosis.” The Cochrane database of systematic reviews (2022). PMID: 35943025 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, History and Evolution of Treatment, 11. Prognosis and Natural History
[216]
Rankine-Mullings AE, Nevitt SJ. “Hydroxyurea (hydroxycarbamide) for sickle cell disease.” The Cochrane database of systematic reviews (2022). PMID: 36047926 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management, 10. Complications, 11. Prognosis and Natural History, 13. Prevention, Screening & Surveillance
[217]
Main E, Rand S. “Conventional chest physiotherapy compared to other airway clearance techniques for cystic fibrosis.” The Cochrane database of systematic reviews (2023). PMID: 37144842 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 11. Prognosis and Natural History
[218]
Poole P, Sathananthan K, Fortescue R. “Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease.” The Cochrane database of systematic reviews (2019). PMID: 31107966 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, History and Evolution of Treatment, 11. Prognosis and Natural History
[219]
Janjua S, Carter D, Threapleton CJ et al.. “Telehealth interventions: remote monitoring and consultations for people with chronic obstructive pulmonary disease (COPD).” The Cochrane database of systematic reviews (2021). PMID: 34693988 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management, 11. Prognosis and Natural History
[220]
Olasupo OO, Noronha N, Lowe MS et al.. “Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B.” The Cochrane database of systematic reviews (2024). PMID: 38411279 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 10. Complications
[221]
Lak R, Yazdizadeh B, Davari M et al.. “Newborn screening for galactosaemia.” The Cochrane database of systematic reviews (2020). PMID: 32567677 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management, 10. Complications
[222]
Lak R, Yazdizadeh B, Davari M et al.. “Newborn screening for galactosaemia.” The Cochrane database of systematic reviews (2017). PMID: 29274129 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 10. Complications
[223]
Hsu CC, Kwan GN, Evans-Barns H et al.. “Embolisation for pulmonary arteriovenous malformation.” The Cochrane database of systematic reviews (2018). PMID: 29298459 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 10. Complications
[224]
Guimbellot JS, Baker E, Chalamalla A et al.. “Unlocking growth potential: Ivacaftor therapy and developmental gains in lung and height in a cohort study of children and young adults with cystic fibrosis.” The European respiratory journal (2026). PMID: 42392826 ↗
L2COHORTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management, 11. Prognosis and Natural History
[225]
Tang Y, Deng F, Pan J. “Oropharyngeal dysphagia and gastroesophageal reflux disease in lung transplant patients: a systematic review and meta-analysis of incidence, risk factors, and clinical outcomes.” PeerJ (2026). PMID: 42428524 ↗
L1TRIAL_NONRANDOMCited in: 3. Epidemiology, Etiology and Risk Factors, 8. Long-term and Definitive Management, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[226]
Singh M, Rebordosa C, Bernholz J et al.. “Epidemiology and genetics of cystic fibrosis in Asia: In preparation for the next-generation treatments.” Respirology (Carlton, Vic.) (2015). PMID: 26437683 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[227]
Raghavan D, Jain R. “Increasing awareness of sex differences in airway diseases.” Respirology (Carlton, Vic.) (2015). PMID: 26677803 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors
[228]
Chotirmall SH, Gellatly SL, Budden KF et al.. “Microbiomes in respiratory health and disease: An Asia-Pacific perspective.” Respirology (Carlton, Vic.) (2017). PMID: 28102970 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors
[229]
Tsuji T, Tanaka E, Yasuda I et al.. “Nontuberculous mycobacteria in diffuse panbronchiolitis.” Respirology (Carlton, Vic.) (2014). PMID: 25269823 ↗
L4OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[230]
Navaratnam V, Forrester DL, Eg KP et al.. “Paediatric and adult bronchiectasis: Monitoring, cross-infection, role of multidisciplinary teams and self-management plans.” Respirology (Carlton, Vic.) (2018). PMID: 30500093 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 6. Severity, Staging and Risk Stratification, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 11. Prognosis and Natural History
[231]
Giubergia V, Alessandrini F, Barrias C et al.. “Risk factors for morbidities and mortality in children following pneumonectomy.” Respirology (Carlton, Vic.) (2016). PMID: 27511212 ↗
L4OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 10. Complications
[232]
Gjoerup J, Hilberg O, Bendstrup E. “Inhaled mannitol in the treatment of non-cystic fibrosis bronchiectasis in adults.” Respirology (Carlton, Vic.) (2012). PMID: 22564014 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[233]
Surette MG. “The cystic fibrosis lung microbiome.” Annals of the American Thoracic Society (2014). PMID: 24437409 ↗
L5OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[234]
Griese M, Scheuch G. “Delivery of Alpha-1 Antitrypsin to Airways.” Annals of the American Thoracic Society (2016). PMID: 27564672 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[235]
Cantin AM. “Cystic Fibrosis Transmembrane Conductance Regulator. Implications in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease.” Annals of the American Thoracic Society (2016). PMID: 27115950 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors
[236]
Smith PJ, Rivelli S, Waters A et al.. “Neurocognitive changes after lung transplantation.” Annals of the American Thoracic Society (2014). PMID: 25375275 ↗
L4OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 12. Special Populations & Pregnancy
[237]
Robinson NB, DiMango E. “Prevalence of gastroesophageal reflux in cystic fibrosis and implications for lung disease.” Annals of the American Thoracic Society (2014). PMID: 24964289 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[238]
Pittman JE, Morgan S, McCreary M et al.. “Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in 6- to 11-Year-Olds with Cystic Fibrosis: An Observational Study.” Annals of the American Thoracic Society (2025). PMID: 40540670 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management, 11. Prognosis and Natural History, 12. Special Populations & Pregnancy
[239]
Waters V, Ratjen F. “Pulmonary Exacerbations in Children with Cystic Fibrosis.” Annals of the American Thoracic Society (2015). PMID: 26595740 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management
[240]
Ajayababu A, Antony A, Goyal B et al.. “Prevalence of allergic bronchopulmonary aspergillosis/Aspergillus sensitization in chronic obstructive pulmonary disease: A systematic review and meta-analysis.” Respiratory investigation (2026). PMID: 42361722 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 11. Prognosis and Natural History
[241]
Ardura-Garcia C, Kainz K, Mallet MC et al.. “ERS International Congress 2022: highlights from the Paediatrics Assembly.” ERJ open research (2023). PMID: 37228264 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors
[242]
Ardura-Garcia C, Cuevas-Ocaña S, Freitag N et al.. “ERS International Congress 2020: highlights from the Paediatric Assembly.” ERJ open research (2021). PMID: 33778048 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 8. Long-term and Definitive Management
[243]
Wee WB, Gatt D, Seidl E et al.. “Estimates of primary ciliary dyskinesia prevalence: a scoping review.” ERJ open research (2024). PMID: 39104959 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation
[244]
Jung A, Orenti A, Dunlevy F et al.. “Factors for severe outcomes following SARS-CoV-2 infection in people with cystic fibrosis in Europe.” ERJ open research (2021). PMID: 34984210 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[245]
Cheng WC, Chang CL, Sheu CC et al.. “Cardiovascular disease as a prognostic factor for mortality in non-cystic fibrosis bronchiectasis: data from the Taiwan Bronchiectasis Research Collaboration.” ERJ open research (2025). PMID: 41257181 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 11. Prognosis and Natural History
[246]
Shteinberg M, Downey DG, Beattie D et al.. “Lung function and disease severity in cystic fibrosis patients heterozygous for p.Arg117His.” ERJ open research (2017). PMID: 28845426 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 10. Complications
[247]
Sobala R, Carlin H, Fretwell T et al.. “An observational study of Pseudomonas aeruginosa in adult long-term ventilation.” ERJ open research (2022). PMID: 35449759 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management
[248]
Muilwijk D, Zomer-van Ommen DD, Gulmans VAM et al.. “Long-term effectiveness of dual CFTR modulator treatment of cystic fibrosis.” ERJ open research (2022). PMID: 36382237 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management
[249]
Bar-On O, Less Elazari S, Ben-Zvi H et al.. “Non-tuberculous mycobacteria in primary ciliary dyskinesia: a national multicenter cohort study.” Respiration; international review of thoracic diseases (2026). PMID: 42207757 ↗
L2COHORTCited in: 3. Epidemiology, Etiology and Risk Factors
[250]
Wilson MJ, McLachlan S, Mann C et al.. “The repertoire of yeast species from human clinical samples in the United Kingdom 2016-2022: epidemiology, clinical relevance, and fluconazole resistance.” Microbiology spectrum (2026). PMID: 42405779 ↗
L4OTHERCited in: 3. Epidemiology, Etiology and Risk Factors
[251]
Goss CH, Heltshe SL, West NE et al.. “A Randomized Clinical Trial of Antimicrobial Duration for Cystic Fibrosis Pulmonary Exacerbation Treatment.” American journal of respiratory and critical care medicine (2021). PMID: 34469706 ↗
L1RCTCited in: 4. Clinical Presentation, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 11. Prognosis and Natural History
[252]
Mall MA, Brugha R, Gartner S et al.. “Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study.” American journal of respiratory and critical care medicine (2022). PMID: 35816621 ↗
L1RCTCited in: 4. Clinical Presentation, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 12. Special Populations & Pregnancy
[253]
Martinez FJ, Criner GJ, Gessner C et al.. “Icenticaftor, a CFTR Potentiator, in COPD: A Multicenter, Parallel-Group, Double-Blind Clinical Trial.” American journal of respiratory and critical care medicine (2023). PMID: 37411039 ↗
L1RCTCited in: 4. Clinical Presentation, 7. Acute Management and Exacerbation Rescue
[254]
Mall MA, Wainwright CE, Legg J et al.. “Elexacaftor/tezacaftor/ivacaftor in children aged ≥6 years with cystic fibrosis heterozygous for F508del and a minimal function mutation: results from a 96-week open-label extension study.” The European respiratory journal (2025). PMID: 40210412 ↗
L4RCTCited in: 4. Clinical Presentation, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
[255]
Serisier DJ, Shute JK, Hockey PM et al.. “Inhaled heparin in cystic fibrosis.” The European respiratory journal (2006). PMID: 16452592 ↗
L1RCTCited in: 4. Clinical Presentation, 7. Acute Management and Exacerbation Rescue, History and Evolution of Treatment
[256]
Bilton D, Robinson P, Cooper P et al.. “Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study.” The European respiratory journal (2011). PMID: 21478216 ↗
L1RCTCited in: 4. Clinical Presentation
[257]
Bolser DC. “Cough suppressant and pharmacologic protussive therapy: ACCP evidence-based clinical practice guidelines.” Chest (2006). PMID: 16428717 ↗
L1GUIDELINECited in: 4. Clinical Presentation, 8. Long-term and Definitive Management
[258]
Rosen MJ. “Chronic cough due to bronchiectasis: ACCP evidence-based clinical practice guidelines.” Chest (2006). PMID: 16428701 ↗
L1GUIDELINECited in: 4. Clinical Presentation, 8. Long-term and Definitive Management
[259]
McCool FD, Rosen MJ. “Nonpharmacologic airway clearance therapies: ACCP evidence-based clinical practice guidelines.” Chest (2006). PMID: 16428718 ↗
L1GUIDELINECited in: 4. Clinical Presentation, 8. Long-term and Definitive Management
[260]
Nichols DP, Paynter AC, Heltshe SL et al.. “Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial.” American journal of respiratory and critical care medicine (2022). PMID: 34784492 ↗
L2TRIAL_NONRANDOMCited in: 4. Clinical Presentation, 6. Severity, Staging and Risk Stratification
[261]
Goralski JL, Hoppe JE, Mall MA et al.. “Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2-5 Years with Cystic Fibrosis and at Least One F508del Allele.” American journal of respiratory and critical care medicine (2023). PMID: 36921081 ↗
L4TRIAL_NONRANDOMCited in: 4. Clinical Presentation, 6. Severity, Staging and Risk Stratification
[262]
Daines CL, Polineni D, Tullis E et al.. “Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Adults and Adolescents with Cystic Fibrosis and at Least One F508del Allele: A Phase 3 Open-Label Extension Study.” American journal of respiratory and critical care medicine (2025). PMID: 40209082 ↗
L4TRIAL_NONRANDOMCited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management
[263]
Keating C, Yonker LM, Vermeulen F et al.. “Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials.” The Lancet. Respiratory medicine (2025). PMID: 39756424 ↗
L1RCTCited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
[264]
Uluer AZ, MacGregor G, Azevedo P et al.. “Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials.” The Lancet. Respiratory medicine (2023). PMID: 36842446 ↗
L1RCTCited in: 4. Clinical Presentation, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
[265]
Kruizinga MD, Essers E, Stuurman FE et al.. “Clinical validation of digital biomarkers for paediatric patients with asthma and cystic fibrosis: potential for clinical trials and clinical care.” The European respiratory journal (2022). PMID: 34887326 ↗
L2TRIAL_NONRANDOMCited in: 4. Clinical Presentation
[266]
Daines CL, Tullis E, Costa S et al.. “Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from a 192-week open-label extension study.” The European respiratory journal (2023). PMID: 37945033 ↗
L4TRIAL_NONRANDOMCited in: 4. Clinical Presentation
[267]
Martínez-García MÁ, Soler-Cataluña JJ, Catalán-Serra P et al.. “Clinical efficacy and safety of budesonide-formoterol in non-cystic fibrosis bronchiectasis.” Chest (2011). PMID: 21778259 ↗
L1RCTCited in: 4. Clinical Presentation, 7. Acute Management and Exacerbation Rescue, History and Evolution of Treatment
[268]
Middleton PG, Mall MA, Dřevínek P et al.. “Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.” The New England journal of medicine (2019). PMID: 31697873 ↗
L1RCTCited in: 4. Clinical Presentation, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
[269]
Donaldson SH, Bennett WD, Zeman KL et al.. “Mucus clearance and lung function in cystic fibrosis with hypertonic saline.” The New England journal of medicine (2006). PMID: 16421365 ↗
L1RCTCited in: 4. Clinical Presentation, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
[270]
Aliberti S, Goeminne PC, O'Donnell AE et al.. “Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations.” The Lancet. Respiratory medicine (2021). PMID: 34570994 ↗
L5TRIAL_NONRANDOMCited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[271]
Hoppe JE, Kasi AS, Pittman JE et al.. “Vanzacaftor-tezacaftor-deutivacaftor for children aged 6-11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial.” The Lancet. Respiratory medicine (2025). PMID: 39756425 ↗
L4TRIAL_NONRANDOMCited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 8. Long-term and Definitive Management, History and Evolution of Treatment
[272]
Chilvers MA, Davies JC, Milla C et al.. “Long-term safety and efficacy of lumacaftor-ivacaftor therapy in children aged 6-11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study.” The Lancet. Respiratory medicine (2021). PMID: 33516285 ↗
L4TRIAL_NONRANDOMCited in: 4. Clinical Presentation, 6. Severity, Staging and Risk Stratification, 10. Complications
[273]
Rosenfeld M, Wainwright CE, Higgins M et al.. “Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study.” The Lancet. Respiratory medicine (2018). PMID: 29886024 ↗
L4TRIAL_NONRANDOMCited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[274]
McNamara JJ, McColley SA, Marigowda G et al.. “Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study.” The Lancet. Respiratory medicine (2019). PMID: 30686767 ↗
L4TRIAL_NONRANDOMCited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification
[275]
Quittner AL, O'Donnell AE, Salathe MA et al.. “Quality of Life Questionnaire-Bronchiectasis: final psychometric analyses and determination of minimal important difference scores.” Thorax (2014). PMID: 25323621 ↗
L2RCTCited in: 4. Clinical Presentation, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 11. Prognosis and Natural History
[276]
Chang AB, Boyd J, Bush A et al.. “A core outcome set for bronchiectasis in children and adolescents for use in clinical research: an international consensus study.” The Lancet. Respiratory medicine (2023). PMID: 38070531 ↗
L1SR_OBSCited in: 4. Clinical Presentation, 11. Prognosis and Natural History
[277]
Yamamoto S, Niitsu T, Fukushima K et al.. “Efficacy of Antiinflammatory Therapies for Adults With Non-Cystic Fibrosis Bronchiectasis: A Systematic Review and Network Meta-Analysis.” Chest (2026). PMID: 41534709 ↗
L1SR_OBSCited in: 4. Clinical Presentation, 8. Long-term and Definitive Management, 11. Prognosis and Natural History
[278]
Hill AT, Barker AF, Bolser DC et al.. “Treating Cough Due to Non-CF and CF Bronchiectasis With Nonpharmacological Airway Clearance: CHEST Expert Panel Report.” Chest (2018). PMID: 29355548 ↗
L1SR_OBSCited in: 4. Clinical Presentation
[279]
Xu JF, Zheng HZ, Lu HW et al.. “Baseline characteristics of patients in the Chinese Bronchiectasis Registry (BE-China): a multicentre prospective cohort study.” The Lancet. Respiratory medicine (2025). PMID: 39805296 ↗
L2COHORTCited in: 4. Clinical Presentation, History and Evolution of Treatment
[280]
Simmonds NJ, Macneill SJ, Cullinan P et al.. “Cystic fibrosis and survival to 40 years: a case-control study.” The European respiratory journal (2010). PMID: 20378603 ↗
L3CASE_CONTROLCited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 10. Complications
[281]
Spinou A, Fragkos KC, Lee KK et al.. “The validity of health-related quality of life questionnaires in bronchiectasis: a systematic review and meta-analysis.” Thorax (2016). PMID: 26869589 ↗
L2SR_OBSCited in: 4. Clinical Presentation
[282]
Chapman N, Cavalheri V, Smith EF et al.. “MetaNeb Versus Usual Care During Exacerbations of Cystic Fibrosis: An RCT.” Respirology (Carlton, Vic.) (2025). PMID: 40716955 ↗
L1RCTCited in: 4. Clinical Presentation, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
[283]
Ozalp O, Inal-Ince D, Cakmak A et al.. “High-intensity inspiratory muscle training in bronchiectasis: A randomized controlled trial.” Respirology (Carlton, Vic.) (2018). PMID: 30209855 ↗
L1RCTCited in: 4. Clinical Presentation, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[284]
Sanders DB, Bartz TM, Zemanick ET et al.. “A Pilot Randomized Clinical Trial of Pediatric Cystic Fibrosis Pulmonary Exacerbations Treatment Strategies.” Annals of the American Thoracic Society (2023). PMID: 37683122 ↗
L1RCTCited in: 4. Clinical Presentation, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 12. Special Populations & Pregnancy
[285]
McElvaney OJ, Heltshe SL, Odem-Davis K et al.. “Adjunctive Systemic Corticosteroids for Pulmonary Exacerbations of Cystic Fibrosis.” Annals of the American Thoracic Society (2024). PMID: 38096105 ↗
L2RCTCited in: 4. Clinical Presentation, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
[286]
Korten I, Kieninger E, Klenja S et al.. “Respiratory viruses in healthy infants and infants with cystic fibrosis: a prospective cohort study.” Thorax (2017). PMID: 28778921 ↗
L2COHORTCited in: 4. Clinical Presentation
[287]
Tarrant BJ, Le Maitre C, Romero L et al.. “Mucoactive agents for chronic, non-cystic fibrosis lung disease: A systematic review and meta-analysis.” Respirology (Carlton, Vic.) (2017). PMID: 28397992 ↗
L1SR_OBSCited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[288]
Habib AR, Manji J, Wilcox PG et al.. “A systematic review of factors associated with health-related quality of life in adolescents and adults with cystic fibrosis.” Annals of the American Thoracic Society (2015). PMID: 25642976 ↗
L2SR_OBSCited in: 4. Clinical Presentation
[289]
Stick S, Tiddens H, Aurora P et al.. “Early intervention studies in infants and preschool children with cystic fibrosis: are we ready?” The European respiratory journal (2013). PMID: 23520316 ↗
L5REVIEW_NARRATIVECited in: 4. Clinical Presentation
[290]
Tiew PY, Ko FWS, Pang SL et al.. “Environmental fungal sensitisation associates with poorer clinical outcomes in COPD.” The European respiratory journal (2020). PMID: 32341102 ↗
L2OTHERCited in: 4. Clinical Presentation
[291]
Murray MP, Turnbull K, MacQuarrie S et al.. “Validation of the Leicester Cough Questionnaire in non-cystic fibrosis bronchiectasis.” The European respiratory journal (2009). PMID: 19196812 ↗
L2OTHERCited in: 4. Clinical Presentation
[292]
Goeminne PC, Vandooren J, Moelants EA et al.. “The Sputum Colour Chart as a predictor of lung inflammation, proteolysis and damage in non-cystic fibrosis bronchiectasis: a case-control analysis.” Respirology (Carlton, Vic.) (2013). PMID: 24286471 ↗
L3CASE_CONTROLCited in: 4. Clinical Presentation
[293]
Reznikov LR. “Cystic Fibrosis and the Nervous System.” Chest (2016). PMID: 27876591 ↗
L5REVIEW_NARRATIVECited in: 4. Clinical Presentation
[294]
Ma JT, Tang C, Kang L et al.. “Cystic Fibrosis Sputum Rheology Correlates With Both Acute and Longitudinal Changes in Lung Function.” Chest (2018). PMID: 29559310 ↗
L4OTHERCited in: 4. Clinical Presentation
[295]
Zeren M, Barlik M, Tosun BNC et al.. “Does Addition of Oscillatory Positive Expiratory Pressure (OPEP) Device to a Chest Physiotherapy Program Provide Further Benefits in Children With Bronchiectasis?: A Randomized Trial.” Pediatric pulmonology (2026). PMID: 41914274 ↗
L1RCTCited in: 4. Clinical Presentation, 7. Acute Management and Exacerbation Rescue, History and Evolution of Treatment
[296]
Mayer-Hamblett N, Boyle M, VanDevanter D. “Advancing clinical development pathways for new CFTR modulators in cystic fibrosis.” Thorax (2016). PMID: 26903594 ↗
L5REVIEW_NARRATIVECited in: 4. Clinical Presentation, History and Evolution of Treatment
[297]
Smyth A, Elborn JS. “Exacerbations in cystic fibrosis: 3--Management.” Thorax (2008). PMID: 18234661 ↗
L5REVIEW_NARRATIVECited in: 4. Clinical Presentation
[298]
Quittner AL, Abbott J, Georgiopoulos AM et al.. “International Committee on Mental Health in Cystic Fibrosis: Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus statements for screening and treating depression and anxiety.” Thorax (2015). PMID: 26452630 ↗
L1OTHERCited in: 4. Clinical Presentation
[299]
de Campos Medeiros J, da Silva AC, Lima ACJDS et al.. “Study protocol for testing a mobile app designed to improve health literacy and self-management in people with bronchiectasis: the ANIMA app.” BMJ open (2026). PMID: 41881528 ↗
L5TRIAL_NONRANDOMCited in: 4. Clinical Presentation
[300]
Srivali N, De Giacomi F. “Obstructive Sleep Apnea in Bronchiectasis: Prevalence, Risk Factors and Clinical Implications-A Systematic Review and Meta-Analysis.” Journal of sleep research (2026). PMID: 41905893 ↗
L2SR_OBSCited in: 4. Clinical Presentation
[301]
Warnock L, Gates A. “Airway clearance techniques compared to no airway clearance techniques for cystic fibrosis.” The Cochrane database of systematic reviews (2023). PMID: 37042825 ↗
L1SR_OBSCited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 8. Long-term and Definitive Management
[302]
McIlwaine M, Button B, Nevitt SJ. “Positive expiratory pressure physiotherapy for airway clearance in people with cystic fibrosis.” The Cochrane database of systematic reviews (2019). PMID: 31774149 ↗
L1SR_OBSCited in: 4. Clinical Presentation, 8. Long-term and Definitive Management, 11. Prognosis and Natural History
[303]
Dentice R, Elkins M. “Timing of dornase alfa inhalation for cystic fibrosis.” The Cochrane database of systematic reviews (2021). PMID: 33686652 ↗
L1SR_OBSCited in: 4. Clinical Presentation
[304]
Kelly C, Grundy S, Lynes D et al.. “Self-management for bronchiectasis.” The Cochrane database of systematic reviews (2018). PMID: 29411860 ↗
L1SR_OBSCited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 8. Long-term and Definitive Management, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 11. Prognosis and Natural History
[305]
Williams NC, Jayaratnasingam J, Prayle AP et al.. “Prebiotics for people with cystic fibrosis.” The Cochrane database of systematic reviews (2023). PMID: 37753791 ↗
L1SR_OBSCited in: 4. Clinical Presentation
[306]
Armstrong M, Vogiatzis I. “Personalized exercise training in chronic lung diseases.” Respirology (Carlton, Vic.) (2019). PMID: 31270909 ↗
L5REVIEW_NARRATIVECited in: 4. Clinical Presentation
[307]
Maglione M, Aksamit T, Santamaria F. “Paediatric and adult bronchiectasis: Specific management with coexisting asthma, COPD, rheumatological disease and inflammatory bowel disease.” Respirology (Carlton, Vic.) (2019). PMID: 31222879 ↗
L5REVIEW_NARRATIVECited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[308]
Sagel SD, Poore TS, Wagner BD et al.. “Long-term reductions in inflammation in people with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor.” Annals of the American Thoracic Society (2026). PMID: 40961158 ↗
L2OTHERCited in: 4. Clinical Presentation, 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management, 11. Prognosis and Natural History
[309]
Fajac I, Jain R, Mall MA et al.. “The clinical, psychosocial, and economic burden of cystic fibrosis lung disease in the era of CFTR modulator therapy.” Annals of the American Thoracic Society (2026). PMID: 40961131 ↗
L5REVIEW_NARRATIVECited in: 4. Clinical Presentation, 7. Acute Management and Exacerbation Rescue, 10. Complications
[310]
Thomsen RS, Mikkelsen C, Olsen NE et al.. “The effect of inhaled dry salt on pulmonary mucociliary clearance in obstructive lung disease: A randomised, placebo-controlled, crossover study.” Clinical physiology and functional imaging (2026). PMID: 41921975 ↗
L1RCTCited in: 4. Clinical Presentation, History and Evolution of Treatment
[311]
Sethi D, Iyer TR, Abu-Al-Timen S. “Predictors of Recurrence Following Bronchial Artery Embolisation (BAE) for Haemoptysis: A Systematic Review and Evidence Synthesis Analyses Using SWiM Guidelines.” Cardiovascular and interventional radiology (2026). PMID: 42414635 ↗
L2SR_OBSCited in: 4. Clinical Presentation, 8. Long-term and Definitive Management, History and Evolution of Treatment, 10. Complications
[312]
Dollimount A, Gerbeza M, Stremick T et al.. “Cystic Fibrosis and Digital Technology: A Systematic Review.” Respiratory care (2026). PMID: 41903112 ↗
L2SR_OBSCited in: 4. Clinical Presentation
[313]
Chalmers JD, Burgel PR, Daley CL et al.. “Brensocatib in non-cystic fibrosis bronchiectasis: ASPEN protocol and baseline characteristics.” ERJ open research (2024). PMID: 39040578 ↗
L5OTHERCited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
[314]
Loebinger MR, van der Laan R, Obradovic M et al.. “Global survey of physician testing practices for nontuberculous mycobacteria.” ERJ open research (2023). PMID: 37143838 ↗
L2OTHERCited in: 4. Clinical Presentation, 7. Acute Management and Exacerbation Rescue
[315]
Flume PA, Feliciano J, Lucci M et al.. “Pulmonary exacerbations in insured patients with bronchiectasis over 2 years.” ERJ open research (2023). PMID: 37404848 ↗
L2OTHERCited in: 4. Clinical Presentation, 8. Long-term and Definitive Management
[316]
Shih VH, Jison M, Bark E et al.. “The Bronchiectasis Exacerbation Diary: a novel patient-reported outcome for non-cystic fibrosis bronchiectasis.” ERJ open research (2023). PMID: 37143836 ↗
L4OTHERCited in: 4. Clinical Presentation, 11. Prognosis and Natural History
[317]
Alwadaei S, Allsup N, Shiferaw D. “Musculoskeletal adverse effects associated with inhaled levofloxacin in a patient with cystic fibrosis: A case report.” Respiratory medicine (2026). PMID: 42259475 ↗
L4CASE_REPORTCited in: 4. Clinical Presentation
[318]
Mayer-Hamblett N, Ratjen F, Russell R et al.. “Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials.” The Lancet. Respiratory medicine (2022). PMID: 36343646 ↗
L1RCTCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
[319]
Kerem E, Konstan MW, De Boeck K et al.. “Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial.” The Lancet. Respiratory medicine (2014). PMID: 24836205 ↗
L1RCTCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue, History and Evolution of Treatment
[320]
Urquhart DS, Taylor E, Cunningham S et al.. “Safety, feasibility and efficacy of exercise as an airway clearance technique in cystic fibrosis: a randomised pilot feasibility trial.” Thorax (2026). PMID: 41033804 ↗
L1RCTCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[321]
McKone EF, Ariti C, Jackson A et al.. “Survival estimates in European cystic fibrosis patients and the impact of socioeconomic factors: a retrospective registry cohort study.” The European respiratory journal (2021). PMID: 33678607 ↗
L2COHORTCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[322]
Shoki AH, Mayer-Hamblett N, Wilcox PG et al.. “Systematic review of blood biomarkers in cystic fibrosis pulmonary exacerbations.” Chest (2013). PMID: 23868694 ↗
L2SR_OBSCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[323]
Milross MA, Piper AJ, Dwyer TJ et al.. “Non-invasive ventilation versus oxygen therapy in cystic fibrosis: A 12-month randomized trial.” Respirology (Carlton, Vic.) (2019). PMID: 31206975 ↗
L1RCTCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 11. Prognosis and Natural History
[324]
Boone PM, Scott RM, Marciniak SJ et al.. “The Genetics of Pneumothorax.” American journal of respiratory and critical care medicine (2019). PMID: 30681372 ↗
L5REVIEW_NARRATIVECited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 10. Complications, 13. Prevention, Screening & Surveillance
[325]
Dougherty GW, Ostrowski LE, Nöthe-Menchen T et al.. “Recessively Inherited Deficiency of Secreted WFDC2 (HE4) Causes Nasal Polyposis and Bronchiectasis.” American journal of respiratory and critical care medicine (2024). PMID: 38626355 ↗
L4OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[326]
Cohen-Cymberknoh M, Shoseyov D, Kerem E. “Managing cystic fibrosis: strategies that increase life expectancy and improve quality of life.” American journal of respiratory and critical care medicine (2011). PMID: 21330455 ↗
L5REVIEW_NARRATIVECited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[327]
Khor YH, Poberezhets V, Buhr RG et al.. “Assessment of Home-based Monitoring in Adults with Chronic Lung Disease: An Official American Thoracic Society Research Statement.” American journal of respiratory and critical care medicine (2025). PMID: 39585746 ↗
L1OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[328]
Long DR, Wolter DJ, Lee M et al.. “Polyclonality, Shared Strains, and Convergent Evolution in Chronic Cystic Fibrosis Staphylococcus aureus Airway Infection.” American journal of respiratory and critical care medicine (2021). PMID: 33296290 ↗
L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[329]
Irving SJ, Ives A, Davies G et al.. “Lung clearance index and high-resolution computed tomography scores in primary ciliary dyskinesia.” American journal of respiratory and critical care medicine (2013). PMID: 23815669 ↗
L4OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[330]
Szczesniak RD, Li D, Su W et al.. “Phenotypes of Rapid Cystic Fibrosis Lung Disease Progression during Adolescence and Young Adulthood.” American journal of respiratory and critical care medicine (2017). PMID: 28410569 ↗
L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[331]
Fathima P, Pan E, Marsh J et al.. “Characteristics, treatment and lung function outcomes of pulmonary exacerbations in cystic fibrosis: insights from the BEAT-CF cohort.” The European respiratory journal (2026). PMID: 41067870 ↗
L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[332]
Bayfield KJ, Weinheimer O, Boyton C et al.. “Implementation and evaluation of ultra-low dose CT in early cystic fibrosis lung disease.” The European respiratory journal (2023). PMID: 37385656 ↗
L4OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[333]
Matheson AM, Willmering MM, Dournes G et al.. “Novel translational pulmonary MRI in pediatrics: A Review of the last 10 years.” The European respiratory journal (2026). PMID: 41748285 ↗
L5REVIEW_NARRATIVECited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 12. Special Populations & Pregnancy
[334]
Filipow N, Stanojevic S, Raywood E et al.. “Real-world effectiveness of airway clearance techniques in children with cystic fibrosis.” The European respiratory journal (2023). PMID: 37652570 ↗
L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[335]
Sonneveld N, Stanojevic S, Amin R et al.. “Lung clearance index in cystic fibrosis subjects treated for pulmonary exacerbations.” The European respiratory journal (2015). PMID: 26160868 ↗
L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[336]
Dournes G, Hall CS, Willmering MM et al.. “Artificial intelligence in computed tomography for quantifying lung changes in the era of CFTR modulators.” The European respiratory journal (2022). PMID: 34266943 ↗
L4OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[337]
Barbato A, Bertuola F, Kuehni C et al.. “Paediatrics in Berlin.” The European respiratory journal (2009). PMID: 19648520 ↗
L5OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[338]
van de Weert-van Leeuwen PB, Slieker MG, Hulzebos HJ et al.. “Chronic infection and inflammation affect exercise capacity in cystic fibrosis.” The European respiratory journal (2011). PMID: 21885387 ↗
L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[339]
Castellani C, Massie J, Sontag M et al.. “Newborn screening for cystic fibrosis.” The Lancet. Respiratory medicine (2016). PMID: 27053341 ↗
L5REVIEW_NARRATIVECited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[340]
Grasemann H, Ratjen F. “Early lung disease in cystic fibrosis.” The Lancet. Respiratory medicine (2013). PMID: 24429095 ↗
L5REVIEW_NARRATIVECited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 10. Complications
[341]
Hull RC, Huang JTJ, Barton AK et al.. “Sputum Proteomics in Nontuberculous Mycobacterial Lung Disease.” Chest (2021). PMID: 34838525 ↗
L3OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[342]
Deshwal H, Avasarala SK, Ghosh S et al.. “Forbearance With Bronchoscopy: A Review of Gratuitous Indications.” Chest (2018). PMID: 30171862 ↗
L5REVIEW_NARRATIVECited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[343]
Barnes PJ, Dweik RA, Gelb AF et al.. “Exhaled nitric oxide in pulmonary diseases: a comprehensive review.” Chest (2010). PMID: 20822990 ↗
L5REVIEW_NARRATIVECited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue
[344]
Field SK, Cowie RL. “Lung disease due to the more common nontuberculous mycobacteria.” Chest (2006). PMID: 16778288 ↗
L5REVIEW_NARRATIVECited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[345]
Ishak A, Stick SM, Turkovic L et al.. “BAL Inflammatory Markers Can Predict Pulmonary Exacerbations in Children With Cystic Fibrosis.” Chest (2020). PMID: 32622821 ↗
L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 13. Prevention, Screening & Surveillance
[346]
Barry PJ, Waterhouse DF, Reilly CM et al.. “Androgens, exercise capacity, and muscle function in cystic fibrosis.” Chest (2008). PMID: 18689588 ↗
L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[347]
O'Neill K, Tunney MM, Johnston E et al.. “Lung Clearance Index in Adults and Children With Cystic Fibrosis.” Chest (2016). PMID: 27395423 ↗
L4OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[348]
Liou TG, Adler FR, Cox DR et al.. “Lung Transplantation and Survival in Children with Cystic Fibrosis.” The New England journal of medicine (2008). PMID: 27559197 ↗
L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 8. Long-term and Definitive Management, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 11. Prognosis and Natural History
[349]
Liou TG, Adler FR, Cox DR et al.. “Lung transplantation and survival in children with cystic fibrosis.” The New England journal of medicine (2007). PMID: 18032764 ↗
L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 8. Long-term and Definitive Management, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 11. Prognosis and Natural History
[350]
Doroudian M, MacLoughlin R, Poynton F et al.. “Nanotechnology based therapeutics for lung disease.” Thorax (2019). PMID: 31285360 ↗
L5REVIEW_NARRATIVECited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[351]
Aziz ZA, Davies JC, Alton EW et al.. “Computed tomography and cystic fibrosis: promises and problems.” Thorax (2007). PMID: 17287306 ↗
L5REVIEW_NARRATIVECited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 10. Complications, 11. Prognosis and Natural History
[352]
Flight WG, Jones AM. “Cystic fibrosis, primary ciliary dyskinesia and non-cystic fibrosis bronchiectasis: update 2008-11.” Thorax (2011). PMID: 21680564 ↗
L5REVIEW_NARRATIVECited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 8. Long-term and Definitive Management, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[353]
Postma DS, Brusselle G, Bush A et al.. “I have taken my umbrella, so of course it does not rain.” Thorax (2011). PMID: 21873323 ↗
L5REVIEW_NARRATIVECited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[354]
Harun SN, Wainwright CE, Grimwood K et al.. “Aspergillus and progression of lung disease in children with cystic fibrosis.” Thorax (2018). PMID: 30275132 ↗
L4OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification
[355]
Safi KH, Filbrun AG, Nasr SZ. “Hypervitaminosis A causing hypercalcemia in cystic fibrosis. Case report and focused review.” Annals of the American Thoracic Society (2014). PMID: 25188737 ↗
L4CASE_REPORTCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 12. Special Populations & Pregnancy
[356]
Wilkinson M, Sugumar K, Milan SJ et al.. “Mucolytics for bronchiectasis.” The Cochrane database of systematic reviews (2014). PMID: 24789119 ↗
L1SR_OBSCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 8. Long-term and Definitive Management
[357]
Jameson E, Remmington T. “Dietary interventions for phenylketonuria.” The Cochrane database of systematic reviews (2020). PMID: 32672365 ↗
L1SR_OBSCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), History and Evolution of Treatment
[358]
Jain K, Wainwright C, Smyth AR. “Bronchoscopy-guided antimicrobial therapy for cystic fibrosis.” The Cochrane database of systematic reviews (2018). PMID: 30221745 ↗
L1SR_OBSCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[359]
Remmington T, Smith S. “Tyrosine supplementation for phenylketonuria.” The Cochrane database of systematic reviews (2021). PMID: 33427303 ↗
L1SR_OBSCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[360]
Jain K, Wainwright CE, Smyth AR. “Bronchoscopy-guided antimicrobial therapy for cystic fibrosis.” The Cochrane database of systematic reviews (2024). PMID: 38700027 ↗
L1SR_OBSCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[361]
Walter JH, Jahnke N, Remmington T. “Newborn screening for homocystinuria.” The Cochrane database of systematic reviews (2015). PMID: 26423208 ↗
L1SR_OBSCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 10. Complications
[362]
Soria-Utrilla V, Piñar-Gutiérrez A, Sánchez-Torralvo FJ et al.. “CT assessment of body composition and lung evolution in cystic fibrosis after Elexacaftor-Tezacaftor-Ivacaftor: A cohort study.” Respiratory medicine (2026). PMID: 42251917 ↗
L4COHORTCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, History and Evolution of Treatment
[363]
Middleton PG, Wagenaar M, Matson AG et al.. “Australian standards of care for cystic fibrosis-related diabetes.” Respirology (Carlton, Vic.) (2013). PMID: 24372844 ↗
L1REVIEW_NARRATIVECited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[364]
Zoumot Z, Boutou AK, Gill SS et al.. “Mycobacterium avium complex infection in non-cystic fibrosis bronchiectasis.” Respirology (Carlton, Vic.) (2014). PMID: 24690015 ↗
L4OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[365]
Lynch SV. “The Lung Microbiome and Airway Disease.” Annals of the American Thoracic Society (2016). PMID: 28005424 ↗
L5REVIEW_NARRATIVECited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[366]
Stewart C, Pepper MS. “Cystic Fibrosis in the African Diaspora.” Annals of the American Thoracic Society (2017). PMID: 27870577 ↗
L5REVIEW_NARRATIVECited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[367]
Mogayzel PJ, Naureckas ET, Robinson KA et al.. “Cystic Fibrosis Foundation pulmonary guideline. pharmacologic approaches to prevention and eradication of initial Pseudomonas aeruginosa infection.” Annals of the American Thoracic Society (2014). PMID: 25549030 ↗
L1REVIEW_NARRATIVECited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[368]
Dong K, Jang J, Shannon CP et al.. “Blood Transcriptomic and Inflammatory Protein Biomarkers Associated with Imminent Pulmonary Exacerbation Risk in Cystic Fibrosis.” Annals of the American Thoracic Society (2024). PMID: 39137349 ↗
L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[369]
Zachariah P, Ryan C, Nadimpalli S et al.. “Culture-Independent Analysis of Pediatric Bronchoalveolar Lavage Specimens.” Annals of the American Thoracic Society (2018). PMID: 29877714 ↗
L4OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 12. Special Populations & Pregnancy
[370]
Salinas DB, Wee CP, Bailey B et al.. “Cystic Fibrosis Screen Positive, Inconclusive Diagnosis Genotypes in People with Cystic Fibrosis from the U.S. Patient Registry.” Annals of the American Thoracic Society (2023). PMID: 36409994 ↗
L3OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[371]
Ratjen FA, Stanojevic S, Munidasa S et al.. “Multicenter Study of Hyperpolarized Xenon Magnetic Resonance Imaging in Children with Cystic Fibrosis Following Initiation of Cystic Fibrosis Transmembrane Regulator Modulator Therapy (HyPOINT).” Annals of the American Thoracic Society (2025). PMID: 40795189 ↗
L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[372]
Sernaglia JEC, Souza AP, Gonçalves AC et al.. “The role of ultrasound of the quadriceps femoris in people with cystic fibrosis: a systematic review and meta-analysis.” Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia (2026). PMID: 42307335 ↗
L2SR_OBSCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[373]
Rubbo B, Kant A, Zhang K et al.. “Associations between respiratory pathogens and lung function in primary ciliary dyskinesia: cross-sectional analysis from the PROVALF-PCD cohort.” ERJ open research (2024). PMID: 39351386 ↗
L4OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[374]
Ostadan F, Donovan AA, Matouk E et al.. “Computed tomography reveals hypertrophic remodelling of the diaphragm in cystic fibrosis but not in COPD.” ERJ open research (2023). PMID: 37753287 ↗
L3OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[375]
Ben-Meir E, Antounians L, Eisha S et al.. “Extracellular vesicles in sputum of children with cystic fibrosis pulmonary exacerbations.” ERJ open research (2024). PMID: 39655173 ↗
L4OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[376]
Zampoli M, Verstraete J, Frauendorf M et al.. “Cystic fibrosis in South Africa: spectrum of disease and determinants of outcome.” ERJ open research (2021). PMID: 34350279 ↗
L4OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[377]
Ziegahn N, Roehmel JF, Pioch CO et al.. “Multiple-breath washout is more sensitive than spirometry to detect lung function impairment in children and adults with bronchiectasis.” ERJ open research (2025). PMID: 40551806 ↗
L4OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 11. Prognosis and Natural History
[378]
Johnson B, Steenbruggen I, Graham BL et al.. “Improving spirometry testing by understanding patient preferences.” ERJ open research (2021). PMID: 33585650 ↗
L4OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[379]
Leo-Hansen C, Faurholt-Jepsen D, Qvist T et al.. “Lung function improvement on triple modulators: high-resolution, nationwide data from the Danish Cystic Fibrosis Cohort.” ERJ open research (2024). PMID: 39655171 ↗
L4OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), History and Evolution of Treatment
[380]
Caverly LJ, Zimbric M, Azar M et al.. “Cystic fibrosis airway microbiota associated with outcomes of nontuberculous mycobacterial infection.” ERJ open research (2021). PMID: 33898611 ↗
L4OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[381]
Alghamdi A, Al-Attas M, Radhi A et al.. “The Impact of Exercise Intervention on Pulmonary and Physical Function in Patients With Cystic Fibrosis: A Comprehensive Systematic Review.” Saudi medical journal (2026). PMID: 42293711 ↗
L1SR_OBSCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[382]
Tavasoli H, Rajabi MM, Sadat Hoseini AS. “The effect of harmonica-based breathing and airway clearance exercises on pulmonary function in children with cystic fibrosis: A randomized controlled trial.” Journal of pediatric nursing (2026). PMID: 42166879 ↗
L1RCTCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[383]
Hunt WR, Merlo C, Keller A et al.. “Meaningful Criteria to Persons Living With Cystic Fibrosis and Their Healthcare Providers in Helping Determine Adjustments to Routine Clinical Follow-Up.” Pediatric pulmonology (2026). PMID: 42429216 ↗
L4OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 12. Special Populations & Pregnancy
[384]
Efthyvoulou C, Semple T, Abkir M et al.. “Postural Influence on Ventilation Efficiency and Relationship With Oxygen-Enhanced MRI in Cystic Fibrosis.” Pediatric pulmonology (2026). PMID: 42400509 ↗
L4OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[385]
Chen Z, Tang Z, Ewing RM et al.. “Artificial intelligence in respiratory medicine: From diagnosis to treatment and future directions.” Chinese medical journal pulmonary and critical care medicine (2026). PMID: 42396189 ↗
L5REVIEW_NARRATIVECited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[386]
Bardin E, Salvator H, Roquencourt C et al.. “Real-time breath metabolomics to assess early response to CFTR modulators in adults with cystic fibrosis: An open-label proof-of-concept study.” Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society (2026). PMID: 42386422 ↗
L4OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[387]
Wainwright C, McColley SA, McNally P et al.. “Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children ≥6 Years with Cystic Fibrosis and at Least One F508del Allele: A 192-Week, Phase 3, Open-Label Extension Study.” American journal of respiratory and critical care medicine (2025). PMID: 40454869 ↗
L4TRIAL_NONRANDOMCited in: 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management, 12. Special Populations & Pregnancy
[388]
Sutharsan S, McKone EF, Downey DG et al.. “Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.” The Lancet. Respiratory medicine (2021). PMID: 34942085 ↗
L1RCTCited in: 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, History and Evolution of Treatment
[389]
Keating D, Marigowda G, Burr L et al.. “VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.” The New England journal of medicine (2018). PMID: 30334692 ↗
L1RCTCited in: 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
[390]
Stahl M, Roehmel J, Eichinger M et al.. “Long-Term Impact of Lumacaftor/Ivacaftor Treatment on Cystic Fibrosis Disease Progression in Children 2-5 Years of Age Homozygous for F508del-CFTR: A Phase 2, Open-Label Clinical Trial.” Annals of the American Thoracic Society (2024). PMID: 39173175 ↗
L4RCTCited in: 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 11. Prognosis and Natural History
[391]
Raidt J, Maitre B, Pennekamp P et al.. “The disease-specific clinical trial network for primary ciliary dyskinesia: PCD-CTN.” ERJ open research (2022). PMID: 35983540 ↗
L5TRIAL_NONRANDOMCited in: 6. Severity, Staging and Risk Stratification
[392]
Stahl M, Dohna M, Graeber SY et al.. “Impact of elexacaftor/tezacaftor/ivacaftor therapy on lung clearance index and magnetic resonance imaging in children with cystic fibrosis and one or two F508del alleles.” The European respiratory journal (2024). PMID: 38901883 ↗
L4OTHERCited in: 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[393]
Faner R, Sibila O, Agustí A et al.. “The microbiome in respiratory medicine: current challenges and future perspectives.” The European respiratory journal (2017). PMID: 28404649 ↗
L5REVIEW_NARRATIVECited in: 6. Severity, Staging and Risk Stratification
[394]
Pohunek P, Manali E, Vijverberg S et al.. “ERS statement on transition of care in childhood interstitial lung diseases.” The European respiratory journal (2024). PMID: 38843911 ↗
L1REVIEW_NARRATIVECited in: 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management
[395]
Martínez-García MÁ, de Gracia J, Vendrell Relat M et al.. “Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score.” The European respiratory journal (2013). PMID: 24232697 ↗
L2OTHERCited in: 6. Severity, Staging and Risk Stratification
[396]
Maisonneuve P, Lowenfels AB. “Cancer in Cystic Fibrosis: A Narrative Review of Prevalence, Risk Factors, Screening, and Treatment Challenges: Adult Cystic Fibrosis Series.” Chest (2021). PMID: 34536383 ↗
L5REVIEW_NARRATIVECited in: 6. Severity, Staging and Risk Stratification
[397]
Dournes G, Walkup LL, Benlala I et al.. “The Clinical Use of Lung MRI in Cystic Fibrosis: What, Now, How?” Chest (2020). PMID: 33345950 ↗
L5REVIEW_NARRATIVECited in: 6. Severity, Staging and Risk Stratification
[398]
Coriati A, Ma X, Sykes J et al.. “Beyond borders: cystic fibrosis survival between Australia, Canada, France and New Zealand.” Thorax (2022). PMID: 36109163 ↗
L2OTHERCited in: 6. Severity, Staging and Risk Stratification
[399]
Greaney C, Cichy N, O'Sullivan G et al.. “Evolution of body image across treatment eras: a systematic review in young people and adults living with cystic fibrosis.” European respiratory review : an official journal of the European Respiratory Society (2026). PMID: 42128482 ↗
L2SR_OBSCited in: 6. Severity, Staging and Risk Stratification, History and Evolution of Treatment
[400]
Strike K, Mulder K, Michael R. “Exercise for haemophilia.” The Cochrane database of systematic reviews (2016). PMID: 27992070 ↗
L1SR_OBSCited in: 6. Severity, Staging and Risk Stratification
[401]
Busby J, McKeever TM, Fogarty AW et al.. “Changes in chronic therapies for cystic fibrosis following initiation of CFTR modulators: A UK retrospective cohort study 2009 - 2023.” Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society (2026). PMID: 42336706 ↗
L2COHORTCited in: 6. Severity, Staging and Risk Stratification
[402]
Horsley A, Siddiqui S. “Putting lung function and physiology into perspective: cystic fibrosis in adults.” Respirology (Carlton, Vic.) (2014). PMID: 25219816 ↗
L5REVIEW_NARRATIVECited in: 6. Severity, Staging and Risk Stratification
[403]
Smith L, Reilly CC, MacBean V et al.. “Physiological markers of exercise capacity and lung disease severity in cystic fibrosis.” Respirology (Carlton, Vic.) (2016). PMID: 27882640 ↗
L4OTHERCited in: 6. Severity, Staging and Risk Stratification
[404]
McDonnell MJ, Ahmed M, Das J et al.. “Hiatal hernias are correlated with increased severity of non-cystic fibrosis bronchiectasis.” Respirology (Carlton, Vic.) (2015). PMID: 25872951 ↗
L4OTHERCited in: 6. Severity, Staging and Risk Stratification
[405]
Smith DJ, Ramsay KA, Yerkovich ST et al.. “Pseudomonas aeruginosa antibiotic resistance in Australian cystic fibrosis centres.” Respirology (Carlton, Vic.) (2015). PMID: 26711802 ↗
L4OTHERCited in: 6. Severity, Staging and Risk Stratification
[406]
Bayomy OF, Bradford MC, Milinic T et al.. “Lung Allocation Score Exceptions in Persons with Cystic Fibrosis Undergoing Lung Transplant.” Annals of the American Thoracic Society (2024). PMID: 37878995 ↗
L4OTHERCited in: 6. Severity, Staging and Risk Stratification, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 10. Complications
[407]
Jung F, Riley L, Lascano J. “Outcomes and survival following lung transplantation in non-cystic fibrosis bronchiectasis.” ERJ open research (2022). PMID: 35174245 ↗
L2OTHERCited in: 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 11. Prognosis and Natural History
[408]
Laffitte Redondo C, Bourdin V, Ait Tayeb AEK et al.. “A descriptive case series of hepatotoxicity associated with CFTR modulators and possible relevance of pharmacogenetic polymorphisms in cystic fibrosis patients.” British journal of clinical pharmacology (2026). PMID: 42346180 ↗
L4CASE_REPORTCited in: 6. Severity, Staging and Risk Stratification
[409]
Sun BZ, Cogen JD, Brown M et al.. “Fine particulate matter exposure and long-term lung-function trajectory in adults with cystic fibrosis.” Annals of the American Thoracic Society (2026). PMID: 42398005 ↗
L2OTHERCited in: 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management
[410]
Castellani C, Mondejar-Lopez P, Van Goor F et al.. “Elexacaftor/tezacaftor/ivacaftor for cystic fibrosis and rare CFTR variants: in vitro translation to a phase 3, double-blind, randomized, placebo-controlled trial, and real-world study.” American journal of respiratory and critical care medicine (2026). PMID: 41738096 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
[411]
Johnson ED, Long MB, Perea L et al.. “Broad Immunomodulatory Effects of the Dipeptidyl Peptidase-1 Inhibitor Brensocatib in Bronchiectasis: Data from the Phase 2, Double-Blind, Placebo-controlled WILLOW Trial.” American journal of respiratory and critical care medicine (2025). PMID: 39938076 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
[412]
Murray MP, Govan JR, Doherty CJ et al.. “A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis.” American journal of respiratory and critical care medicine (2010). PMID: 20870753 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue
[413]
Balfour-Lynn IM, Lees B, Hall P et al.. “Multicenter randomized controlled trial of withdrawal of inhaled corticosteroids in cystic fibrosis.” American journal of respiratory and critical care medicine (2006). PMID: 16556691 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 12. Special Populations & Pregnancy
[414]
Hebestreit H, Kriemler S, Schindler C et al.. “Effects of a Partially Supervised Conditioning Program in Cystic Fibrosis: An International Multicenter, Randomized Controlled Trial (ACTIVATE-CF).” American journal of respiratory and critical care medicine (2022). PMID: 34735776 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management
[415]
Mayer-Hamblett N, Retsch-Bogart G, Kloster M et al.. “Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis. The OPTIMIZE Randomized Trial.” American journal of respiratory and critical care medicine (2018). PMID: 29890086 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management
[416]
Accurso FJ, Moss RB, Wilmott RW et al.. “Denufosol tetrasodium in patients with cystic fibrosis and normal to mildly impaired lung function.” American journal of respiratory and critical care medicine (2010). PMID: 21169471 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue
[417]
Waters V, Shaw M, Perrem L et al.. “A randomised trial of oral prednisone for cystic fibrosis pulmonary exacerbation treatment.” The European respiratory journal (2024). PMID: 38697648 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
[418]
Plant BJ, Einarsson GG, Deasy KF et al.. “Cystic Fibrosis Microbiome-directed Antibiotic Therapy Trial in Exacerbations Results Stratified (CFMATTERS): results of a multicentre randomised controlled trial.” The European respiratory journal (2025). PMID: 40506211 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
[419]
Xu X, Abdalla T, Bratcher PE et al.. “Doxycycline improves clinical outcomes during cystic fibrosis exacerbations.” The European respiratory journal (2017). PMID: 28381428 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
[420]
Dwyer TJ, Elkins MR, Dentice R et al.. “Saline at lower tonicity in cystic fibrosis (SALTI-CF) trial comparing 0.9% versus 3% versus 6% nebulised saline.” The European respiratory journal (2023). PMID: 37343977 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, History and Evolution of Treatment
[421]
Goss CH, Fajac I, Jain R et al.. “Efficacy and safety of inhaled ENaC inhibitor BI 1265162 in patients with cystic fibrosis: BALANCE-CF 1, a randomised, phase II study.” The European respiratory journal (2022). PMID: 34385272 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, History and Evolution of Treatment
[422]
McCormack J, Bell S, Senini S et al.. “Daily versus weekly azithromycin in cystic fibrosis patients.” The European respiratory journal (2007). PMID: 17537764 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue
[423]
Tiddens HAWM, Chen Y, Andrinopoulou ER et al.. “The effect of inhaled hypertonic saline on lung structure in children aged 3-6 years with cystic fibrosis (SHIP-CT): a multicentre, randomised, double-blind, controlled trial.” The Lancet. Respiratory medicine (2022). PMID: 35286860 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, History and Evolution of Treatment, 11. Prognosis and Natural History
[424]
Wainwright CE, Vidmar S, Anderson V et al.. “Long-term outcomes of early exposure to repeated general anaesthesia in children with cystic fibrosis (CF-GAIN): a multicentre, open-label, randomised controlled phase 4 trial.” The Lancet. Respiratory medicine (2024). PMID: 38851197 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, History and Evolution of Treatment
[425]
Ratjen F, Davis SD, Stanojevic S et al.. “Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial.” The Lancet. Respiratory medicine (2019). PMID: 31178421 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue
[426]
Moss RB, Flume PA, Elborn JS et al.. “Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial.” The Lancet. Respiratory medicine (2015). PMID: 26070913 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 11. Prognosis and Natural History
[427]
Agarwal R, Dhooria S, Singh Sehgal I et al.. “A Randomized Trial of Itraconazole vs Prednisolone in Acute-Stage Allergic Bronchopulmonary Aspergillosis Complicating Asthma.” Chest (2018). PMID: 29331473 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue
[428]
Vicendese D, Yerkovich S, Grimwood K et al.. “Long-term Azithromycin in Children With Bronchiectasis Unrelated to Cystic Fibrosis: Treatment Effects Over Time.” Chest (2022). PMID: 36030839 ↗
L2RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
[429]
Jaques A, Daviskas E, Turton JA et al.. “Inhaled mannitol improves lung function in cystic fibrosis.” Chest (2008). PMID: 18339790 ↗
L4RCTCited in: 7. Acute Management and Exacerbation Rescue, History and Evolution of Treatment
[430]
Dwyer TJ, Alison JA, McKeough ZJ et al.. “Effects of exercise on respiratory flow and sputum properties in patients with cystic fibrosis.” Chest (2010). PMID: 20829339 ↗
L2RCTCited in: 7. Acute Management and Exacerbation Rescue
[431]
Retsch-Bogart GZ, Quittner AL, Gibson RL et al.. “Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis.” Chest (2009). PMID: 19420195 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, History and Evolution of Treatment
[432]
Grasemann H, Stehling F, Brunar H et al.. “Inhalation of Moli1901 in patients with cystic fibrosis.” Chest (2007). PMID: 17494794 ↗
L2RCTCited in: 7. Acute Management and Exacerbation Rescue
[433]
Dovey M, Aitken ML, Emerson J et al.. “Oral corticosteroid therapy in cystic fibrosis patients hospitalized for pulmonary exacerbation: a pilot study.” Chest (2007). PMID: 17646219 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue
[434]
Dong K, Singh A, Ng RT et al.. “Proteomic Profiling to Identify Blood Biomarkers Predictive of Response to Azithromycin in Children and Adolescents With Cystic Fibrosis.” Chest (2019). PMID: 31201785 ↗
L2RCTCited in: 7. Acute Management and Exacerbation Rescue, History and Evolution of Treatment
[435]
Davies JC, Moskowitz SM, Brown C et al.. “VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.” The New England journal of medicine (2018). PMID: 30334693 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
[436]
Accurso FJ, Rowe SM, Clancy JP et al.. “Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation.” The New England journal of medicine (2010). PMID: 21083385 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
[437]
Elkins MR, Robinson M, Rose BR et al.. “A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.” The New England journal of medicine (2006). PMID: 16421364 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 11. Prognosis and Natural History
[438]
Nichols DP, Singh PK, Baines A et al.. “Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial.” Thorax (2021). PMID: 34706982 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
[439]
Bilton D, Tino G, Barker AF et al.. “Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial.” Thorax (2014). PMID: 25246664 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
[440]
Wildman MJ, O'Cathain A, Maguire C et al.. “Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial.” Thorax (2021). PMID: 34556552 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
[441]
Dentice RL, Elkins MR, Middleton PG et al.. “A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis.” Thorax (2016). PMID: 26769016 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue
[442]
Cox NS, Eldridge B, Rawlings S et al.. “Web-based physical activity promotion in young people with CF: a randomised controlled trial.” Thorax (2022). PMID: 36180067 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, History and Evolution of Treatment, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[443]
Hoo ZH, Gardner B, Arden MA et al.. “Role of habit in treatment adherence among adults with cystic fibrosis.” Thorax (2018). PMID: 29886416 ↗
L2RCTCited in: 7. Acute Management and Exacerbation Rescue
[444]
Byrnes CA, Vidmar S, Cheney JL et al.. “Prospective evaluation of respiratory exacerbations in children with cystic fibrosis from newborn screening to 5 years of age.” Thorax (2013). PMID: 23345574 ↗
L2RCTCited in: 7. Acute Management and Exacerbation Rescue
[445]
Serisier DJ, Bilton D, De Soyza A et al.. “Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial.” Thorax (2013). PMID: 23681906 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue
[446]
Parreira VF, Janaudis-Ferreira T, Evans RA et al.. “Measurement properties of the incremental shuttle walk test. a systematic review.” Chest (2014). PMID: 24384555 ↗
L2SR_OBSCited in: 7. Acute Management and Exacerbation Rescue, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[447]
Diego AD, Milara J, Martinez-Moragón E et al.. “Effects of long-term azithromycin therapy on airway oxidative stress markers in non-cystic fibrosis bronchiectasis.” Respirology (Carlton, Vic.) (2013). PMID: 23714268 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
[448]
Mayer-Hamblett N, Gifford AH, Kloster M et al.. “Impact of Discontinuing Both Hypertonic Saline and Dornase Alfa after Elexacaftor-Tezacaftor-Ivacaftor in Cystic Fibrosis.” Annals of the American Thoracic Society (2024). PMID: 39041864 ↗
L2RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
[449]
Thornton CS, Caverly LJ, Kalikin LM et al.. “Prevalence and Clinical Impact of Respiratory Viral Infections from the STOP2 Study of Cystic Fibrosis Pulmonary Exacerbations.” Annals of the American Thoracic Society (2024). PMID: 37963297 ↗
L2RCTCited in: 7. Acute Management and Exacerbation Rescue, History and Evolution of Treatment
[450]
Kerem E, Cohen-Cymberknoh M, Tsabari R et al.. “Ivacaftor in People with Cystic Fibrosis and a 3849+10kb C→T or D1152H Residual Function Mutation.” Annals of the American Thoracic Society (2021). PMID: 33095038 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, History and Evolution of Treatment
[451]
Stahl M, Roehmel J, Eichinger M et al.. “Effects of Lumacaftor/Ivacaftor on Cystic Fibrosis Disease Progression in Children 2 through 5 Years of Age Homozygous for F508del-CFTR: A Phase 2 Placebo-controlled Clinical Trial.” Annals of the American Thoracic Society (2023). PMID: 36943405 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, History and Evolution of Treatment
[452]
Mall MA, Criner GJ, Miravitlles M et al.. “Cystic fibrosis transmembrane conductance regulator in COPD: a role in respiratory epithelium and beyond.” The European respiratory journal (2023). PMID: 37003609 ↗
L5REVIEW_NARRATIVECited in: 7. Acute Management and Exacerbation Rescue
[453]
Cavinato L, Luly FR, Pastore V et al.. “Elexacaftor/tezacaftor/ivacaftor corrects monocyte microbicidal deficiency in cystic fibrosis.” The European respiratory journal (2023). PMID: 36455959 ↗
L4OTHERCited in: 7. Acute Management and Exacerbation Rescue
[454]
Sexton P, Harrison AC. “Susceptibility to nontuberculous mycobacterial lung disease.” The European respiratory journal (2008). PMID: 18515557 ↗
L2REVIEW_NARRATIVECited in: 7. Acute Management and Exacerbation Rescue
[455]
McKeon DJ, Cadwallader KA, Idris S et al.. “Cystic fibrosis neutrophils have normal intrinsic reactive oxygen species generation.” The European respiratory journal (2009). PMID: 19840964 ↗
L3OTHERCited in: 7. Acute Management and Exacerbation Rescue
[456]
Jones T, O'Grady KF, Goyal V et al.. “Short and long-term effects of a play-based therapeutic exercise programme in children with non-cystic fibrosis bronchiectasis: A randomised controlled trial.” Journal of science and medicine in sport (2026). PMID: 41720729 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue
[457]
Kakkoura MG, Anagnostopoulou P, Kouis P et al.. “The CARMUCI Study Design: A Double-Blind, Cross-Over Sham-Controlled Trial of Indoor Air Purification in People With Cystic Fibrosis and Primary Ciliary Dyskinesia.” Pediatric pulmonology (2026). PMID: 41674312 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue
[458]
Oates GR, Geurs R, Mims C et al.. “Clinical effort against smoke exposure in cystic fibrosis (CEASE-CF): feasibility, acceptability, and preliminary efficacy.” Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society (2026). PMID: 41611592 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 13. Prevention, Screening & Surveillance
[459]
Taylor E, Soilemezi D, Urquhart DS et al.. “Exploring Exercise as Airway Clearance in Cystic Fibrosis: A Qualitative Study From the ExACT-CF Feasibility Trial.” Pediatric pulmonology (2026). PMID: 41587390 ↗
L5RCTCited in: 7. Acute Management and Exacerbation Rescue
[460]
Hoppe JE, Paisley A, Vigers T et al.. “Reliability of Clinic-Obtained vs Self-Obtained Respiratory Samples From the Self-Sample Accuracy and Benefit Implementation Trial (S2wAB-IT).” Chest (2026). PMID: 41534707 ↗
L4RCTCited in: 7. Acute Management and Exacerbation Rescue, 13. Prevention, Screening & Surveillance
[461]
McElvaney OJ, Heltshe SL, Sanders DB et al.. “Correlates of FEV₁ deficit in pulmonary exacerbations of cystic fibrosis and associated clinical outcomes.” Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society (2025). PMID: 41387145 ↗
L2RCTCited in: 7. Acute Management and Exacerbation Rescue
[462]
Rivilla Rivilla R, Méndez Alonso AY, Roque Betancourt E et al.. “Electrovest®: A novel portable electro-vibratory device for airway clearance in chronic hypersecretory lung diseases.” Pulmonology (2025). PMID: 41324124 ↗
L4RCTCited in: 7. Acute Management and Exacerbation Rescue
[463]
Miller P, Repplinger D, Zhu R et al.. “Randomized, phase I studies to evaluate the safety, tolerability, and pharmacokinetics of an inhaled, TMEM16A potentiator, GDC-6988, in healthy subjects.” Therapeutic advances in respiratory disease (2025). PMID: 41318901 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue
[464]
Upadhyay H, Robinson-Barella A, Husband A et al.. “Improving patient engagement in clinical trials: Launching the BOAT trial with key stakeholders.” Respiratory medicine (2025). PMID: 41412269 ↗
L5TRIAL_NONRANDOMCited in: 7. Acute Management and Exacerbation Rescue
[465]
von Stackelberg C, Moritz S, Gabbert T et al.. “MukoHelp: A self-help manual for patients with cystic fibrosis-Results from a randomized controlled trial.” Acta psychologica (2026). PMID: 41619375 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue
[466]
Wilson LM, Saldanha IJ, Robinson KA. “Active cycle of breathing technique for cystic fibrosis.” The Cochrane database of systematic reviews (2023). PMID: 36727723 ↗
L1SR_OBSCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 11. Prognosis and Natural History
[467]
Elphick HE, Mallory G. “Oxygen therapy for cystic fibrosis.” The Cochrane database of systematic reviews (2013). PMID: 23888484 ↗
L1SR_OBSCited in: 7. Acute Management and Exacerbation Rescue, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[468]
Sousa AS, Rocha-Filho CR, Rocha A et al.. “Non-invasive ventilation for cystic fibrosis.” The Cochrane database of systematic reviews (2025). PMID: 41251249 ↗
L1SR_OBSCited in: 7. Acute Management and Exacerbation Rescue
[469]
Stanford G, Ryan H, Solis-Moya A. “Respiratory muscle training for cystic fibrosis.” The Cochrane database of systematic reviews (2020). PMID: 33331663 ↗
L1SR_OBSCited in: 7. Acute Management and Exacerbation Rescue, 12. Special Populations & Pregnancy
[470]
Elphick HE, Mallory G. “Oxygen therapy for cystic fibrosis.” The Cochrane database of systematic reviews (2009). PMID: 19160226 ↗
L1SR_OBSCited in: 7. Acute Management and Exacerbation Rescue, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[471]
Nicholson TT, Barry PJ, Waterhouse DF et al.. “Relationship between pulmonary hyperinflation and dyspnoea severity during acute exacerbations of cystic fibrosis.” Respirology (Carlton, Vic.) (2016). PMID: 27614791 ↗
L4OTHERCited in: 7. Acute Management and Exacerbation Rescue
[472]
Gu X, Wang Z, Xu J et al.. “Denopamine stimulates alveolar fluid clearance via cystic fibrosis transmembrane conductance regulator in rat lungs.” Respirology (Carlton, Vic.) (2006). PMID: 16916328 ↗
L5OTHERCited in: 7. Acute Management and Exacerbation Rescue
[473]
Bayomy OF, Ramos KJ, Hee Wai T et al.. “Hemoptysis and the Risk for Lung Transplant or Death without Transplant in Individuals with Cystic Fibrosis in the United States.” Annals of the American Thoracic Society (2022). PMID: 35759341 ↗
L2REVIEW_NARRATIVECited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[474]
Burgel PR, Paillasseur JL, Durieu I et al.. “Multisystemic Effects of Elexacaftor-Tezacaftor-Ivacaftor in Adults with Cystic Fibrosis and Advanced Lung Disease.” Annals of the American Thoracic Society (2024). PMID: 38579175 ↗
L4OTHERCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[475]
Ahmed MI, Dayman N, Blyth N et al.. “Impact of CFTR modulators on exercise capacity in adolescents with cystic fibrosis.” ERJ open research (2024). PMID: 38375430 ↗
L4OTHERCited in: 7. Acute Management and Exacerbation Rescue
[476]
Gaupmann R, Stöger L, Schmidthaler K et al.. “Long-term exercise capacity in paediatric cystic fibrosis: a modern era perspective.” ERJ open research (2025). PMID: 40630381 ↗
L4OTHERCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 13. Prevention, Screening & Surveillance
[477]
Button BM, Wilson LM, Burge AT et al.. “The AWESCORE, a patient-reported outcome measure: development, feasibility, reliability, validity and responsiveness for adults with cystic fibrosis.” ERJ open research (2021). PMID: 34549047 ↗
L2OTHERCited in: 7. Acute Management and Exacerbation Rescue
[478]
Brunel SF, Willment JA, Brown GD et al.. “Aspergillus-induced superoxide production by cystic fibrosis phagocytes is associated with disease severity.” ERJ open research (2018). PMID: 29651422 ↗
L5OTHERCited in: 7. Acute Management and Exacerbation Rescue
[479]
Moeller A, Thanikkel L, Duijts L et al.. “COVID-19 in children with underlying chronic respiratory diseases: survey results from 174 centres.” ERJ open research (2020). PMID: 33263054 ↗
L4OTHERCited in: 7. Acute Management and Exacerbation Rescue
[480]
Button BM, Wilson C, Dentice R et al.. “Physiotherapy for cystic fibrosis in Australia and New Zealand: A clinical practice guideline.” Respirology (Carlton, Vic.) (2016). PMID: 27086904 ↗
L1GUIDELINECited in: 8. Long-term and Definitive Management, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[481]
Wu Q, Shen W, Cheng H et al.. “Long-term macrolides for non-cystic fibrosis bronchiectasis: a systematic review and meta-analysis.” Respirology (Carlton, Vic.) (2014). PMID: 24417869 ↗
L1SR_OBSCited in: 8. Long-term and Definitive Management, 11. Prognosis and Natural History
[482]
Wang S, Niroula S, Hoffman A et al.. “Inflammatory Activity of Epithelial Stem Cell Variants from Cystic Fibrosis Lungs Is Not Resolved by CFTR Modulators.” American journal of respiratory and critical care medicine (2023). PMID: 37695863 ↗
L5OTHERCited in: 8. Long-term and Definitive Management, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[483]
Nichols DP, Odem-Davis K, Cogen JD et al.. “Pulmonary Outcomes Associated with Long-Term Azithromycin Therapy in Cystic Fibrosis.” American journal of respiratory and critical care medicine (2020). PMID: 31661302 ↗
L2OTHERCited in: 8. Long-term and Definitive Management
[484]
Fischer AJ, Singh SB, LaMarche MM et al.. “Sustained Coinfections with Staphylococcus aureus and Pseudomonas aeruginosa in Cystic Fibrosis.” American journal of respiratory and critical care medicine (2021). PMID: 32750253 ↗
L2OTHERCited in: 8. Long-term and Definitive Management
[485]
Burgel PR, Mall MA. “Advances in cystic fibrosis: CFTR modulator triple combinations.” The European respiratory journal (2026). PMID: 41309268 ↗
L5OTHERCited in: 8. Long-term and Definitive Management, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 10. Complications
[486]
Spagnolo P, Fabbri LM, Bush A. “Long-term macrolide treatment for chronic respiratory disease.” The European respiratory journal (2012). PMID: 23180583 ↗
L5REVIEW_NARRATIVECited in: 8. Long-term and Definitive Management, 11. Prognosis and Natural History
[487]
Crosbie PA, Woodhead MA. “Long-term macrolide therapy in chronic inflammatory airway diseases.” The European respiratory journal (2009). PMID: 19118228 ↗
L5REVIEW_NARRATIVECited in: 8. Long-term and Definitive Management
[488]
Muilwijk D, de Poel E, van Mourik P et al.. “Forskolin-induced organoid swelling is associated with long-term cystic fibrosis disease progression.” The European respiratory journal (2022). PMID: 35086832 ↗
L2OTHERCited in: 8. Long-term and Definitive Management
[489]
Elborn JS, Bell SC, Madge SL et al.. “Report of the European Respiratory Society/European Cystic Fibrosis Society task force on the care of adults with cystic fibrosis.” The European respiratory journal (2015). PMID: 26453627 ↗
L5OTHERCited in: 8. Long-term and Definitive Management, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 10. Complications
[490]
Le Ribeuz H, To L, Ghigna MR et al.. “Involvement of CFTR in the pathogenesis of pulmonary arterial hypertension.” The European respiratory journal (2021). PMID: 33926975 ↗
L5OTHERCited in: 8. Long-term and Definitive Management, 10. Complications
[491]
Khanal S, Webster M, Niu N et al.. “SPLUNC1: a novel marker of cystic fibrosis exacerbations.” The European respiratory journal (2021). PMID: 33958427 ↗
L2OTHERCited in: 8. Long-term and Definitive Management
[492]
Turkovic L, Caudri D, Rosenow T et al.. “Structural determinants of long-term functional outcomes in young children with cystic fibrosis.” The European respiratory journal (2020). PMID: 32139454 ↗
L2OTHERCited in: 8. Long-term and Definitive Management
[493]
De Soyza A, Mawson P, Hill AT et al.. “BronchUK: protocol for an observational cohort study and biobank in bronchiectasis.” ERJ open research (2021). PMID: 33898620 ↗
L5COHORTCited in: 8. Long-term and Definitive Management, History and Evolution of Treatment, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[494]
Bry C, Hubert D, Reynaud-Gaubert M et al.. “Pregnancy after lung and heart-lung transplantation: a French multicentre retrospective study of 39 pregnancies.” ERJ open research (2019). PMID: 31687369 ↗
L4COHORTCited in: 8. Long-term and Definitive Management, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 10. Complications, 11. Prognosis and Natural History, 12. Special Populations & Pregnancy
[495]
Burgel PR, Sermet-Gaudelus I, Girodon E et al.. “The expanded French compassionate programme for elexacaftor-tezacaftor-ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study.” The Lancet. Respiratory medicine (2024). PMID: 39151434 ↗
L2OTHERCited in: 8. Long-term and Definitive Management
[496]
Lobo LJ, Noone PG. “Respiratory infections in patients with cystic fibrosis undergoing lung transplantation.” The Lancet. Respiratory medicine (2013). PMID: 24461904 ↗
L5REVIEW_NARRATIVECited in: 8. Long-term and Definitive Management, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 10. Complications, 13. Prevention, Screening & Surveillance
[497]
Mayer-Hamblett N, Kerper NR, Clancy JP et al.. “Maximising opportunity for therapeutic success: sequential participation in cystic fibrosis nucleic acid-based therapy trials.” The Lancet. Respiratory medicine (2025). PMID: 40752498 ↗
L5REVIEW_NARRATIVECited in: 8. Long-term and Definitive Management
[498]
Plant BJ, Goss CH, Plant WD et al.. “Management of comorbidities in older patients with cystic fibrosis.” The Lancet. Respiratory medicine (2013). PMID: 24429097 ↗
L5REVIEW_NARRATIVECited in: 8. Long-term and Definitive Management, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 10. Complications
[499]
Downey DG, Houston C, Mayer-Hamblett N et al.. “Contributors to the heterogeneity of response to CFTR modulators.” The Lancet. Respiratory medicine (2026). PMID: 42030963 ↗
L5REVIEW_NARRATIVECited in: 8. Long-term and Definitive Management
[500]
Hoppe JE, Chilvers M, Ratjen F et al.. “Long-term safety of lumacaftor-ivacaftor in children aged 2-5 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a multicentre, phase 3, open-label, extension study.” The Lancet. Respiratory medicine (2021). PMID: 33965000 ↗
L2OTHERCited in: 8. Long-term and Definitive Management
[501]
Hadjiliadis D. “Special considerations for patients with cystic fibrosis undergoing lung transplantation.” Chest (2007). PMID: 17426231 ↗
L5REVIEW_NARRATIVECited in: 8. Long-term and Definitive Management, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[502]
Breuer O, Shoseyov D, Koretz S et al.. “Ethical Dilemma: Elexacaftor-Tezacaftor-Ivacaftor or Lung Transplantation in Cystic Fibrosis and End-Stage Lung Disease?” Chest (2021). PMID: 34506793 ↗
L4REVIEW_NARRATIVECited in: 8. Long-term and Definitive Management, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[503]
Friedlander AL, Albert RK. “Chronic macrolide therapy in inflammatory airways diseases.” Chest (2010). PMID: 21051396 ↗
L5REVIEW_NARRATIVECited in: 8. Long-term and Definitive Management
[504]
Ramos KJ, Hee Wai T, Stephenson AL et al.. “Development and Internal Validation of a Prognostic Model of the Probability of Death or Lung Transplantation Within 2 Years for Patients With Cystic Fibrosis and FEV1 ≤ 50% Predicted.” Chest (2022). PMID: 35643116 ↗
L2OTHERCited in: 8. Long-term and Definitive Management, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[505]
Ramos KJ, Kapnadak SG, Bradford MC et al.. “Underweight Patients With Cystic Fibrosis Have Acceptable Survival Following Lung Transplantation: A United Network for Organ Sharing Registry Study.” Chest (2020). PMID: 31958441 ↗
L2OTHERCited in: 8. Long-term and Definitive Management, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[506]
Heltshe SL, Goss CH, Thompson V et al.. “Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis.” Thorax (2015). PMID: 25911223 ↗
L2OTHERCited in: 8. Long-term and Definitive Management
[507]
Merlo CA, Thorat T, DerSarkissian M et al.. “Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis.” Thorax (2024). PMID: 38937105 ↗
L2OTHERCited in: 8. Long-term and Definitive Management
[508]
Nelson MT, Wolter DJ, Eng A et al.. “Maintenance tobramycin primarily affects untargeted bacteria in the CF sputum microbiome.” Thorax (2020). PMID: 32631930 ↗
L2OTHERCited in: 8. Long-term and Definitive Management
[509]
Granger E, Davies G, Keogh RH. “Emulated trial investigating effects of multiple treatments: estimating combined effects of mucoactive nebulisers in cystic fibrosis using registry data.” Thorax (2023). PMID: 37451864 ↗
L2OTHERCited in: 8. Long-term and Definitive Management
[510]
AlMunefi F, Dyce JP, Zhao JY et al.. “Impact of Elexacaftor/Tezacaftor/Ivacaftor (ETI) on Airway and Aystemic Inflammation in Cystic Fibrosis: A Systematic Review.” Annals of the American Thoracic Society (2026). PMID: 42397988 ↗
L4SR_OBSCited in: 8. Long-term and Definitive Management, 11. Prognosis and Natural History
[511]
Venditto L, Neece A, Forgione F et al.. “Safety and extrapulmonary effects of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis following lung transplantation: A systematic review and meta-analysis.” Paediatric respiratory reviews (2026). PMID: 42120233 ↗
L2SR_OBSCited in: 8. Long-term and Definitive Management, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 10. Complications
[512]
Ertan SN, Alomari O, Mokresh ME et al.. “Endoscopic sinus surgery for lung transplanted cystic fibrosis patients: a systematic review and meta-analysis.” European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery (2026). PMID: 41940930 ↗
L2SR_OBSCited in: 8. Long-term and Definitive Management, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 10. Complications
[513]
Onady GM, Stolfi A. “Insulin and oral agents for managing cystic fibrosis-related diabetes.” The Cochrane database of systematic reviews (2016). PMID: 27087121 ↗
L1SR_OBSCited in: 8. Long-term and Definitive Management
[514]
Sharma A, Easow Mathew M, Sriganesh V et al.. “Gene therapy for haemophilia.” The Cochrane database of systematic reviews (2020). PMID: 32342499 ↗
L1SR_OBSCited in: 8. Long-term and Definitive Management
[515]
Kharraz R, Tullis E, Sykes J et al.. “Real-world impact of elexacaftor/tezacaftor/ivacaftor on health-related quality of life in adults with cystic fibrosis: A 12-month multicenter cohort study.” Respiratory medicine (2026). PMID: 42019640 ↗
L2COHORTCited in: 8. Long-term and Definitive Management
[516]
Jang EJ, Lee CH, Yoon HI et al.. “Association between inhaler use and risk of haemoptysis in patients with non-cystic fibrosis bronchiectasis.” Respirology (Carlton, Vic.) (2015). PMID: 26293490 ↗
L3OTHERCited in: 8. Long-term and Definitive Management
[517]
Park J, Kim S, Lee YJ et al.. “Factors associated with radiologic progression of non-cystic fibrosis bronchiectasis during long-term follow-up.” Respirology (Carlton, Vic.) (2016). PMID: 26997422 ↗
L2OTHERCited in: 8. Long-term and Definitive Management
[518]
Cox NS, Alison JA, Button BM et al.. “Physical activity participation by adults with cystic fibrosis: An observational study.” Respirology (Carlton, Vic.) (2015). PMID: 26715596 ↗
L2OTHERCited in: 8. Long-term and Definitive Management
[519]
Kwok WC, Ho JCM, Tam TCC et al.. “Increased exacerbations of bronchiectasis following recovery from mild COVID-19 in patients with non-cystic fibrosis bronchiectasis.” Respirology (Carlton, Vic.) (2024). PMID: 38290828 ↗
L2OTHERCited in: 8. Long-term and Definitive Management
[520]
Miranda Afonso P, Zhou GC, Su W et al.. “Evaluating Long-Term Effectiveness of Cystic Fibrosis Modulator Therapies after Rapid Adoption: A Dual-Approach Study.” Annals of the American Thoracic Society (2026). PMID: 40920855 ↗
L2OTHERCited in: 8. Long-term and Definitive Management
[521]
Denis A, Touzet S, Diabaté L et al.. “Quantifying Long-Term Changes in Lung Function and Exacerbations after Initiation of Azithromycin in Cystic Fibrosis.” Annals of the American Thoracic Society (2020). PMID: 31604024 ↗
L2OTHERCited in: 8. Long-term and Definitive Management
[522]
Davis CS, Faino AV, Onchiri F et al.. “Systemic Corticosteroids in the Management of Pediatric Cystic Fibrosis Pulmonary Exacerbations.” Annals of the American Thoracic Society (2023). PMID: 36044723 ↗
L2OTHERCited in: 8. Long-term and Definitive Management, 12. Special Populations & Pregnancy
[523]
Lu W, Li Q, Zheng S et al.. “Inhaled tobramycin for chronic pseudomonas aeruginosa infection in non-cystic fibrosis bronchiectasis: an updated systematic review and meta-analysis.” BMC pulmonary medicine (2026). PMID: 42032539 ↗
L1SR_OBSCited in: 8. Long-term and Definitive Management
[524]
Vijverberg SJH, Kampouras A, Nayir Büyükşahin H et al.. “ERS International Congress 2023: highlights from the Paediatrics Assembly.” ERJ open research (2024). PMID: 38410713 ↗
L5OTHERCited in: 8. Long-term and Definitive Management
[525]
Granger E, Keogh RH, Frost F. “The long-term effects of insulin use in incident cystic fibrosis-related diabetes: a target trial emulated using longitudinal national registry data.” ERJ open research (2022). PMID: 36382232 ↗
L2OTHERCited in: 8. Long-term and Definitive Management
[526]
King SJ, Keating D, Williams E et al.. “Lumacaftor/ivacaftor-associated health stabilisation in adults with severe cystic fibrosis.” ERJ open research (2021). PMID: 33569502 ↗
L4OTHERCited in: 8. Long-term and Definitive Management, History and Evolution of Treatment, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[527]
Matsumoto T, Suga H, Kajiwara Y et al.. “Impact of erythromycin discontinuation owing to supply disruption on exacerbations in non-cystic fibrosis bronchiectasis: A retrospective cohort study.” Respiratory investigation (2026). PMID: 42013504 ↗
L2COHORTCited in: 8. Long-term and Definitive Management
[528]
Gaglani B, Andermann TM, Wate C et al.. “Sulbactam-durlobactam and cefiderocol combination treatment of Burkholderia cenocepacia-associated Fitz-Hugh-Curtis syndrome.” Antimicrobial agents and chemotherapy (2026). PMID: 42059812 ↗
L4CASE_REPORTCited in: 8. Long-term and Definitive Management, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[529]
Wang LW, Peters S, Hannikainen P et al.. “The role, evaluation, and effects of comorbidities in patients with chronic rhinosinusitis.” The journal of allergy and clinical immunology. In practice (2026). PMID: 42386153 ↗
L5OTHERCited in: 8. Long-term and Definitive Management
[530]
Maslennikov R, Agarkova V, Poluektova E et al.. “Treatment of Small Intestinal Bacterial Overgrowth (SIBO) in Gastrointestinal, Hepatic, Endocrine, Neurological, and Postoperative Diseases: A Comprehensive Narrative Review.” Medical sciences (Basel, Switzerland) (2026). PMID: 42346839 ↗
L5REVIEW_NARRATIVECited in: 8. Long-term and Definitive Management
[531]
Döring G, Conway SP, Heijerman HG et al.. “Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus.” The European respiratory journal (2000). PMID: 11106223 ↗
L5GUIDELINECited in: History and Evolution of Treatment
[532]
Hodson ME, Gallagher CG, Govan JR. “A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis.” The European respiratory journal (2002). PMID: 12358344 ↗
L1RCTCited in: History and Evolution of Treatment
[533]
Grasemann H, Grasemann C, Kurtz F et al.. “Oral L-arginine supplementation in cystic fibrosis patients: a placebo-controlled study.” The European respiratory journal (2005). PMID: 15640324 ↗
L1RCTCited in: History and Evolution of Treatment
[534]
Alothman GA, Ho B, Alsaadi MM et al.. “Bronchial constriction and inhaled colistin in cystic fibrosis.” Chest (2005). PMID: 15705991 ↗
L1RCTCited in: History and Evolution of Treatment
[535]
Zeitlin PL, Boyle MP, Guggino WB et al.. “A phase I trial of intranasal Moli1901 for cystic fibrosis.” Chest (2004). PMID: 14718433 ↗
L1RCTCited in: History and Evolution of Treatment
[536]
Ranganathan SC, Hall GL, Sly PD et al.. “Early Lung Disease in Infants and Preschool Children with Cystic Fibrosis. What Have We Learned and What Should We Do about It?” American journal of respiratory and critical care medicine (2017). PMID: 27911585 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[537]
Hoffman LR, Ramsey BW. “Cystic fibrosis therapeutics: the road ahead.” Chest (2013). PMID: 23276843 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[538]
Geller DE, Pitlick WH, Nardella PA et al.. “Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis.” Chest (2002). PMID: 12114362 ↗
L2REVIEW_NARRATIVECited in: History and Evolution of Treatment
[539]
Field SK, Fisher D, Cowie RL. “Mycobacterium avium complex pulmonary disease in patients without HIV infection.” Chest (2004). PMID: 15302746 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[540]
Calthorpe RJ, Smith S, Gathercole K et al.. “Using digital technology for home monitoring, adherence and self-management in cystic fibrosis: a state-of-the-art review.” Thorax (2019). PMID: 31594802 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[541]
Mackie A, Rascher J, Schmid M et al.. “First clinical trials of the inhaled epithelial sodium channel inhibitor BI 1265162 in healthy volunteers.” ERJ open research (2021). PMID: 33569494 ↗
L4TRIAL_NONRANDOMCited in: History and Evolution of Treatment
[542]
Newman JH. “Pulmonary hypertension.” American journal of respiratory and critical care medicine (2005). PMID: 15994464 ↗
L5OTHERCited in: History and Evolution of Treatment
[543]
Halfhide C, Evans HJ, Couriel J. “WITHDRAWN: Inhaled bronchodilators for cystic fibrosis.” The Cochrane database of systematic reviews (2016). PMID: 26866910 ↗
L5SR_OBSCited in: History and Evolution of Treatment
[544]
Poustie VJ, Rutherford P. “Dietary interventions for phenylketonuria.” The Cochrane database of systematic reviews (2000). PMID: 10796766 ↗
L1SR_OBSCited in: History and Evolution of Treatment
[545]
Spencer S, Donovan T, Chalmers JD et al.. “Intermittent prophylactic antibiotics for bronchiectasis.” The Cochrane database of systematic reviews (2022). PMID: 34985761 ↗
L1SR_OBSCited in: History and Evolution of Treatment
[546]
Almeida PRL, Person OC, Puga ME et al.. “Surgery for nasal polyposis in cystic fibrosis.” The Cochrane database of systematic reviews (2023). PMID: 38063253 ↗
L1SR_OBSCited in: History and Evolution of Treatment
[547]
Smith S, Rowbotham NJ, Edwards CT. “Short-acting inhaled bronchodilators for cystic fibrosis.” The Cochrane database of systematic reviews (2022). PMID: 35749226 ↗
L1SR_OBSCited in: History and Evolution of Treatment
[548]
Hnin K, Nguyen C, Carson KV et al.. “Prolonged antibiotics for non-cystic fibrosis bronchiectasis in children and adults.” The Cochrane database of systematic reviews (2015). PMID: 26270620 ↗
L1SR_OBSCited in: History and Evolution of Treatment
[549]
Spencer S, Felix LM, Milan SJ et al.. “Oral versus inhaled antibiotics for bronchiectasis.” The Cochrane database of systematic reviews (2018). PMID: 29587336 ↗
L1SR_OBSCited in: History and Evolution of Treatment
[550]
Oniyangi O, Cohall DH. “Phytomedicines (medicines derived from plants) for sickle cell disease.” The Cochrane database of systematic reviews (2018). PMID: 29446825 ↗
L1SR_OBSCited in: History and Evolution of Treatment
[551]
Kolbe J, Wells A, Ram FS. “Inhaled steroids for bronchiectasis.” The Cochrane database of systematic reviews (2000). PMID: 10796575 ↗
L1SR_OBSCited in: History and Evolution of Treatment
[552]
O'Connor TM, O'Donnell A, Hurley M et al.. “Allergic bronchopulmonary aspergillosis: a rare cause of pleural effusion.” Respirology (Carlton, Vic.) (2001). PMID: 11844130 ↗
L4CASE_REPORTCited in: History and Evolution of Treatment
[553]
Georgiopoulou VV, Denker A, Bishop KL et al.. “Metabolic abnormalities in adults with cystic fibrosis.” Respirology (Carlton, Vic.) (2010). PMID: 20497385 ↗
L4OTHERCited in: History and Evolution of Treatment, 10. Complications
[554]
Venning V, Bartlett J, Jayaram L. “Patients hospitalized with an infective exacerbation of bronchiectasis unrelated to cystic fibrosis: Clinical, physiological and sputum characteristics.” Respirology (Carlton, Vic.) (2017). PMID: 28236369 ↗
L4OTHERCited in: History and Evolution of Treatment
[555]
Blackall SR, Hong JB, King P et al.. “Bronchiectasis in indigenous and non-indigenous residents of Australia and New Zealand.” Respirology (Carlton, Vic.) (2018). PMID: 29502335 ↗
L2OTHERCited in: History and Evolution of Treatment
[556]
Szczesniak R, Andrinopoulou ER, Su W et al.. “Lung Function Decline in Cystic Fibrosis: Impact of Data Availability and Modeling Strategies on Clinical Interpretations.” Annals of the American Thoracic Society (2023). PMID: 36884219 ↗
L2OTHERCited in: History and Evolution of Treatment
[557]
Chmiel JF, McBennett K, Quon BS et al.. “Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in adolescents and adults with cystic fibrosis and F508del-gating and F508del-residual function genotypes: Results from an open-label extension study.” Annals of the American Thoracic Society (2026). PMID: 41837895 ↗
L4OTHERCited in: History and Evolution of Treatment
[558]
Hong G, Walsh J, Koshy A et al.. “Home sputum collection for Aspergillus fumigatus detection in adults with cystic fibrosis.” ERJ open research (2025). PMID: 41333983 ↗
L2OTHERCited in: History and Evolution of Treatment
[559]
Woo TE, Lim R, Surette MG et al.. “Epidemiology and natural history of Pseudomonas aeruginosa airway infections in non-cystic fibrosis bronchiectasis.” ERJ open research (2018). PMID: 29930949 ↗
L2OTHERCited in: History and Evolution of Treatment
[560]
Hatziagorou E, Fieuws S, Orenti A et al.. “Risk factors for forced expiratory volume in 1 s decline in European patients with cystic fibrosis: data from the European Cystic Fibrosis Society Patient Registry.” ERJ open research (2023). PMID: 37483280 ↗
L2OTHERCited in: History and Evolution of Treatment
[561]
Keir HR, Fong CJ, Crichton ML et al.. “Personalised anti-inflammatory therapy for bronchiectasis and cystic fibrosis: selecting patients for controlled trials of neutrophil elastase inhibition.” ERJ open research (2019). PMID: 30918898 ↗
L4OTHERCited in: History and Evolution of Treatment
[562]
Chalmers JD, Aliberti S, Polverino E et al.. “The EMBARC European Bronchiectasis Registry: protocol for an international observational study.” ERJ open research (2016). PMID: 27730179 ↗
L5OTHERCited in: History and Evolution of Treatment
[563]
Urquhart DS, Linnane B, Saunders CJ et al.. “ENHANCE: a community partnership charting the evolution of early-life cystic fibrosis disease manifestations in a new era of management.” ERJ open research (2026). PMID: 41878283 ↗
L5OTHERCited in: History and Evolution of Treatment, 12. Special Populations & Pregnancy
[564]
Miranda M, Brown M, van Haren FMP et al.. “Nebulised heparin as a treatment for lung diseases: formulation challenges and pulmonary drug delivery strategies.” Lung (2026). PMID: 42384225 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[565]
Gautiez R, Reix P, Poupon-Bourdy S et al.. “Transformations within cystic fibrosis model of care in the era of CFTR modulators: a Scoping Review.” Respiratory medicine (2026). PMID: 42379530 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[566]
Lopatina M, Demchenko A, Smirnikhina S. “Cellular Models and Functional Assays for Assessing CFTR Function: A Comprehensive Review.” International journal of molecular sciences (2026). PMID: 42353213 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[567]
Lo Mascolo F, Lipani A, Giuffrida S et al.. “A critical analysis on ENaC inhibitors, unravelling molecular medicinal insights and promising research roadmap in the treatment of cystic fibrosis.” European journal of medicinal chemistry (2026). PMID: 42184559 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[568]
Pawlak KM, Jagielski M, Papanikolaou IS et al.. “Pancreatic cystic lesions in hereditary syndromes: Diagnostic role of endoscopic ultrasound.” Best practice & research. Clinical gastroenterology (2026). PMID: 42167859 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[569]
Altan G. “Pulmonary infections in cystic fibrosis: A bibliometric mapping of global research themes (1950-2025).” Respiratory medicine (2026). PMID: 41997546 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[570]
Regamey N, Hilliard TN, Saglani S et al.. “Quality, size, and composition of pediatric endobronchial biopsies in cystic fibrosis.” Chest (2007). PMID: 17317731 ↗
L4TRIAL_NONRANDOMCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 12. Special Populations & Pregnancy
[571]
Taylor D, Jenkins AR, Parrott K et al.. “Efficacy of unsupervised exercise in adults with obstructive lung disease: a systematic review and meta-analysis.” Thorax (2021). PMID: 33685962 ↗
L1SR_OBSCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 11. Prognosis and Natural History
[572]
Jabbarian LJ, Zwakman M, van der Heide A et al.. “Advance care planning for patients with chronic respiratory diseases: a systematic review of preferences and practices.” Thorax (2017). PMID: 29109233 ↗
L5SR_OBSCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[573]
McElvaney OJ, Zaslona Z, Becker-Flegler K et al.. “Specific Inhibition of the NLRP3 Inflammasome as an Antiinflammatory Strategy in Cystic Fibrosis.” American journal of respiratory and critical care medicine (2019). PMID: 31454256 ↗
L5OTHERCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[574]
Malet K, Faure E, Adam D et al.. “Intracellular Pseudomonas aeruginosa within the Airway Epithelium of Cystic Fibrosis Lung Tissues.” American journal of respiratory and critical care medicine (2024). PMID: 38324627 ↗
L5OTHERCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[575]
Murray S, Charbeneau J, Marshall BC et al.. “Impact of burkholderia infection on lung transplantation in cystic fibrosis.” American journal of respiratory and critical care medicine (2008). PMID: 18535253 ↗
L2OTHERCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[576]
Burgel PR, Durieu I, Chiron R et al.. “Rapid Improvement after Starting Elexacaftor-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease.” American journal of respiratory and critical care medicine (2021). PMID: 33600738 ↗
L2OTHERCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[577]
Thabut G, Christie JD, Mal H et al.. “Survival benefit of lung transplant for cystic fibrosis since lung allocation score implementation.” American journal of respiratory and critical care medicine (2013). PMID: 23590274 ↗
L2OTHERCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[578]
Kolaitis NA, Chen H, Calabrese DR et al.. “The Lung Allocation Score Remains Inequitable for Patients with Pulmonary Arterial Hypertension, Even after the 2015 Revision.” American journal of respiratory and critical care medicine (2023). PMID: 36094471 ↗
L2OTHERCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[579]
Chen H, Shiboski SC, Golden JA et al.. “Impact of the lung allocation score on lung transplantation for pulmonary arterial hypertension.” American journal of respiratory and critical care medicine (2009). PMID: 19520906 ↗
L2OTHERCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[580]
Quon BS, Psoter K, Mayer-Hamblett N et al.. “Disparities in access to lung transplantation for patients with cystic fibrosis by socioeconomic status.” American journal of respiratory and critical care medicine (2012). PMID: 22983958 ↗
L2OTHERCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[581]
Lederer DJ, Wilt JS, D'Ovidio F et al.. “Obesity and underweight are associated with an increased risk of death after lung transplantation.” American journal of respiratory and critical care medicine (2009). PMID: 19608717 ↗
L2OTHERCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[582]
Hebestreit H, Hulzebos EHJ, Schneiderman JE et al.. “Cardiopulmonary Exercise Testing Provides Additional Prognostic Information in Cystic Fibrosis.” American journal of respiratory and critical care medicine (2019). PMID: 30321487 ↗
L2OTHERCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[583]
Belkin RA, Henig NR, Singer LG et al.. “Risk factors for death of patients with cystic fibrosis awaiting lung transplantation.” American journal of respiratory and critical care medicine (2005). PMID: 16387803 ↗
L2OTHERCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[584]
Warren WA, Franco-Palacios D, King CS et al.. “A 24-Year-Old Woman With Precipitous Respiratory Failure After Lung Transplantation.” Chest (2018). PMID: 29519311 ↗
L4CASE_REPORTCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[585]
Kurz JM, Ramsey KA, Rodriguez R et al.. “Association of lung clearance index with survival in individuals with cystic fibrosis.” The European respiratory journal (2022). PMID: 34289977 ↗
L2OTHERCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 11. Prognosis and Natural History
[586]
Coriati A, Sykes J, Lemonnier L et al.. “Impact of a high emergency lung transplantation programme for cystic fibrosis in France: insight from a comparison with Canada.” The European respiratory journal (2022). PMID: 34140297 ↗
L2OTHERCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[587]
Dilokthornsakul P, Hansen RN, Campbell JD. “Forecasting US ivacaftor outcomes and cost in cystic fibrosis patients with the G551D mutation.” The European respiratory journal (2016). PMID: 27126691 ↗
L2OTHERCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[588]
Burgel PR, Sermet-Gaudelus I, Durieu I et al.. “The French compassionate programme of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del CFTR variant.” The European respiratory journal (2023). PMID: 36796836 ↗
L4OTHERCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[589]
Lachenal F, Nkana K, Nove-Josserand R et al.. “Prevalence and clinical significance of auto-antibodies in adults with cystic fibrosis.” The European respiratory journal (2009). PMID: 19443536 ↗
L2OTHERCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[590]
Vos R, Vanaudenaerde BM, Geudens N et al.. “Pseudomonal airway colonisation: risk factor for bronchiolitis obliterans syndrome after lung transplantation?” The European respiratory journal (2008). PMID: 18256072 ↗
L2OTHERCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[591]
Blondeau K, Mertens V, Vanaudenaerde BA et al.. “Gastro-oesophageal reflux and gastric aspiration in lung transplant patients with or without chronic rejection.” The European respiratory journal (2007). PMID: 18057058 ↗
L3OTHERCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[592]
Brodlie M, Aseeri A, Lordan JL et al.. “Bile acid aspiration in people with cystic fibrosis before and after lung transplantation.” The European respiratory journal (2015). PMID: 26493787 ↗
L4OTHERCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[593]
Garriga-Grimau L, Kantar A, Grimwood K et al.. “First results from the international paediatric bronchiectasis registry (Child-BEAR-Net Registry) describing multicountry variations in childhood bronchiectasis and its management: a multicentre, cross-sectional study.” The Lancet. Respiratory medicine (2025). PMID: 40757932 ↗
L4OTHERCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[594]
Li SS, Miller R, Tumin D et al.. “Lung Allocation Score Thresholds Prioritize Survival After Lung Transplantation.” Chest (2019). PMID: 30664859 ↗
L2OTHERCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[595]
Meachery G, De Soyza A, Nicholson A et al.. “Outcomes of lung transplantation for cystic fibrosis in a large UK cohort.” Thorax (2008). PMID: 18487317 ↗
L2OTHERCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[596]
Frayman KB, Armstrong DS, Carzino R et al.. “The lower airway microbiota in early cystic fibrosis lung disease: a longitudinal analysis.” Thorax (2017). PMID: 28280235 ↗
L2OTHERCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[597]
Chalermskulrat W, Sood N, Neuringer IP et al.. “Non-tuberculous mycobacteria in end stage cystic fibrosis: implications for lung transplantation.” Thorax (2006). PMID: 16601086 ↗
L2OTHERCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[598]
Benden C, Harpur-Sinclair O, Ranasinghe AS et al.. “Surveillance bronchoscopy in children during the first year after lung transplantation: Is it worth it?” Thorax (2006). PMID: 16928706 ↗
L2OTHERCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 10. Complications, 13. Prevention, Screening & Surveillance
[599]
de Boer K, Vandemheen KL, Tullis E et al.. “Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis.” Thorax (2011). PMID: 21680566 ↗
L2OTHERCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[600]
Hayes D, Murphy BS, Mullett TW et al.. “Aerosolized vancomycin for the treatment of MRSA after lung transplantation.” Respirology (Carlton, Vic.) (2009). PMID: 19895389 ↗
L4CASE_REPORTCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[601]
Cinar B, Demir R, Zeren M et al.. “Effectiveness of the hippotherapy simulator in children and adolescents with cystic fibrosis: A randomized controlled trial.” Heart & lung : the journal of critical care (2025). PMID: 41385838 ↗
L1RCTCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[602]
Aksel-Uylar AA, Topcuoglu C, Saglam M et al.. “Effects of inspiratory muscle training on physical fitness in cystic fibrosis: a systematic review and meta-analysis.” BMC sports science, medicine & rehabilitation (2025). PMID: 41310767 ↗
L1SR_OBSCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[603]
Jain K, Wainwright C, Smyth AR. “Bronchoscopy-guided antimicrobial therapy for cystic fibrosis.” The Cochrane database of systematic reviews (2016). PMID: 26797965 ↗
L1SR_OBSCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[604]
Nonoyama ML, Brooks D, Lacasse Y et al.. “Oxygen therapy during exercise training in chronic obstructive pulmonary disease.” The Cochrane database of systematic reviews (2007). PMID: 17443585 ↗
L1SR_OBSCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[605]
Saldanha IJ, Akinyede O, Robinson KA. “Immunosuppressive drug therapy for preventing rejection following lung transplantation in cystic fibrosis.” The Cochrane database of systematic reviews (2018). PMID: 29921013 ↗
L1SR_OBSCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[606]
Jain K, Wainwright C, Smyth AR. “Bronchoscopy-guided antimicrobial therapy for cystic fibrosis.” The Cochrane database of systematic reviews (2013). PMID: 24363033 ↗
L1SR_OBSCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[607]
Saldanha IJ, Akinyede O, Robinson KA. “Immunosuppressive drug therapy for preventing rejection following lung transplantation in cystic fibrosis.” The Cochrane database of systematic reviews (2015). PMID: 26559561 ↗
L1SR_OBSCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[608]
Jeffery TC, Chang AB, Conwell LS. “Bisphosphonates for osteoporosis in people with cystic fibrosis.” The Cochrane database of systematic reviews (2023). PMID: 36625789 ↗
L1SR_OBSCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[609]
Volpi S, Ambroni M, Buzzetti R et al.. “Real-World Safety and Effectiveness of Elexacaftor, Tezacaftor, and Ivacaftor in People with Cystic Fibrosis and Advanced Lung Disease: A Two-Year Multicenter Cohort Study.” International journal of molecular sciences (2025). PMID: 41226552 ↗
L2COHORTCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[610]
He W, Wang Z, Luo C et al.. “Impact of Age Difference Between Donor and Recipient on Intermediate- and Long-Term Survival in Lung Transplant Recipients: A Cohort Study Based on Recipient Age Stratification.” European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery (2025). PMID: 41206072 ↗
L3COHORTCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[611]
Radtke T, Urquhart DS, Braun J et al.. “Cardiopulmonary Exercise Testing Provides Prognostic Information in Advanced Cystic Fibrosis Lung Disease.” Annals of the American Thoracic Society (2024). PMID: 37879036 ↗
L3OTHERCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[612]
Milinic T, Hobler MR, Bartlett LE et al.. “Qualitative Analysis of Perspectives on Lung Transplant among People with Cystic Fibrosis.” Annals of the American Thoracic Society (2024). PMID: 38259137 ↗
L5OTHERCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[613]
Thompson K, Staffa SJ, Nasr VG et al.. “Mortality after Lung Transplantation for Children Bridged with Extracorporeal Membrane Oxygenation.” Annals of the American Thoracic Society (2022). PMID: 34619069 ↗
L3OTHERCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 10. Complications
[614]
Vock DM, Durheim MT, Tsuang WM et al.. “Survival Benefit of Lung Transplantation in the Modern Era of Lung Allocation.” Annals of the American Thoracic Society (2017). PMID: 27779905 ↗
L3OTHERCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[615]
Sethi J, Bugajski A, Patel KN et al.. “Recipient Age Impacts Long-Term Survival in Adult Subjects with Cystic Fibrosis after Lung Transplantation.” Annals of the American Thoracic Society (2021). PMID: 32795188 ↗
L3OTHERCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[616]
Siuba M, Attaway A, Zein J et al.. “Mortality in Adults with Cystic Fibrosis Requiring Mechanical Ventilation. Cross-Sectional Analysis of Nationwide Events.” Annals of the American Thoracic Society (2019). PMID: 31026405 ↗
L2OTHERCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 10. Complications
[617]
Arya R, Sharpe I, Cheng SY et al.. “Elevated Rates and Earlier Onset of Nonpulmonary Comorbidities in Adults with Cystic Fibrosis: A Population-based Study.” Annals of the American Thoracic Society (2025). PMID: 40720184 ↗
L3OTHERCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 10. Complications
[618]
Udaikumar J, Achuta KM, Lella VV et al.. “Prevalence and Risk Factors of Colorectal Cancer in Solid Organ Transplant Recipients: A Systematic Review and Meta Analysis.” Clinical transplantation (2026). PMID: 41615266 ↗
L1SR_OBSCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 13. Prevention, Screening & Surveillance
[619]
King PT, Dousha L, Clarke N et al.. “Phagocyte extracellular traps in children with neutrophilic airway inflammation.” ERJ open research (2021). PMID: 34164555 ↗
L4OTHERCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[620]
Mansilla-Polo M, Martín-Torregrosa D, Becerril-Andrés S et al.. “'Herpes simplex virus infection in a bipulmonary transplant recipient'.” Infection (2025). PMID: 41212338 ↗
L4CASE_REPORTCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[621]
Kurgansky KE, Collaco JM, Ng DK et al.. “Effectiveness of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy on Risk of Death for Individuals With Cystic Fibrosis.” Chest (2026). PMID: 42107694 ↗
L3OTHERCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[622]
Bianchi ML, Colombo C, Assael BM et al.. “Treatment of low bone density in young people with cystic fibrosis: a multicentre, prospective, open-label observational study of calcium and calcifediol followed by a randomised placebo-controlled trial of alendronate.” The Lancet. Respiratory medicine (2013). PMID: 24429202 ↗
L1RCTCited in: 10. Complications
[623]
Talbot NP, Downs M, Cane J et al.. “Intravenous iron for the treatment of iron deficiency in adults with cystic fibrosis: a prospective observational cohort study.” The European respiratory journal (2025). PMID: 41005983 ↗
L4COHORTCited in: 10. Complications
[624]
Gifford AH, Hinton AC, Jia S et al.. “Complications and Practice Variation in the Use of Peripherally Inserted Central Venous Catheters in People With Cystic Fibrosis: The Prospective Study of Peripherally Inserted Venous Catheters in People With Cystic Fibrosis Study.” Chest (2023). PMID: 37019356 ↗
L2COHORTCited in: 10. Complications
[625]
Hayes D, Tobias JD, Mansour HM et al.. “Pulmonary hypertension in cystic fibrosis with advanced lung disease.” American journal of respiratory and critical care medicine (2014). PMID: 25222938 ↗
L3OTHERCited in: 10. Complications
[626]
Brodlie M, McKean MC, Johnson GE et al.. “Ceramide is increased in the lower airway epithelium of people with advanced cystic fibrosis lung disease.” American journal of respiratory and critical care medicine (2010). PMID: 20395562 ↗
L4OTHERCited in: 10. Complications
[627]
Singer LG, Chowdhury NA, Faughnan ME et al.. “Effects of Recipient Age and Diagnosis on Health-related Quality-of-Life Benefit of Lung Transplantation.” American journal of respiratory and critical care medicine (2015). PMID: 26131729 ↗
L2OTHERCited in: 10. Complications
[628]
Gilboy JW, O'Brien D, Zuckerman JB. “Unusual Cause of Hemoptysis in a Woman With Cystic Fibrosis.” Chest (2024). PMID: 38336441 ↗
L4CASE_REPORTCited in: 10. Complications
[629]
Çolak Y, Nordestgaard BG, Afzal S. “Morbidity and mortality in carriers of the cystic fibrosis mutation CFTR Phe508del in the general population.” The European respiratory journal (2020). PMID: 32398304 ↗
L2OTHERCited in: 10. Complications
[630]
Henno P, Maurey C, Danel C et al.. “Pulmonary vascular dysfunction in end-stage cystic fibrosis: role of NF-kappaB and endothelin-1.” The European respiratory journal (2009). PMID: 19460784 ↗
L4OTHERCited in: 10. Complications
[631]
Liu CM, Fischer JL, Zemanick ET et al.. “The impact of highly effective modulator therapy on sinusitis and dysosmia in young children with cystic fibrosis: a prospective study protocol.” ERJ open research (2025). PMID: 39811548 ↗
L5COHORTCited in: 10. Complications
[632]
McElvaney OJ, Huizing M, Gahl WA et al.. “Hermansky-Pudlak syndrome with a novel genetic variant in HPS1 and subsequent accelerated pulmonary fibrosis: significance for phenocopy diseases.” Thorax (2018). PMID: 29941477 ↗
L4CASE_REPORTCited in: 10. Complications
[633]
Orenti A, Boeck K, Kerem E et al.. “Clinical characteristics and outcomes in the adult cystic fibrosis population in Europe from 2014 to 2024: analysis of the European Cystic Fibrosis Society Patient Registry.” The Lancet. Respiratory medicine (2026). PMID: 42235564 ↗
L2OTHERCited in: 10. Complications
[634]
Shteinberg M, Taylor-Cousar JL, Durieu I et al.. “Fertility and Pregnancy in Cystic Fibrosis.” Chest (2021). PMID: 34284004 ↗
L5REVIEW_NARRATIVECited in: 10. Complications, 11. Prognosis and Natural History, 12. Special Populations & Pregnancy
[635]
Mingora CM, Flume PA. “Pulmonary Complications in Cystic Fibrosis: Past, Present, and Future: Adult Cystic Fibrosis Series.” Chest (2021). PMID: 34147501 ↗
L5REVIEW_NARRATIVECited in: 10. Complications, 11. Prognosis and Natural History
[636]
King CS, Brown AW, Aryal S et al.. “Critical Care of the Adult Patient With Cystic Fibrosis.” Chest (2018). PMID: 30077689 ↗
L5REVIEW_NARRATIVECited in: 10. Complications
[637]
Du Y, Guo M, Wu Y et al.. “Lymphangioleiomyomatosis (LAM) Cell Atlas.” Thorax (2022). PMID: 36599466 ↗
L4OTHERCited in: 10. Complications
[638]
Bessonova L, Volkova N, Higgins M et al.. “Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor.” Thorax (2018). PMID: 29748252 ↗
L2OTHERCited in: 10. Complications
[639]
Goodwin AT, Singanayagam A, Jenkins G. “Review of the British Thoracic Society Winter Meeting 2018, 5-7 December 2018, London, UK.” Thorax (2019). PMID: 31383777 ↗
L5REVIEW_NARRATIVECited in: 10. Complications
[640]
Gallardo R, Silva BS, Salgado LS et al.. “Systematic Review of Nasal Endoscopy Scores in Cystic Fibrosis Patients Treated With Cystic Fibrosis Transmembrane Conductance Regulator Modulators.” Pediatric pulmonology (2026). PMID: 41919747 ↗
L2SR_OBSCited in: 10. Complications
[641]
Hsu CC, Kwan GN, Thompson SA et al.. “Embolisation for pulmonary arteriovenous malformation.” The Cochrane database of systematic reviews (2015). PMID: 25634560 ↗
L1SR_OBSCited in: 10. Complications
[642]
Perrotta N, Fiorito LA, Vescovo R et al.. “Long-term impact of Elexacaftor/Tezacaftor/ivacaftor on pulmonary, nutritional and metabolic outcomes in homozygous F508del cystic fibrosis patients: A real-world cohort study.” British journal of clinical pharmacology (2026). PMID: 41578635 ↗
L4COHORTCited in: 10. Complications
[643]
Jones A, Bilton D, Evans TW et al.. “Predictors of outcome in patients with cystic fibrosis requiring endotracheal intubation.” Respirology (Carlton, Vic.) (2013). PMID: 23323684 ↗
L4OTHERCited in: 10. Complications
[644]
Nacharaju D, Zelnick LR, Ramos KJ et al.. “Risk factors for longitudinal estimated glomerular filtration rate decline in adults with cystic fibrosis.” Annals of the American Thoracic Society (2026). PMID: 41734009 ↗
L2OTHERCited in: 10. Complications
[645]
Das L, Kovesi TA. “Bronchiectasis in children from Qikiqtani (Baffin) Region, Nunavut, Canada.” Annals of the American Thoracic Society (2015). PMID: 25496305 ↗
L4OTHERCited in: 10. Complications
[646]
Weber R, Haas N, Baghdasaryan A et al.. “Volatile organic compound breath signatures of children with cystic fibrosis by real-time SESI-HRMS.” ERJ open research (2020). PMID: 31956658 ↗
L3OTHERCited in: 10. Complications
[647]
Mei-Zahav M, Dotan M, Annicchiarico L et al.. “Methicillin-resistant Staphylococcus aureus and pulmonary outcome in people with cystic fibrosis: a European Cystic Fibrosis Patient Registry data analysis.” ERJ open research (2025). PMID: 40901377 ↗
L2OTHERCited in: 10. Complications
[648]
Mainz JG, Erdmann N, Duckstein F et al.. “Would it have happened without Christmas? Thoracic emphysema and allergic bronchopulmonary aspergillosis in a juvenile cystic fibrosis patient with the G551D mutation receiving ivacaftor.” ERJ open research (2021). PMID: 34046494 ↗
L4OTHERCited in: 10. Complications
[649]
Abacan MAR, Baltazar-Braganza KR, Cabaluna ITG et al.. “Philippine Clinical Practice Guidelines for Periodic Health Examination: Screening for Congenital and Developmental Disorders.” Acta medica Philippina (2026). PMID: 42382931 ↗
L1GUIDELINECited in: 10. Complications
[650]
Sun Y, Du J, Gong L et al.. “Current Status and the Need for CFTR Modulator Therapy in Cystic Fibrosis Patients in Mainland China: A Case Report and Literature Review.” Pediatric pulmonology (2026). PMID: 41918264 ↗
L4CASE_REPORTCited in: 10. Complications
[651]
Mogayzel PJ, Naureckas ET, Robinson KA et al.. “Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health.” American journal of respiratory and critical care medicine (2013). PMID: 23540878 ↗
L5REVIEW_NARRATIVECited in: 11. Prognosis and Natural History
[652]
Uhlig S, Gulbins E. “Sphingolipids in the lungs.” American journal of respiratory and critical care medicine (2008). PMID: 18755926 ↗
L5OTHERCited in: 11. Prognosis and Natural History
[653]
Zhang S, Shrestha CL, Robledo-Avila F et al.. “Cystic fibrosis macrophage function and clinical outcomes after elexacaftor/tezacaftor/ivacaftor.” The European respiratory journal (2023). PMID: 36265882 ↗
L4OTHERCited in: 11. Prognosis and Natural History
[654]
Loeve M, Krestin GP, Rosenfeld M et al.. “Chest computed tomography: a validated surrogate endpoint of cystic fibrosis lung disease?” The European respiratory journal (2012). PMID: 23258780 ↗
L5REVIEW_NARRATIVECited in: 11. Prognosis and Natural History
[655]
Ratjen F, Stanojevic S, Gunawardena T et al.. “Relationship between theratyping in nasal epithelial cells and clinical outcomes in people with cystic fibrosis.” The European respiratory journal (2025). PMID: 40210411 ↗
L3OTHERCited in: 11. Prognosis and Natural History
[656]
Rollet-Cohen V, Roux AL, Le Bourgeois M et al.. “Mycobacterium bolletii Lung Disease in Cystic Fibrosis.” Chest (2019). PMID: 30935892 ↗
L4OTHERCited in: 11. Prognosis and Natural History
[657]
O'Grady KF, Cripps AW, Grimwood K. “Paediatric and adult bronchiectasis: Vaccination in prevention and management.” Respirology (Carlton, Vic.) (2018). PMID: 30477047 ↗
L5REVIEW_NARRATIVECited in: 11. Prognosis and Natural History, 13. Prevention, Screening & Surveillance
[658]
Ramsey KA, Ranganathan S. “Interpretation of lung function in infants and young children with cystic fibrosis.” Respirology (Carlton, Vic.) (2014). PMID: 24948040 ↗
L5REVIEW_NARRATIVECited in: 11. Prognosis and Natural History, 13. Prevention, Screening & Surveillance
[659]
Balfour L, Armstrong M, Holly C et al.. “Development and psychometric validation of a cystic fibrosis knowledge scale.” Respirology (Carlton, Vic.) (2014). PMID: 25208592 ↗
L4OTHERCited in: 11. Prognosis and Natural History
[660]
Essilfie AT, Houston N, Maniam P et al.. “Anti-protease levels in cystic fibrosis are associated with lung function, recovery from pulmonary exacerbations and may be gender-related.” Respirology (Carlton, Vic.) (2023). PMID: 36642534 ↗
L3OTHERCited in: 11. Prognosis and Natural History
[661]
Pittman JE, Cutting G, Davis SD et al.. “Cystic fibrosis: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases.” Annals of the American Thoracic Society (2014). PMID: 24754825 ↗
L5REVIEW_NARRATIVECited in: 11. Prognosis and Natural History, 13. Prevention, Screening & Surveillance
[662]
Pryor JB, Bradford MC, Jennerich AL et al.. “Body Mass Index Recovery after Lung Transplant for Cystic Fibrosis.” Annals of the American Thoracic Society (2022). PMID: 35044894 ↗
L3OTHERCited in: 11. Prognosis and Natural History
[663]
Chmiel JF, Aksamit TR, Chotirmall SH et al.. “Antibiotic management of lung infections in cystic fibrosis. II. Nontuberculous mycobacteria, anaerobic bacteria, and fungi.” Annals of the American Thoracic Society (2014). PMID: 25167882 ↗
L5REVIEW_NARRATIVECited in: 11. Prognosis and Natural History
[664]
Sandvik RM, Schmidt MN, Voldby CM et al.. “Nationwide lung function monitoring from infancy in newborn-screened children with cystic fibrosis.” ERJ open research (2023). PMID: 37908398 ↗
L2OTHERCited in: 11. Prognosis and Natural History, 13. Prevention, Screening & Surveillance
[665]
Thornton CS, Somayaji R, Lim RK. “Assessment of factors and interventions towards therapeutic adherence among persons with non-cystic fibrosis bronchiectasis.” ERJ open research (2022). PMID: 36382236 ↗
L5REVIEW_NARRATIVECited in: 11. Prognosis and Natural History
[666]
Schembri LK, Carr SB, Davies JC et al.. “Diet composition and quality in children with cystic fibrosis in the modulator era: A scoping review.” Clinical nutrition (Edinburgh, Scotland) (2026). PMID: 42424717 ↗
L2REVIEW_NARRATIVECited in: 11. Prognosis and Natural History
[667]
Wainwright C, McColley SA, McNally P et al.. “Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged ⩾6 Years with Cystic Fibrosis and at Least One F508del Allele: A Phase 3, Open-Label Clinical Trial.” American journal of respiratory and critical care medicine (2023). PMID: 37154609 ↗
L4TRIAL_NONRANDOMCited in: 12. Special Populations & Pregnancy
[668]
Stahl M, Wielpütz MO, Graeber SY et al.. “Comparison of Lung Clearance Index and Magnetic Resonance Imaging for Assessment of Lung Disease in Children with Cystic Fibrosis.” American journal of respiratory and critical care medicine (2017). PMID: 27575911 ↗
L4TRIAL_NONRANDOMCited in: 12. Special Populations & Pregnancy
[669]
Ratjen F, Hug C, Marigowda G et al.. “Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.” The Lancet. Respiratory medicine (2017). PMID: 28606620 ↗
L1RCTCited in: 12. Special Populations & Pregnancy
[670]
Chang AB, Robertson CF, Van Asperen PP et al.. “A multicenter study on chronic cough in children : burden and etiologies based on a standardized management pathway.” Chest (2012). PMID: 22459773 ↗
L3RCTCited in: 12. Special Populations & Pregnancy
[671]
Wexler ID, Johannesson M, Edenborough FP et al.. “Pregnancy and chronic progressive pulmonary disease.” American journal of respiratory and critical care medicine (2006). PMID: 17110647 ↗
L5REVIEW_NARRATIVECited in: 12. Special Populations & Pregnancy
[672]
Mills DR, Masters IB, Yerkovich ST et al.. “Radiographic Outcomes in Pediatric Bronchiectasis and Factors Associated with Reversibility.” American journal of respiratory and critical care medicine (2024). PMID: 38631023 ↗
L3OTHERCited in: 12. Special Populations & Pregnancy
[673]
Ramsey KA, Rosenow T, Turkovic L et al.. “Lung Clearance Index and Structural Lung Disease on Computed Tomography in Early Cystic Fibrosis.” American journal of respiratory and critical care medicine (2016). PMID: 26359952 ↗
L4OTHERCited in: 12. Special Populations & Pregnancy, 13. Prevention, Screening & Surveillance
[674]
Middleton PG, Gade EJ, Aguilera C et al.. “ERS/TSANZ Task Force Statement on the management of reproduction and pregnancy in women with airways diseases.” The European respiratory journal (2020). PMID: 31699837 ↗
L5REVIEW_NARRATIVECited in: 12. Special Populations & Pregnancy
[675]
Martiniano SL, Wagner BD, Levin A et al.. “Safety and Effectiveness of Clofazimine for Primary and Refractory Nontuberculous Mycobacterial Infection.” Chest (2017). PMID: 28483608 ↗
L3OTHERCited in: 12. Special Populations & Pregnancy
[676]
McMullen AH, Pasta DJ, Frederick PD et al.. “Impact of pregnancy on women with cystic fibrosis.” Chest (2006). PMID: 16537871 ↗
L2OTHERCited in: 12. Special Populations & Pregnancy
[677]
Kapur N, Masters IB, Newcombe P et al.. “The burden of disease in pediatric non-cystic fibrosis bronchiectasis.” Chest (2011). PMID: 21885727 ↗
L2OTHERCited in: 12. Special Populations & Pregnancy
[678]
Loeve M, Gerbrands K, Hop WC et al.. “Bronchiectasis and pulmonary exacerbations in children and young adults with cystic fibrosis.” Chest (2010). PMID: 21148242 ↗
L2OTHERCited in: 12. Special Populations & Pregnancy
[679]
Jain R, Peng G, Lee M et al.. “Impact of Cystic Fibrosis Transmembrane Conductance Regulator Modulators on Maternal Outcomes During and After Pregnancy.” Chest (2024). PMID: 39343292 ↗
L2OTHERCited in: 12. Special Populations & Pregnancy
[680]
Schlüter DK, Griffiths R, Adam A et al.. “Impact of cystic fibrosis on birthweight: a population based study of children in Denmark and Wales.” Thorax (2018). PMID: 30026297 ↗
L2OTHERCited in: 12. Special Populations & Pregnancy
[681]
Hilton N, Solis-Moya A. “Respiratory muscle training for cystic fibrosis.” The Cochrane database of systematic reviews (2018). PMID: 29797578 ↗
L1SR_OBSCited in: 12. Special Populations & Pregnancy
[682]
Hussein N, Weng SF, Kai J et al.. “Preconception risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease.” The Cochrane database of systematic reviews (2018). PMID: 29537064 ↗
L1SR_OBSCited in: 12. Special Populations & Pregnancy
[683]
Hussein N, Weng SF, Kai J et al.. “Preconception risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease.” The Cochrane database of systematic reviews (2015). PMID: 26264938 ↗
L1SR_OBSCited in: 12. Special Populations & Pregnancy
[684]
Hussein N, Henneman L, Kai J et al.. “Preconception risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease.” The Cochrane database of systematic reviews (2021). PMID: 34634131 ↗
L1SR_OBSCited in: 12. Special Populations & Pregnancy
[685]
Hirst C, Williamson L. “Preoperative blood transfusions for sickle cell disease.” The Cochrane database of systematic reviews (2012). PMID: 22258951 ↗
L1SR_OBSCited in: 12. Special Populations & Pregnancy
[686]
Martí-Carvajal AJ, Peña-Martí GE, Comunián-Carrasco G et al.. “Interventions for treating painful sickle cell crisis during pregnancy.” The Cochrane database of systematic reviews (2009). PMID: 19160301 ↗
L1SR_OBSCited in: 12. Special Populations & Pregnancy
[687]
Estcourt LJ, Kimber C, Trivella M et al.. “Preoperative blood transfusions for sickle cell disease.” The Cochrane database of systematic reviews (2020). PMID: 32614473 ↗
L1SR_OBSCited in: 12. Special Populations & Pregnancy
[688]
Karanth L, Barua A, Kanagasabai S et al.. “Desmopressin acetate (DDAVP) for preventing and treating acute bleeds during pregnancy in women with congenital bleeding disorders.” The Cochrane database of systematic reviews (2019). PMID: 30758840 ↗
L1SR_OBSCited in: 12. Special Populations & Pregnancy
[689]
Vlajkovic T, Grigore M, van Eekelen R et al.. “Day 5 versus day 3 embryo biopsy for preimplantation genetic testing for monogenic/single gene defects.” The Cochrane database of systematic reviews (2022). PMID: 36423200 ↗
L1SR_OBSCited in: 12. Special Populations & Pregnancy
[690]
Son JW, Kim YJ, Cho HM et al.. “Promoter hypermethylation of the CFTR gene and clinical/pathological features associated with non-small cell lung cancer.” Respirology (Carlton, Vic.) (2011). PMID: 21585618 ↗
L3OTHERCited in: 12. Special Populations & Pregnancy
[691]
Cogen JD, Sanders DB, Slaven JE et al.. “Antibiotic Regimen Changes during Cystic Fibrosis Pediatric Pulmonary Exacerbation Treatment.” Annals of the American Thoracic Society (2023). PMID: 37327485 ↗
L2OTHERCited in: 12. Special Populations & Pregnancy
[692]
Cogen JD, Onchiri F, Emerson J et al.. “Chronic Azithromycin Use in Cystic Fibrosis and Risk of Treatment-Emergent Respiratory Pathogens.” Annals of the American Thoracic Society (2018). PMID: 29474110 ↗
L2OTHERCited in: 12. Special Populations & Pregnancy
[693]
Cogen JD, Faino AV, Onchiri F et al.. “Effect of Concomitant Azithromycin and Tobramycin Use on Cystic Fibrosis Pulmonary Exacerbation Treatment.” Annals of the American Thoracic Society (2021). PMID: 32810412 ↗
L2OTHERCited in: 12. Special Populations & Pregnancy
[694]
Cogen JD, Faino AV, Onchiri F et al.. “Clinical Outcomes of Antipseudomonal versus Other Antibiotics among Children with Cystic Fibrosis without Pseudomonas aeruginosa.” Annals of the American Thoracic Society (2022). PMID: 35289740 ↗
L2OTHERCited in: 12. Special Populations & Pregnancy
[695]
Toh CC, Makmor Bakry M, Mohamed Shah N et al.. “Population Pharmacokinetics of Amikacin in Non-Neonatal Pediatric Patients: A Scoping Review.” European journal of drug metabolism and pharmacokinetics (2026). PMID: 42360659 ↗
L4SR_OBSCited in: 12. Special Populations & Pregnancy
[696]
Williams C, Johnson B, Middleton PG et al.. “Family planning, pregnancy and birth in women with lung conditions: a worldwide survey.” ERJ open research (2021). PMID: 34938801 ↗
L4OTHERCited in: 12. Special Populations & Pregnancy
[697]
Downes A, Bokobza I, Weitnauer L et al.. “Maternal, Infant, Reproductive and Child Health in Cystic Fibrosis (MATRIARCH_CF): a prospective, observational study to evaluate pregnancy and parenthood in females with cystic fibrosis and health of the offspring in the CFTR-modulator era.” BMJ open respiratory research (2026). PMID: 42379640 ↗
L5OTHERCited in: 12. Special Populations & Pregnancy
[698]
Buendía JA, Vásquez C. “Administrative Prevalence and Healthcare Utilization of Pediatric Cystic Fibrosis in a Middle-Income Country: A 10-Year Analysis of National Administrative Data.” Pediatric pulmonology (2026). PMID: 42366899 ↗
L2OTHERCited in: 12. Special Populations & Pregnancy
[699]
Ziminski A, Zimbric M, McCaffery H et al.. “Respiratory bacterial epidemiology at three primary ciliary dyskinesia clinical centers.” Journal of the Pediatric Infectious Diseases Society (2026). PMID: 42364173 ↗
L4OTHERCited in: 12. Special Populations & Pregnancy
[700]
Ünlü A, Akyan ŞS, Özkan Tabakçı S et al.. “Evaluation of the effect of CFTR modulator therapy on lipid profiles in children.” Pediatric research (2026). PMID: 42332244 ↗
L2OTHERCited in: 12. Special Populations & Pregnancy
[701]
Sereme Y, Villeret B, Caboche S et al.. “A novel cystic fibrosis-mimetic Pseudomonas auxotrophic vaccine is protective in vivo and is associated with IL-17/IgA mucosal Immunity.” Molecular therapy : the journal of the American Society of Gene Therapy (2026). PMID: 42310961 ↗
L5OTHERCited in: 12. Special Populations & Pregnancy
[702]
Garbacz K, Piechowicz L, Mroczkowska A et al.. “Molecular epidemiology of Staphylococcus aureus in pediatric cystic fibrosis patients: a single-center study.” Frontiers in cellular and infection microbiology (2026). PMID: 42291320 ↗
L4OTHERCited in: 12. Special Populations & Pregnancy
[703]
Aerssens N, Vermeulen F, Boon M et al.. “Real-World Clinical Outcomes of Lumacaftor-Ivacaftor or Tezacaftor-Ivacaftor Therapy in Children With Cystic Fibrosis Homozygous for Phe508del.” Pediatric pulmonology (2026). PMID: 42272190 ↗
L4OTHERCited in: 12. Special Populations & Pregnancy
[704]
Ronchetti K, Tame JD, Paisey C et al.. “The CF-Sputum Induction Trial (CF-SpIT) to assess lower airway bacterial sampling in young children with cystic fibrosis: a prospective internally controlled interventional trial.” The Lancet. Respiratory medicine (2018). PMID: 29778403 ↗
L2TRIAL_NONRANDOMCited in: 13. Prevention, Screening & Surveillance
[705]
Rogers GB, van der Gast CJ, Cuthbertson L et al.. “Clinical measures of disease in adult non-CF bronchiectasis correlate with airway microbiota composition.” Thorax (2013). PMID: 23564400 ↗
L4RCTCited in: 13. Prevention, Screening & Surveillance
[706]
Breuer O, Schultz A, Garratt LW et al.. “Aspergillus Infections and Progression of Structural Lung Disease in Children with Cystic Fibrosis.” American journal of respiratory and critical care medicine (2020). PMID: 31747309 ↗
L2OTHERCited in: 13. Prevention, Screening & Surveillance
[707]
Knowles MR, Daniels LA, Davis SD et al.. “Primary ciliary dyskinesia. Recent advances in diagnostics, genetics, and characterization of clinical disease.” American journal of respiratory and critical care medicine (2013). PMID: 23796196 ↗
L5REVIEW_NARRATIVECited in: 13. Prevention, Screening & Surveillance
[708]
Belessis Y, Dixon B, Hawkins G et al.. “Early cystic fibrosis lung disease detected by bronchoalveolar lavage and lung clearance index.” American journal of respiratory and critical care medicine (2012). PMID: 22323305 ↗
L4OTHERCited in: 13. Prevention, Screening & Surveillance
[709]
Breuer O, Schultz A, Turkovic L et al.. “Changing Prevalence of Lower Airway Infections in Young Children with Cystic Fibrosis.” American journal of respiratory and critical care medicine (2019). PMID: 30811949 ↗
L2OTHERCited in: 13. Prevention, Screening & Surveillance
[710]
de Jong PA, Mayo JR, Golmohammadi K et al.. “Estimation of cancer mortality associated with repetitive computed tomography scanning.” American journal of respiratory and critical care medicine (2005). PMID: 16254271 ↗
L5OTHERCited in: 13. Prevention, Screening & Surveillance
[711]
Rosenow T, Oudraad MC, Murray CP et al.. “PRAGMA-CF. A Quantitative Structural Lung Disease Computed Tomography Outcome in Young Children with Cystic Fibrosis.” American journal of respiratory and critical care medicine (2015). PMID: 25756857 ↗
L4OTHERCited in: 13. Prevention, Screening & Surveillance
[712]
Hilliam Y, Moore MP, Lamont IL et al.. “Pseudomonas aeruginosa adaptation and diversification in the non-cystic fibrosis bronchiectasis lung.” The European respiratory journal (2017). PMID: 28446558 ↗
L4OTHERCited in: 13. Prevention, Screening & Surveillance
[713]
Brennan S, Sly PD, Gangell CL et al.. “Alveolar macrophages and CC chemokines are increased in children with cystic fibrosis.” The European respiratory journal (2009). PMID: 19386685 ↗
L4OTHERCited in: 13. Prevention, Screening & Surveillance
[714]
Smyth AR, Barbato A, Beydon N et al.. “Respiratory medicines for children: current evidence, unlicensed use and research priorities.” The European respiratory journal (2009). PMID: 19840958 ↗
L5REVIEW_NARRATIVECited in: 13. Prevention, Screening & Surveillance
[715]
Rosenow T, Mok LC, Turkovic L et al.. “The cumulative effect of inflammation and infection on structural lung disease in early cystic fibrosis.” The European respiratory journal (2019). PMID: 31023850 ↗
L2OTHERCited in: 13. Prevention, Screening & Surveillance
[716]
Frauchiger BS, Binggeli S, Yammine S et al.. “Longitudinal course of clinical lung clearance index in children with cystic fibrosis.” The European respiratory journal (2021). PMID: 33361098 ↗
L2OTHERCited in: 13. Prevention, Screening & Surveillance
[717]
Esther CR, Turkovic L, Rosenow T et al.. “Metabolomic biomarkers predictive of early structural lung disease in cystic fibrosis.” The European respiratory journal (2016). PMID: 27836957 ↗
L4OTHERCited in: 13. Prevention, Screening & Surveillance
[718]
Douglas TA, Brennan S, Gard S et al.. “Acquisition and eradication of P. aeruginosa in young children with cystic fibrosis.” The European respiratory journal (2008). PMID: 19010992 ↗
L4OTHERCited in: 13. Prevention, Screening & Surveillance
[719]
Fothergill JL, Walshaw MJ, Winstanley C. “Transmissible strains of Pseudomonas aeruginosa in cystic fibrosis lung infections.” The European respiratory journal (2012). PMID: 22323572 ↗
L5OTHERCited in: 13. Prevention, Screening & Surveillance
[720]
Stutz MD, Gangell CL, Berry LJ et al.. “Cyanide in bronchoalveolar lavage is not diagnostic for Pseudomonas aeruginosa in children with cystic fibrosis.” The European respiratory journal (2010). PMID: 20562125 ↗
L4OTHERCited in: 13. Prevention, Screening & Surveillance
[721]
Simpson SJ, Ranganathan S, Park J et al.. “Progressive ventilation inhomogeneity in infants with cystic fibrosis after pulmonary infection.” The European respiratory journal (2015). PMID: 26381521 ↗
L2OTHERCited in: 13. Prevention, Screening & Surveillance
[722]
Wolter DJ, Onchiri FM, Emerson J et al.. “Prevalence and clinical associations of Staphylococcus aureus small-colony variant respiratory infection in children with cystic fibrosis (SCVSA): a multicentre, observational study.” The Lancet. Respiratory medicine (2019). PMID: 31727592 ↗
L2OTHERCited in: 13. Prevention, Screening & Surveillance
[723]
Kidd TJ, Soares Magalhães RJ, Paynter S et al.. “The social network of cystic fibrosis centre care and shared Pseudomonas aeruginosa strain infection: a cross-sectional analysis.” The Lancet. Respiratory medicine (2015). PMID: 26208994 ↗
L4OTHERCited in: 13. Prevention, Screening & Surveillance
[724]
Ortiz JR, Neuzil KM, Victor JC et al.. “Influenza-associated cystic fibrosis pulmonary exacerbations.” Chest (2009). PMID: 19965953 ↗
L2OTHERCited in: 13. Prevention, Screening & Surveillance
[725]
Ortiz JR, Neuzil KM, Victor JC et al.. “Predictors of influenza vaccination in the Cystic Fibrosis Foundation patient registry, 2006 through 2007.” Chest (2010). PMID: 20495106 ↗
L2OTHERCited in: 13. Prevention, Screening & Surveillance
[726]
Glikman D, Siegel JD, David MZ et al.. “Complex molecular epidemiology of methicillin-resistant staphylococcus aureus isolates from children with cystic fibrosis in the era of epidemic community-associated methicillin-resistant S aureus.” Chest (2008). PMID: 18347206 ↗
L2OTHERCited in: 13. Prevention, Screening & Surveillance
[727]
Ranganathan SC, Parsons F, Gangell C et al.. “Evolution of pulmonary inflammation and nutritional status in infants and young children with cystic fibrosis.” Thorax (2011). PMID: 21398685 ↗
L2OTHERCited in: 13. Prevention, Screening & Surveillance
[728]
Douglas TA, Brennan S, Berry L et al.. “Value of serology in predicting Pseudomonas aeruginosa infection in young children with cystic fibrosis.” Thorax (2010). PMID: 20889526 ↗
L4OTHERCited in: 13. Prevention, Screening & Surveillance
[729]
Russell CD, Claxton P, Doig C et al.. “Non-tuberculous mycobacteria: a retrospective review of Scottish isolates from 2000 to 2010.” Thorax (2013). PMID: 23986391 ↗
L4REVIEW_NARRATIVECited in: 13. Prevention, Screening & Surveillance
[730]
Mitchelmore PJ, Randall J, Bull MJ et al.. “Molecular epidemiology of Pseudomonas aeruginosa in an unsegregated bronchiectasis cohort sharing hospital facilities with a cystic fibrosis cohort.” Thorax (2017). PMID: 28844058 ↗
L4OTHERCited in: 13. Prevention, Screening & Surveillance
[731]
Pillarisetti N, Linnane B, Ranganathan S. “Early bronchiectasis in cystic fibrosis detected by surveillance CT.” Respirology (Carlton, Vic.) (2010). PMID: 20456672 ↗
L4CASE_REPORTCited in: 13. Prevention, Screening & Surveillance
[732]
Terlizzi V, Timitilli E, Fiumara MS et al.. “Detection of Pseudomonas aeruginosa in cystic fibrosis after initiation of CFTR modulators: a systematic review.” Paediatric respiratory reviews (2026). PMID: 41638998 ↗
L2SR_OBSCited in: 13. Prevention, Screening & Surveillance
[733]
Eperjesi O, Németh J, Rancz A et al.. “Risk factors for calcification in chronic pancreatitis: a systematic review and meta-analysis.” Frontiers in medicine (2025). PMID: 41346984 ↗
L2SR_OBSCited in: 13. Prevention, Screening & Surveillance
[734]
Xu Q, Zhu J. “The cGAS-STING signaling pathway in the regulation of pulmonary infections: a systematic review.” Frontiers in cellular and infection microbiology (2025). PMID: 40697819 ↗
L5SR_OBSCited in: 13. Prevention, Screening & Surveillance
[735]
Shahrebabak AG, Rezaei M, Shahpar A et al.. “The efficacy of COVID-19 vaccination in cystic fibrosis patients: a systematic review.” BMC infectious diseases (2025). PMID: 40082759 ↗
L2SR_OBSCited in: 13. Prevention, Screening & Surveillance
[736]
Burgess L, Southern KW. “Pneumococcal vaccines for cystic fibrosis.” The Cochrane database of systematic reviews (2014). PMID: 25093421 ↗
L1SR_OBSCited in: 13. Prevention, Screening & Surveillance
[737]
Nevitt SJ, Jones AP, Howard J. “Hydroxyurea (hydroxycarbamide) for sickle cell disease.” The Cochrane database of systematic reviews (2017). PMID: 28426137 ↗
L1SR_OBSCited in: 13. Prevention, Screening & Surveillance
[738]
Allali S, Chalumeau M, Launay O et al.. “Conjugate Haemophilus influenzae type b vaccines for sickle cell disease.” The Cochrane database of systematic reviews (2018). PMID: 30125338 ↗
L1SR_OBSCited in: 13. Prevention, Screening & Surveillance
[739]
Johansen HK, Gøtzsche PC. “Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis.” The Cochrane database of systematic reviews (2015). PMID: 26298311 ↗
L1SR_OBSCited in: 13. Prevention, Screening & Surveillance
[740]
Dharmaraj P, Smyth RL. “Vaccines for preventing influenza in people with cystic fibrosis.” The Cochrane database of systematic reviews (2014). PMID: 24604671 ↗
L1SR_OBSCited in: 13. Prevention, Screening & Surveillance
[741]
Skilton M, Krishan A, Patel S et al.. “Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.” The Cochrane database of systematic reviews (2019). PMID: 30616300 ↗
L1SR_OBSCited in: 13. Prevention, Screening & Surveillance
[742]
Burgess L, Southern KW. “Pneumococcal vaccines for cystic fibrosis.” The Cochrane database of systematic reviews (2012). PMID: 22972126 ↗
L1SR_OBSCited in: 13. Prevention, Screening & Surveillance
[743]
Johansen HK, Gøtzsche PC. “Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis.” The Cochrane database of systematic reviews (2008). PMID: 18843616 ↗
L1SR_OBSCited in: 13. Prevention, Screening & Surveillance
[744]
Allali S, Chalumeau M, Launay O et al.. “Conjugate Haemophilus influenzae type b vaccines for sickle cell disease.” The Cochrane database of systematic reviews (2016). PMID: 26881484 ↗
L1SR_OBSCited in: 13. Prevention, Screening & Surveillance
[745]
Conte DD, Watanabe RAS, Chaves APC et al.. “Impact of Variants, Epidemiological Trends, and Comorbidities on Hospitalization Rates of Unvaccinated Children in Brazil: A Retrospective Study (2020-2022).” Influenza and other respiratory viruses (2024). PMID: 39686624 ↗
L4COHORTCited in: 13. Prevention, Screening & Surveillance
[746]
O'Regan PW, Ibrahim HIS, Blackburn S et al.. “Ultra-Low Dose Thoracic Computed Tomography-derived Morphomics in Patients with Cystic Fibrosis on Elexacaftor/Tezacaftor/Ivacaftor.” Annals of the American Thoracic Society (2025). PMID: 40587244 ↗
L4OTHERCited in: 13. Prevention, Screening & Surveillance
[747]
Davidson RM, Hasan NA, Epperson LE et al.. “Population Genomics of Mycobacterium abscessus from U.S. Cystic Fibrosis Care Centers.” Annals of the American Thoracic Society (2021). PMID: 33856965 ↗
L4OTHERCited in: 13. Prevention, Screening & Surveillance
[748]
Zemanick ET, Wagner BD, Robertson CE et al.. “Assessment of airway microbiota and inflammation in cystic fibrosis using multiple sampling methods.” Annals of the American Thoracic Society (2015). PMID: 25474078 ↗
L4OTHERCited in: 13. Prevention, Screening & Surveillance
[749]
Ramsey KA, Foong RE, Grdosic J et al.. “Multiple-Breath Washout Outcomes Are Sensitive to Inflammation and Infection in Children with Cystic Fibrosis.” Annals of the American Thoracic Society (2017). PMID: 28481640 ↗
L2OTHERCited in: 13. Prevention, Screening & Surveillance
[750]
Woodworth MH, Saullo JL, Lantos PM et al.. “Increasing Nocardia Incidence Associated with Bronchiectasis at a Tertiary Care Center.” Annals of the American Thoracic Society (2017). PMID: 28231023 ↗
L2OTHERCited in: 13. Prevention, Screening & Surveillance
[751]
Leutz-Schmidt P, Optazaite DE, Sommerburg O et al.. “Magnetic resonance imaging detects onset and association with lung disease severity of bronchial artery dilatation in cystic fibrosis.” ERJ open research (2023). PMID: 37009019 ↗
L2OTHERCited in: 13. Prevention, Screening & Surveillance
[752]
Ramsey KA, Hart E, Turkovic L et al.. “Respiratory infection rates differ between geographically distant paediatric cystic fibrosis cohorts.” ERJ open research (2016). PMID: 27957481 ↗
L3OTHERCited in: 13. Prevention, Screening & Surveillance
[753]
Foong RE, Harper AJ, Skoric B et al.. “The clinical utility of lung clearance index in early cystic fibrosis lung disease is not impacted by the number of multiple-breath washout trials.” ERJ open research (2018). PMID: 29707562 ↗
L4OTHERCited in: 13. Prevention, Screening & Surveillance
[754]
Gilchrist FJ, Belcher J, Jones AM et al.. “Exhaled breath hydrogen cyanide as a marker of early Pseudomonas aeruginosa infection in children with cystic fibrosis.” ERJ open research (2015). PMID: 27730156 ↗
L2OTHERCited in: 13. Prevention, Screening & Surveillance